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Abstract 
In this thesis I report three related studies that utilise state-of-the-art technologies to 
investigate germline and somatic chromosomal rearrangements in humans. Firstly, 16 patients 
with cytogenetically detectable deletions of 3p25-p26 were analysed with high density single 
nucleotide polymorphism (SNP) microarrays; Affymetrix 250K SNP microarrays (n=14) and 
Affymetrix SNP6.0 (n=2). Assuming complete penetrance, a critical region for congenital 
heart disease (CHD) susceptibility gene was refined to approximately 200 kb and a candidate 
critical region for mental retardation was mapped to ~1 Mb interval containing SRGAP3. 
Secondly, I used SNP microarray and molecular cytogenetic studies to characterise 
chromosome 11p15 in 8 patients with the imprinting disorder Beckwith-Wiedemann 
syndrome (BWS). In addition to characterising 11p duplications in three patients, the 
breakpoints in two patients with balanced rearrangements were mapped to two distinct 
regions. Thirdly, I used high resolution SNP arrays (Affymetrix 250K Sty1 and 6.0 arrays) to 
identify copy number changes in renal cell carcinoma (RCC) primary tumours (n=81) and cell 
lines (n=23). Copy number changes most frequently involved large segments (>10Mb) and 
loss of 3p and gain of 5q were the most common copy number changes. A comparison of 
copy number changes in RCC cell lines and inherited and sporadic primary tumours was 
made. 
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1 General introduction 
 
 1.1 The history of human cytogenetics 
The concept of chromosomes was first introduced in 1873 by a German zoologist, Anton 
Schneider who described the process of mitosis. Later, in 1882, a detailed description of 
mitosis in animals was published by Walther Flemming and he was the first to use the term 
mitosis. In 1888, an anatomy professor in Germany, Heinrich Waldeyer, introduced the 
term, chromosome which was derived from the Greek words for ‘coloured body’. 
Subsequently, Walter Sutton and Theodor Boveri, independently proposed that 
chromosomes carry the hereditary factors in accordance with Mendelian laws. The 
suggestions were put forward by the observation of the behaviour of chromosomes at cell 
division which they thought could provide an explanation of how genes could segregate. 
Sutton referred to the study of chromosomes as cytogenetics; a combination of the 
disciplines of cytology and genetics.  
 
Significant discoveries in tissue culture techniques eventually led to the important findings 
by Tjio and Levan in 1956. They worked on human embryonic lung fibroblasts cultures 
and optimized the colchicines/hypotonic method. They then determined for the first time 
the correct number of human chromosomes as 46.  
 
With the new technique, congenital anomalies associated with chromosomal number 
started to be identified for example Down syndrome associated with trisomy 21 (Lejeune 
et al., 1959), Turner syndrome in females with 45,X karyotype (Ford et al., 1959), 
Klinefelter syndrome in males with 47,XXY karyotype (Jacobs and Strong, 1959), triple X 
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(XXX) syndrome (Jacobs et al., 1959), Patau syndrome which also known as trisomy 13 
and Edward syndrome or trisomy 18  (Edwards et al., 1960; Patau et al., 1960; Smith et al., 
1960). Nowell and Hungerford reported the presence of the ‘Philadelphia chromosome’ in 
chronic myelogenous leukemia demonstrating, for the first time, an association between 
chromosomes and cancer (Nowell and Hungerford, 1960). Lejeune et al (1963 and 1964) 
identified partial deletion of the short arm of chromosome 5 in cri du chat (cat-cry) 
syndrome patients.   
 
Moorhead et al (1960) introduced the short-term culture technique using peripheral 
lymphocytes from blood samples. The effectiveness of the technique was based on the 
mitosis-inducing ability of phytohemagglutinin, a bean extract. The technique eliminated 
the need for bone marrow aspiration that had previously been the best way to obtain a 
sufficient number of spontaneously dividing cells.  
 
Identification of each of human chromosomes was made possible by Caspersson et al 
(1970). They discovered the nucleobase-specific fluorochrome quinacrin. When stained 
with quinacrin, each chromosome will show a specific pattern of bands, the Q-bands. 
These bands allowed for the first time the identification of all 22 human autosomal pairs 
and the two human sex chromosomes. Sumner, Schnedl, Seabright (1971) introduced 
additional stains and preparation methods, that brought forward new banding types: 
Giemsa banding (G-banding), Reverse banding (R-banding), Telomere banding (T-
banding), centromere banding (C-banding). Banding greatly improved the accuracy of 
chromosome analysis (Caspersson et al., 1970; Seabright, 1972) by permitting the analysis 
of many different tissues and diseases which led to the discovery of a large number of 
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different chromosome aberrations including terminal deletions, interstitial deletions and 
duplications.  
 
1.2 Chromosome rearrangements 
 
Chromosomal rearrangements encompass several different classes of events: deletions, 
duplications, inversions, insertions and translocations.  They result from chromosome 
breakage with subsequent reunion in a different configuration. Chromosomal 
rearrangements originating in the germ line, whether inherited from the parents or from a 
de novo mutation in the gametes, are referred to as constitutional. On the other hand, any 
changes in the chromosomes which arise during development or during the life of an 
organism are referred as acquired chromosomal rearrangements. In human live births, the 
presence of a chromosome aberration is ~0.5-0.6% and, of these, 0.1–0.3% corresponds to 
structural chromosome rearrangements such as translocations, inversions, insertions and 
deletions (De Braekeleer and Dao, 1991; Nielsen and Wohlert, 1991). 
 
Chromosome rearrangements can be categorised as a balanced or unbalanced.  It is 
estimated that 1 in 200 live births have an apparently balanced translocation and 1 in 500 
have an unbalanced translocation (Jacobs et al., 1992). In a balanced rearrangement the 
chromosome complement is complete with no gain or loss of genetic material. Although 
balanced reciprocal translocation carriers are usually phenotypically normal (with the 
exception of rare cases which involve breakpoint in an important functional gene), they are 
often at risk of having offspring with an unbalanced chromosomal complement or 
reproductive failure. On the other hand, unbalanced rearrangements involve gain or loss of 
genetic materials and very often resulted in phenotypic abnormalities.  
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Conventional cytogenetics enabled the identification of the chromosomes and the specific 
bands involved in the rearrangements (Caspersson et al., 1972; Yunis, 1976) while 
molecular cytogenetic methods ie. fluorescence in situ hybridisation (FISH) and 
comparative genomic hybridisation (CGH) are required to visualize microdeletions which 
cannot be detected by the conventional method.  Analysis of rearrangement breakpoints in 
relation to the banding pattern observed along Giemsa banded metaphase chromosomes 
showed that 84% of breakpoints occurred in Giemsa negative, gene rich regions of the 
genome (Warburton, 1991; Niimura and Gojobori, 2002).  
 
 1.2.1 Translocations 
Translocations involve a transfer of genetic material from one chromosome to another and 
consequently join two otherwise separated genes. The frequency of various chromosomal 
rearrangements in the general population varies from 1/625 to 1/5,000 (Bandyopadhyay et 
al., 2002). Translocations can be classified into two different types: reciprocal and 
Robertsonian. It was found that reciprocal translocations occur more frequently than 
Robertsonian (Bandyopadhyay et al., 2002).  The major impact of translocations is that 
they can generate significant chromosome imbalance during segregation at meiosis, 
predisposing the carrier to the birth of abnormal child, stillbirth, miscarriage or infertility.  
 
Many published translocation breakpoints have shown that direct disruption of a gene can 
lead to an associated phenotype (Bhalla et al., 2004; Bocciardi et al., 2005; Klar et al., 
2005) but studies also showed that translocation breakpoints can cause an effect on genes 
several kilobases away. Examples include a t(2;8)(q31;p21) which affects the HOXD gene 
60 Kb away from the chromosome 2 breakpoint in a patient with mesomelic dysplasia and 
vertebral defects (Spitz et al., 2002) and a t(6;11)(q14.2;q25) translocation affecting the 
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B3GAT1 gene which lies 299 Kb centromeric to the chromosome 11 breakpoint in a 
patient with psychosis (Jeffries et al., 2003). The position effect phenomenon arises from 
the disruption of cis-acting regulatory elements such as promoters, enhancers and silencers 
which can be directly altered, distanced from the gene they influence or brought into 
proximity of a gene not normally under their control when a chromosome undergoes a 
rearrangement. These elements have been observed as far away as 1.1 Mb from the gene 
they regulate as in the case of the SOX9cre1 element which was identified upstream of the 
SOX9 gene (Bien-Willner et al., 2007).  
 
 1.2.1.1 Reciprocal translocations 
These involve breakage of at least two non-homologous chromosomes and exchange of the 
fragments. The incidence of reciprocal translocations is ~1/625 in the general population 
(Van Dyke et al., 1983). The first reciprocal translocation to be associated with human 
cancer is t(9;22) which formed a shortened derivative chromosome 22, also known as 
Philadelphia chromosome (Ph) (Nowell and Hungerford,1960; Rowley,1973).  
 
Most reciprocal translocations are nonrecurring rearrangements except for the t(11;22) 
reported in more than 160 unrelated families (Fraccaro et al., 1980; Zackai et al., 1980;  
Iselius et al.,1983).  Breakpoint studies on both 11q and 22q have demonstrated a common 
site for rearrangement (Edelmann et al., 1999b; Shaikh et al., 1999). It was later suggested 
that a highly specific Alu-mediated recombination in the breakpoints could be the cause in 
the translocation (Hill et al., 2000).  
 
The breakpoint on chromosome 22 maps within a low-copy region-specific repeat 
(LCR22) that is also associated with the breakpoints seen in del(22)(q11.2) in 
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DiGeorge/VCF syndrome (Edelmann et al., 1999a). The breakpoint on the long arm of 
chromosome 11 is consistently found between two genetic markers, in a genomic region of 
about 185–190 kb (Edelmann et al., 1999b; Shaikh et al., 1999), and then narrowed to a 
190-bp region harbouring an AT-rich repeat (Edelmann et al., 1999b; Kurahashi et al., 
2000). The repetitive sequence found in the low-copy repeats on 22q also has multiple 
copies of an AT-rich sequence (Edelmann et al., 1999b). These findings suggest that AT-
rich regions may be prone to recombination events that lead to rearrangements.  
 
 1.2.1.2 Robertsonian translocations 
Robertsonian translocation (abbreviation rob) is named after the American insect 
geneticist, W.R.B. Robertson, who first described the translocation in grasshoppers in 
1916. They are found in ~1 in 1,000 individuals (Hamerton et al., 1975; Blouin et al., 
1994) making it the most common, recurrent structural rearrangements in human. These 
translocations involve exchanges of the whole arm of acrocentric chromosomes (13-15, 21 
and 22). The result is one long chromosome with a single centromere and the total number 
of chromosomes is reduced to 45. In the short arm, the p11 includes satellite DNAs I, II, 
III, IV and β; the p12 region contains multiple copies of the genes coding for the 18S and 
28S ribosomal RNA (nucleolar organizer region); and the p13 region terminates with β-
satellite DNA and telomeric sequences (Page et al., 1996; Bandyopadhyay et al., 2001). 
Thus, the short-arm regions of the five pairs of human acrocentric chromosomes have 
extensive sequence homology although some sequences are not common to all acrocentric 
chromosomes (Bandyopadhyay et al., 2001).   
 
 
7 
 
Although all acrocentric chromosomes are capable of participating in the translocation, the 
distribution of chromosomes was shown to be non-random (Therman et al., 1989). rob 
(13q;14q) and rob(14q21q) are the most common, constituting ~85% of all Robertsonian 
translocations (Therman et al., 1989). In ~50% of Robertsonian translocations, the 
rearrangements occur de novo (Shaffer et al., 1992) and in ~95% of the de novo cases, 
rob(13q14q) and rob(14q21q) originate during maternal meiosis (Page and Shaffer, 1997).   
 
 1.2.2 Deletions 
Deletion involves loss of part of a chromosome either terminal or interstitial, resulting in 
monosomy in that region of the chromosome. Deletion therefore is an unbalanced 
rearrangement. It can involve deletion of a single base to an entire piece of chromosome 
(Lewis, 2005). In most cases, large cytogenetically visible deletions cause embryopathy 
which presents after birth as mental retardation, growth failure and multiple 
malformations.  
 
In humans, cytogenetically visible autosomal deletions have a live birth incidence of about 
1 in 7,000 (Jacobs et al., 1992).  The first chromosomal deletions identified in humans 
were the deletion of distal 5p associated with the cri-du-chat syndrome (Lejeune et al., 
1963; Lejeune et al., 1964) and the distal deletion of 4p, subsequently named the Wolf-
Hirschhorn syndrome (Wolf et al., 1965). 
 
A principal method of producing deletions is by unequal crossing-over between region 
specific low copy-number repeat sequences that flank the deleted regions (figure 1.1) 
(Lupski et al., 1996; Chen et al., 1997; Lupski, 1998; Shaikh et al., 2000). 
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Figure 1.1: Unequal crossing over results in deletion and duplication rearrangements  
(Adapted from Nussbaum, McInnes and Willard, 2001).  
 
 
 
 
 1.2.2.1 Terminal deletions 
Even though terminal deletions have been identified for all human chromosomes, only a 
few have a significant incidence. Common terminal deletions include 1p-, 4p-, 5p-, 9p-, 
11q-, 17p-, 18q-, and 22q- (Shaffer and Lupski, 2000). Terminal deletions usually do not 
occur at a single site but involve breakpoints at various regions with variable sizes (Shaffer 
and Lupski, 2000). However, some cases of terminal deletion demonstrated clustering at a 
number of locations (Christ et al., 1999; Wu et al., 1999). In Jacobsen syndrome (deletion 
11q23) , molecular investigations have shown that the terminal 11q23 deletions cluster in a 
defined region in most patients (Jones et al., 1994; Tunnacliffe et al., 1999; Jones et al., 
2000).  
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Breakage of fragile site can cause terminal deletions in chromosomes (Jones et al., 1994; 
Jones et al., 1995). In Jacobsen syndrome, the 11q23 region contains the proto-oncogene 
CBL2, which also contains a CCG trinucleotide repeat (Jones et al., 1994; Jones et al., 
1995; Jones et al., 2000). Expansion of this repeat may result in the folate-sensitive fragile 
site FRA11B that is potentially the site of breakage for terminal deletions of 11q23. 
Analysis on five Jacobsen syndrome patients and their parents found two cases of deletion 
to be derived from a FRA11B-expressing chromosome (Jones et al., 1995; Jones et al., 
2000). However, for the remaining three families investigated, the site of breakage was 
proximal to FRA11B (Jones et al., 1995). 
 
Terminal deletion can also be due to double-strand DNA breaks of unknown cause 
followed by the addition of the telomeric sequence (TTAGGG)n as described in an α 
thalassemia mutation associated with terminal truncation of chromosome 16p13.3 (Wilkie 
et al., 1990; Lamb et al., 1993; Flint et al., 1994). Another characteristic of terminal 
deletions may be a preference for the maternal or paternal chromosome and it was found 
that in deletion 1p36,  78% of the cases involve a deletion on the maternally inherited 
chromosome (Wu et al., 1999).  
 
1.2.2.2 Interstitial deletions 
 
A number of genetic syndromes have been recognised to be caused by interstitial deletions 
and in majority of the patients, the deletion size is similar (Greenberg et al., 1991; 
Guzzetta et al., 1992; Mutirangura et al., 1993; Chen et al., 1995; Juyal et al., 1996; 
Carlson et al., 1997; Chen et al., 1997; Wu et al., 1999).                                                                                                                              
The common deletion in 7q11.23 found in Williams syndrome is about 1.6 Mb in size 
(Peoples et al., 2000) and is present in more than 99% of patients (Morris and Mervis, 
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2000). The deletion size in most patients with Prader-Willi syndrome or Angelman 
syndrome is about 4 Mb (Mutirangura et al., 1993).  However, two different proximal 
breakpoints have been identified in both the maternally derived deletions of Angelman 
syndrome and the paternally derived deletions of Prader-Willi syndrome (Christian et al., 
1995). The common Smith-Magenis syndrome deletion within 17p11.2 is approximately 5 
Mb (Trask et al., 1996; Chen et al., 1997) and is found in the vast majority of patients 
(Juyal et al., 1996; Chen et al., 1997). For most patients with DiGeorge syndrome/VCFS, 
the deletion in 22q11.2 is about 3Mb (Morrow et al., 1995; Carlson et al., 1997). Some 
patients have an alternate distal deletion breakpoint, resulting in a smaller, 1.5-Mb deletion 
(Carlson et al., 1997). Although altered sized deletions, or even rarer unique deletions, can 
be found in patients with these syndromes, the finding of the same-sized deletions in the 
majority of patients points to a specific mechanism giving rise to most of these structural 
rearrangements. 
 
 1.2.3 Duplications 
Crossing over between nonallelic, directly repeated, homologous segments between sister 
chromatids (intrachromosomal) or between homologous chromosomes (interchromosomal) 
would be expected to produce two reciprocal products: a tandem or direct duplication and 
a deletion (Figure 1.1). Duplication in 17p12 results Charcot-Marie tooth disease type 1A 
(CMT1A) while Smith Magenis syndrome is cause by the corresponding deletion. 
Homologous recombination between 24-kb flanking repeats, termed CMT1A−REPs, 
results in a 1.5-Mb deletion that is associated with hereditary neuropathy with liability to 
pressure palsy (HNPP) and the reciprocal duplication product is associated with CMT1A 
(Lupski, 1998). del(17)(11.2) causes Smith-Magenis syndrome (SMS) and this same 
region was identified to be duplicated in seven unrelated patients (Potocki et al., 2000). 
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Molecular analyses on dup(p11.2) or Potocki-Lupski syndrome (PTLS syndrome),  
suggest that the de novo17p11.2 duplication is preferentially paternal in origin, arises from 
unequal crossing over due to homologous recombination between flanking repeat gene 
clusters and probably represents the reciprocal recombination product of the SMS deletion 
(Potocki et al., 2000). Further study involving 35 patients has shown that 22 of them 
harbour the homologous recombination reciprocal product of the common SMS 
microdeletion (~3.7 Mb), 13 subjects (~37%) have nonrecurrent duplications ranging in 
size from 1.3 to 15.2 Mb.  
 
 1.2.4 Inversions and insertions  
An inversion involves two breaks in a chromosome and the segment is reversed or inverted 
in the position. If the inversion is outside the centromere, it is termed a paracentric 
inversion whereas inversion spanning the centromere, involving both the chromosome 
arms, is known as pericentric inversion.  Since it is a balanced rearrangement, it usually 
has no adverse effect on the carriers unless one of the breakpoint disrupts an important 
gene. Pericentric inversion of chromosome 9 is an example of a common structural variant 
or polymorphism and is not thought to be of any functional importance. A study of 
377,357 amniocentesis estimated the rate of inversions to be 1 in 10,000 with a 9.4% risk 
of an associated congenital abnormality (Warburton, 1991).  
 
An insertion occurs when a segment of a chromosome is inserted in another chromosome. 
If the inserted material has moved from another chromosome then the karyotype is 
balanced. Otherwise it causes an unbalanced chromosome complement. It can be 
hazardous if it involves the coding region of a gene.  
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 1.2.5   Copy number variations (CNVs) 
Recently, Redon et al (2006) has discovered copy number variations (CNVs) in 270 
normal individuals using microarray platforms.  They identified almost 1,500 regions of 
the genome which were variable in copy number, encompassing 360 Mb and thousands of 
genes. CNVs can be caused by genomic rearrangements such as deletions, duplications, 
inversions and translocations. Low copy repeats (LCRs), which are region-specific repeat 
sequences are susceptible to such genomic rearrangements resulting in CNVs. Although 
CNVs is a widespread and common phenomenon in humans, some of them have been 
associated with susceptibility or resistance to disease. For example, a higher copy number 
of CCL3L1 has been associated with lower susceptibility to human HIV infection 
(Gonzalez et al., 2005) and a low copy number of FCGR3B (the CD16 cell surface 
immunoglobulin receptor) can increase susceptibility to systemic lupus erythematosus and 
similar inflammatory autoimmune disorders (Aitman et al., 2006). CNV has also been 
associated with autism (Sebat, 2007; Cook and Scherer, 2008; Pinto et al., 2010) 
schizophrenia (Cook and Scherer, 2008; St Clair, 2008) and idiopathic learning disability 
(Knight, 1999).  
 
1.3 Analysis of chomosome rearrangements  
Different methods of chromosome analysis have been applied to the analysis of 
chromosome rearrangements. Conventional method is generally applied for the initial 
identification of rearrangements. Molecular methods such as fluorescence in situ 
hybridisation (FISH) can be used to identify precise breakpoints, but more recently 
microarray based techniques have been developed which allows genome wide analysis of 
the chromosomes.  
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 1.3.1 Metaphase chromosome banding  
This method is universally applied in cytogenetic laboratories to analyse the chromosome 
constitution of an individual. The method involved tissue culture from samples of 
peripheral blood, skin, bone marrow, chorionic villi or cells from amniotic fluid 
(amniocytes). The metaphase chromosomes obtained from the cells are treated with 
Trypsin and then stained for example with Giemsa. This creates unique banding patterns 
on the chromosomes that enable them to be analysed. Analysis of this pattern in relation to 
the human genome reference sequence showed that Giemsa positive bands (dark) were AT 
rich and gene poor and Giemsa negative bands (light) were GC rich and gene rich 
(Niimura and Gojobori, 2002). Analysis of chromosome banding patterns can identify 
chromosome rearrangements and localise the breakpoints to within approximately 3Mb 
depending on the quality and length of the prepared chromosomes (Lichter et al., 2000). 
Although conventional method examines the whole genome at once, chromosomal 
changes smaller than ~5 Mb cannot usually be detected by the method (Lupski, 2007). 
Subsequently, molecular genetics methods were introduced to address this problem. 
 
1.3.2 Flow cytometry 
 
Fluorescent dyes are used to bind specifically to GC (gene rich) or AT (gene poor) 
sequences in the chromosomes. Due to the differing size and DNA composition, 
chromosomes bind different amounts of the dye and allow it to be separated by the process 
of flow cytometry or fluorescent activated cell sorting (FACS). Rearrangements such as 
reciprocal translocations which alter the size and basepair constitution of chromosomes 
can be detected using flow cytometry.  
 
 
14 
 
1.3.3  Multiple ligation-duplex probes amplification (MLPA) 
Multiplex ligation-dependent probe amplification (MLPA) is a multiplex PCR method that 
detects abnormal copy numbers of up to 50 different genomic DNA or RNA sequences, 
and which is able to distinguish sequences differing in only one nucleotide (Schouten et 
al., 2002). This makes it suitable to be applied in both diagnostic laboratories and cancer 
studies for detection of deletions and duplications in a gene, gains and losses of 
chromosomal regions, trisomies, SNP and mutation detection (Schouten et al., 2002; Gille 
et al., 2002; Taylor et al., 2003; Kluwe et al., 2005; Gerdes et al., 2005; Aldred et al., 
2006; Aretz et al., 2007; Kanno, et al., 2007; Depienne et al., 2007; Redeker et al., 2008; 
Kozlowski et al., 2009).   
 
This technology is based on the identification of target sequences by hybridisation of pairs 
of MLPA probes. Each probe consists of a two oligonucleotides which recognise adjacent 
target sites on the DNA. One probe oligonucleotide contains the sequence recognised by 
the forward primer, the other the sequence recognised by the reverse primer. When both 
probe oligonucleotides are hybridised to their respective targets, they are then ligated into 
a complete probe.  Each complete probe has a unique length (130-472 bp) so that its 
resulting amplicons can be separated and identified on a capillary sequencer or on a gel, 
resulting in size separated chromatograms. Since the forward primer used for probe 
amplification is fluorescently labelled, each amplicon generates a fluorescent peak which 
can be detected by a capillary sequencer. Comparing the peak pattern obtained on a given 
sample with that obtained on various reference samples, the relative quantity of each 
amplicon can be determined (figure 1.2). This ratio is a measure for the ratio in which the 
target sequence is present in the sample DNA. 
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Figure1.2: Steps in multiplex ligation-dependent probe amplification (MLPA). Denatured 
genomic DNA is hybridised with a mixture of probes. Each MLPA probe consists of two 
oligonucleotides. The two parts of each probe hybridise to adjacent target sequences and are 
ligated by a thermostable ligase. All probe ligation products are amplified simultaneously by PCR 
using a single primer pair. The amplification product of each probe has a unique length (130–
472 bp). Amplification products are separated by capillary electrophoresis. Relative amounts of 
probe amplification products reflect the relative copy number of target sequences.  
 
 
 
Compared to conventional karyotyping and fluorescence in situ hybridisation (FISH), the 
MLPA method is technically uncomplicated, less expensive, less laborious, has shorter 
turnaround time and allows for relative quantification of up to 40 DNA target sequences in 
one PCR (Schouten et al., 2002). In addition, it does not require living cells or cell culture, 
but the input of 20 ng or more DNA. As the probe target sequences are small (50-70 nt), 
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MLPA can identify single gene aberrations and have proven to be useful for studies 
involving archival formalin fixed paraffin embedded tissue (van Dijk et al., 2005).  
 
1.3.4 Fluorescence in situ hybridisation (FISH) 
 
This method is based on the ability of a portion of single-stranded DNA (ie. a probe) to 
anneal with its complementary target sequence on a metaphase spread or interphase cells. 
In principle, the DNA probe is conjugated with modified nucleotides which after 
hybridisation with the patient sample allow the region where hybridisation has occurred to 
be visualised using a fluorescent microscope.  
 
FISH is routinely used to identify, confirm and characterise chromosomal abnormalities or 
confirm the clinical suspicion of known microdeletion syndromes (Speicher and Carter, 
2005). However, this method is targeted and can only screen individual DNA targets rather 
than the entire genome (Vermeesch et al., 2007). To overcome this problem, multicolour 
FISH-based karyotyping (SKY, MFISH and COBRA FISH) was developed, which enables 
simultaneous detection of all chromosomes (Speicher et al., 1996; Speicher and Carter, 
2005; Szuhai and Tanke, 2006). Another technology allowing genome wide detection of 
copy number aberrations was introduced in 1992 and termed comparative genomic 
hybridisation (Kallioniemi et al., 1992). 
 
1.3.5 Comparative genomic hybridisation (CGH) 
 
The method has been widely used for the analysis of tumour genomes and constitutional 
chromosomal aberrations since it was first reported by Kallioniemi and colleagues 
(Kallionemi et al., 1992). It involves competitive hybridisation of differentially labeled 
total genomic DNA from control tissue and tumour DNA to normal chromosome spreads. 
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Hybridisation of repetitive sequences is blocked by the addition of Cot-1 DNA. The ratio 
of the fluorescence intensities, generated by two different fluorochromes incorporated into 
test and control DNA is used to differentiate chromosomal regions between the normal and 
tumour DNA. The fluorescence ratio of the test and reference hybridisation signals is 
determined at different positions along the genome and provides information on the 
relative copy number of sequences in the test genome compared with a normal diploid 
genome. 
 
CGH is applied for identifying regions of chromosomes associated with amplification, loss 
and gain in specific tumours (Forozan et al., 1997; Knuutila et al., 1998), particularly for 
solid tumours where, it is often technically difficult to obtain sufficient G-banded 
metaphases of good quality for detailed analysis (Bejjani and Shaffer, 2006). However, 
one disadvantage of CGH is that it is unable to detect balanced rearrangements such as 
inversions or translocations (Pandita et al., 1999). Subsequently microarray-based formats 
for CGH (array CGH) were introduced and are beginning to be widely used in preference 
to chromosome-based CGH. The main advantages of array CGH are higher resolution and 
dynamic range, direct mapping of aberrations to the genome sequence and higher 
throughput (Pandita et al., 1999). 
 
1.3.6 Microarray-based comparative genomic hybridisation (array CGH) 
 
Array comparative genome hybridisation (array CGH) was developed based on DNA 
microarrays and dedicated to the investigation and mapping of changes in DNA copy 
number (Solinas-Toldo et al., 1997; Pinkel et al., 1998; Snijders et al., 2001; Ishkanian et 
al., 2004). The technique uses cDNAs (Pollack et al., 1999) or genomic fragments that are 
cloned in a variety of vectors such as plasmids, fosmids, cosmids (Pinkel and Albertson, 
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2005), bacterial artificial chromosomes (BAC) (Pinkel et al., 1998; Bejjani et al., 2005) or 
P1-derived artificial chromosomes (PAC) (Fiegler et al., 2003; Bejjani et al., 2005) arrayed 
onto a glass slides as the hybridisation targets. Following hybridisation of differentially 
labelled test and reference genomic DNAs to the target sequences on the microarray, the 
slide is scanned to measure the fluorescence intensities at each target on the array. The 
normalised fluorescent ratio for the test and reference DNAs is then plotted against the 
position of the sequence along the chromosomes. Gains or losses across the genome are 
identified by values increased or decreased from a 1:1 ratio (log2 value of 0) (figure 1.3).  
The resolution of the array is limited only by the size and the number of the cloned DNA 
targets and the natural distance between these sequences located on the chromosome 
(Bejjani and Shaffer, 2006; Vermeesch et al., 2007). 
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Figure 1.3: Schematic representation of CGH microarray technology. Whole genomic DNA from 
a control or reference (left) and genomic DNA from a test or patient (right) are differentially 
labeled with two different fluorophores. The two genomic DNA samples are competitively 
cohybridized with large-insert clone DNA targets. Computer imaging programs assess the relative 
fluorescence levels of each DNA for each target on the array (lower left). The ratio between 
control and test DNA for each clone can be linearly plotted using data analysis software to 
visualise dosage variations (lower right), indicated by a deviation from the normal log2 ratio of 
zero. (Adapted from Bejjani and Shaffer,2006). 
 
 
 
Recently, a high-density oligonucleotide-based single nucleotide polymorphism arrays 
(SNP arrays) have been introduced and applied particularly in cancer studies to identify 
copy number and LOH of chromosomal regions throughout the entire genome (Zhao et al., 
2004; Huang et al., 2004). One of the main advantages of a combined SNP-CGH approach 
is the identification of allele specific gain and loss by SNP array and the robust copy 
number detection by array CGH (Kloth et al., 2007). 
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1.3.7 Single nucleotide polymorphism (SNP) arrays 
 
Single nucleotide polymorphisms (SNPs) are a form of genome variation. Each 
polymorphism, or variant, occurs at a frequency of greater than 1% in the population 
(Brookes 1999). SNPs are common throughout the genome, have relatively high levels of 
heterozygosity and can be easily genotyped. SNPs were recognised as the most frequent 
type of variation in the human genome and therefore would provide a powerful tool for 
human genetic studies (Risch et al., 1996; Kruglyak, 1999). Due to their abundance, 
estimated to be 10 million in the human genome (Kruglyak and Nickerson, 2001), even 
spacing and stability across the genome, SNPs provide a significant diagnostic potential 
for human diseases and cancers compared to restriction fragment length polymorphisms 
and microsatellite markers (Zhao X et al., 2004). This feature also makes it easier for 
automation.  
 
SNP arrays were developed in 1998 for genotyping (Wang et al., 1998). With the 
improvement of the arrays in the subsequent years, their use has been successfully 
extended from investigation of genomic alterations in cancer and cell lines (Lindblad-Toh 
et al., 2000; Hodgson et al., 2001; Cai et al., 2002; Wilhelm et al., 2002; Fiegler et al., 
2003; Kraus et al., 2003; Paris et al., 2003; Albertson and Pinkel, 2003; Bignell et al., 
2004; Huang et al., 2004; Janne et al., 2004; Rauch et al., 2004; Zhou et al., 2004; Gibbs 
and Singleton, 2006; van Beers, 2006) to identification of unbalanced constitutional 
rearrangements (Vissers et al., 2003; Shaw-Smith et al., 2004), single copy gains and 
losses in specific chromosomal regions (Bruder et al., 2001; Yu et al., 2003; Veltman, 
2003), telomeres and subtelomeres (Veltman et al., 2002; Schoumans et al., 2005; de Vries 
et al., 2005) and an entire chromosome (Buckley et al., 2002). Importantly, this technique 
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can detect copy neutral loss of heterozygosity (LOH) events, which comprise 50–70% of 
the LOH detected in human tumours (Huang et al., 2004; Ishikawa et al., 2005; Beroukhim 
et al., 2006). 
Currently, Affymetrix and Illumina are among the main manufacturers of SNP arrays. 
Although the technology applied in producing the arrays is different, they both rely on the 
basic principle that nucleotides bases bind to their complementary partners, A-T and G-C. 
Both array protocols
 
call for the hybridisation of fragmented single-stranded DNA
 
to 
arrays containing hundreds of thousands of unique nucleotide
 
probe sequences. Each probe 
is designed to bind to a target
 
DNA subsequence. Following hybridisation, signal intensity 
associated with each
 
probe and its target is measured using specialized equipment and 
software (figure 1.4).  
 
The underlying principle
 
is that the signal intensity depends upon the amount of target
 
DNA in the sample, as well as the affinity between target and
 
probe. For example, the 
Affymetrix Mapping 500K Array Set includes more than 6.5 million features, each 
consisting of more than one million copies of a 25-bp oligonucleotide probe of a defined 
sequence, synthesized in parallel by proven photolithographic manufacturing. Each SNP is 
interrogated by 6- or 10-probe quartets where each probe quartet is comprised of a perfect 
match (PM; perfectly complementary to one of the target alleles), and a mismatch probe 
(MM; identical to a perfect match probe except
 
that the centre base is altered so as to be 
perfectly complementary
 
to neither allele) for each allele. In total, there are 24 or 40 
different 25-bp oligonucleotides per SNP (http://www.affymetrix.com/) (Zhao et al., 
2004). The scheme yields quartets comprised of four
 
types of probes: PMA, MMA, PMB and 
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MMB. The computational goal
 
is to convert these probe quartet intensity measures
 
from 
raw array data into a genotype inference AA, AB or
 
BB. 
 
 
Figure 1.4: Overview of SNP array technology. At the top is the fragment of DNA harbouring an 
A/C SNP to be interrogated by the probes shown. (a) In the Affymetrix assay, there are 25-mer 
probes for both alleles, and the location of the SNP locus varies from probe to probe. The DNA 
binds to both probes regardless of the allele it carries, but it does so more efficiently when it is 
complementary to all 25 bases (bright yellow) rather than mismatching the SNP site (dimmer 
yellow). This impeded binding manifests itself in a dimmer signal. (b) Attached to each Illumina 
bead is a 50-mer sequence complementary to the sequence adjacent to the SNP site. The single-
base extension (T or G) that is complementary to the allele carried by the DNA (A or C, 
respectively) then binds and results in the appropriately-colored signal (red or green, respectively). 
For both platforms, the computational algorithms convert the raw signals into inferences regarding 
the presence or absence of each of the two alleles. (Adapted from LaFramboise, 2009) 
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1.4 Genetic alterations and human cancers  
 
The idea that numerical alterations in the chromosome contribute to tumourigenesis was 
put forward by David von Hansemann in 1890 from his study on 13 different carcinoma 
samples. In each of the cases, he found examples of aberrant mitotic figures that showed 
asymmetric distribution of 'chromatin loops' or chromosomes. He postulated that these 
aberrant cell divisions were responsible for the decreased or increased chromatin content 
found in cancer cells. His idea was abandoned for many decades until Theodor Boveri 
(Boveri, 1914) pursued the concept by inducing multipolar mitoses on sea urchin eggs.  
From his observation of the abnormal cells bearing abnormal chromosomal number, he 
suggested that individual chromosomes were qualitatively dissimilar and transmitted 
different inheritance factors. He proposed that aberrant mitoses led to the unequal 
distribution of chromosomes, which, in most cases, would be detrimental. Yet, on 
occasion, a "particular, incorrect combination of chromosomes" would generate a 
malignant cell endowed with the ability of unlimited growth, which would pass the defect 
on to its progeny. This idea has laid a foundation for viewing cancer as a genetic disease.  
 
However, the hypotheses only became evident almost 40 years later when it was 
discovered that all tumour cell lines had chromosomal aberrations, frequently containing 
more than 100 chromosomes per cell including ring and dicentric chromosomes (Levan, 
1967; Rowley, 2001). The identification of Philadelphia chromosome (Ph) due to 
t(9;22)(q34;q11) in bone marrow patients with chronic myelogenous leukaemia (CML) 
(Nowell and Hungerford, 1960; Rowley, 1973) further supported the findings. It is also 
well established that abnormal chromosome segregation in cell division is one way by 
which tumour cells may accumulate the many genetic abnormalities required for tumour 
progression (Lengauer et al., 1998; Brinkley 2001; Saunders, 2005). Now, with the advent 
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of high throughput and high resolution technologies to identify genetic and epigenetic 
alterations in cancers, it has been reported that some 45,000 cytogenetic aberrations are 
associated with human neoplasms (Mitelman et al., 2004). It has also been observed that 
most recurrent aberrations and rearranged genes have been found in hematological 
disorders whereas numerous genomic imbalances have been identified in solid tumours 
(Look, 1997; Mertens et al., 1997; Rowley, 2001; Rabbits, 2003; Helman and Meltzer, 
2003; Albertson et al., 2003).  
In 1971, Alfred G. Knudson proposed a ‘two-hit’ hypothesis to explain the genetic 
mechanism underlying retinoblastoma (a childhood form of retinal cancer) which occurs in 
both hereditary and nonhereditary forms.  He performed statistical analysis on his data of 
48 patients with retinoblastoma combined with similar data from two previous 
publications (Vogel, 1957; Schappert-Kimmijser et al., 1966). He found that in the 
hereditary form, most children with an affected parent develop bilateral retinoblastoma, 
however some develop unilateral and others are not affected but have an affected child. 
These observations led to the theory that a single mutation is not sufficient for 
tumourigenesis. He hypothesized that in children with hereditary retinoblastoma, the first 
hit was inherited in the DNA and the second hit would rapidly cause cancer.  His findings 
also led to conclusions that patients who inherit the mutation would develop tumours 
earlier, and they would often develop more than one tumour. In contrast, individuals who 
did not inherit a mutation would almost always be affected by a single tumour. This 
statement, which called the two-mutation hypothesis is now known as the two-hit 
hypothesis (Knudson, 1971). Later, cloning of retinoblastoma gene confirmed the 
requirement for two mutations and that the gene, RB, occur on the two alleles on 
chromosome 13q14 (Benedict et al., 1983; Cavenee et al.,1983; Friend et al., 1986). 
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Disruption of the gene on both alleles causes loss of RB1 protein and subsequently leads to 
cancer formation. Following this seminal findings, more tumour suppressor genes (TSG) 
were later identified for example p53, BRCA1, BRCA2, APC, PTE, VHL. 
A variety of genetic alterations leading to tumour suppressor gene inactivation, including 
point mutations, small insertions, deletions, structural changes of the chromosome, or 
chromosomal loss, can constitute the first hit. All of these events plus mitotic 
recombination can occur as the second hit (Nowak et al., 2004). However, usually large 
deletions or chromosome loss do not account both for the first and second step in one cell, 
because large homozygous deletions are often lethal for a cell (Nowak et al., 2004).  
 
Experiments in mice, however, have highlighted some exceptions to this rule such that 
deletion of a single tumour suppressor gene allele can lead to cancer. Such 
haploinsufficiency is observed in p53 and p27
Kip1
 (Venkatachalam et al., 1998; Fero et al., 
1998). In the p53 study, the penetrance of spontaneous tumours in p53+/- mice was 95%, 
with a median age of morbidity of 460 days and less than half of the tumours had lost the 
wild-type p53 allele. Thus approximately 50% of the tumours harvested before 550 days, 
and 85% of the late-arising tumours, retained one expressed allele (Venkatachalam et al., 
1998).  
 
The alleles retained in two of the p53+/- tumours were completely sequenced in the coding 
region, and found to be wild-type. Five tumours were examined in a wide range of tests of 
p53 function and all of the results were consistent with the presence of a functional p53 
protein, as were the Western blot data. The evidence suggests that fatally malignant 
tumours retaining the wild-type p53 allele appear slightly later than tumours which have 
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lost it, but significantly more frequently and earlier than tumours in the +/+ mice. This 
study is consistent with the earlier reports which implied that although p53 hemizygous 
cells respond to DNA damage signals, the efficiency of the response is lower, allowing 
some cells to escape and continue to proliferate, and thus become targets for further 
mutations in other genes (Clarke et al., 1993, 1994; Gottlieb et al., 1997). 
 
Similar findings were observed in mice hemizygous for p27
Kip1
 in which 32% of them 
were shown to develop tumours. Despite a relatively late onset (median 570 days), all 
arose before any appeared in the +/+ control mice. None of the tumours examined showed 
loss of the second allele, whose sequence was shown to be wild-type (complete coding 
regions sequenced from one spontaneous tumour and from 13 tumours induced by 
radiation or ethyl nitrosourea). The gene product was expressed at levels comparable to 
those of normal tissues, and was appropriately localised to the nucleus. And so it was 
concluded that for both p53 and p27
Kip1
, loss of two alleles was more tumourigenic than 
loss of one and tumours arose more quickly in homozygous than hemizygous deficient 
mice (Venkatachalam et al., 1998; Fero et al., 1998). Several other examples of 
haploinsufficiency for tumour suppression have been demonstrated, for example p16
Ink4a
 
(Krimpenfort et al., 2001) and PTE (Sulis and Parsons, 2003; Trotman et al., 2003).  
 
In contrast to the usual function of a tumour suppressor gene, somatic mutation on one 
allele or ‘one hit’ is believe to be sufficient for oncogene to confer a selective growth 
advantage on the cell  (Vogelstein and Kinzler, 2004). Oncogenes were first identified in 
oncogenic retroviruses that had picked up a cellular oncogene (c-onc) and incorporated it 
into the viral genome to produce a viral oncogene (v-onc) (Stehelin et al., 1976a; Stehelin 
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et al., 1976b; Stehelin et al., 1977). An oncogene can be the result of several DNA 
alterations; mutation, structural rearrangement or gene copy number gains (Albertson et 
al., 2003; Vogelstein and Kinzler, 2004). K-ras point mutation has been shown to be 
associated with poor prognosis of lung adenocarcinoma (Slebos et al., 1990), mutation of 
BRAF in human cancers changes a valine to a glutamate at codon 599 which is a residue 
within the activation loop of the kinase domain
 
(Davies et al., 2002), translocation 
t(8;14)(q24;q32) found in about 85% of cases of Burkitt lymphoma places the c-myc gene 
located at chromosome 8q24 under control of regulatory elements from the 
immunoglobulin heavy chain locus located at 14q32 resulting in transcriptional activation 
of c-myc, which encodes a nuclear protein involved in the regulation of cell proliferation 
(Siebert et al., 1998; Mann et al., 2002).  
 
Peter Nowell in 1976 has proposed a model for the evolution of tumour cell populations in 
terms of stepwise genetic variation based from his observation that (1) in many primary 
tumours, all cells show the same abnormal karyotype, and even when several chromosome 
patterns are present within a single tumour, marker chromosomes in each cell often 
indicate that the different subpopulations derive from a common stemline (Sandberg, 
1970) (2) the isoenzymes of glucose-6-phosphate dehydrogenase in a variety of neoplasms 
in heterozygous women have indicated that typically the same member of the X 
chromosome pair is functional in all cells of a given tumour (Linder and Gartler, 1965). 
(iii) the immunoglobulin produced by plasma cell tumours (and perhaps other 
lymphoproliferative neoplasms as well) has in almost every case the homogeneity 
characteristic of a single clone (Linder and Gartler, 1965; Milstein et al., 1967). Nowell 
suggested that, following an initiating event that converts a normal cell to a neoplastic cell, 
cancer progression results from the acquisition of genetic instability, leading to the 
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accumulation of genetic alterations and the continual selective outgrowth of variant 
subpopulations of tumour cells with a proliferative advantage.  
 
In 1997, Kinzler and Vogelstein proposed a division of TSG genes to ‘gatekeepers’ and 
‘caretakers’. Gatekeeper genes function by directly controlling cell growth, thus inhibiting 
proliferation, leading to apoptosis and/or promoting terminal differentiation (Russo et al., 
2003). These genes are frequently mutated in both sporadic and hereditary tumours and 
their functional loss is rate limiting for tumour growth of a specific tissue type. Alteration 
of a particular gatekeeper gene can lead to the development of a particular form of 
predisposition to cancer (Kinzler and Vogelstein, 1997). Caretaker genes are involved in 
the maintenance of genomic stability by reducing the mutation rates in gatekeepers and 
oncogenes. Mutations in these genes are frequently found in hereditary tumours (Kinzler 
and Vogelstein, 1997). Consequently, an altered gatekeeper gene could affect mainly 
tumour initiation, while a caretaker gene could accelerate the tumour progression, even if 
in certain cases their functions may partly overlap; as such the same gene may act either as 
a gatekeeper or as a caretaker. 
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1.5 Aims of this thesis 
The principal aim of my thesis is to apply molecular cytogenetic technique and high 
resolution SNP array to characterise constitutional and acquired cytogenetic abnormalities 
in specific human disease situations i.e. developmental disorders (3p- syndrome and 
Beckwith-Wiedemann syndrome) and human renal cancers. 
 1.5.1 Array CGH analysis of 3p25-p26 deletion (3p- syndrome) 
The two main aims of this study are to investigate phenotype-genotype 
correlations and to accurately map the deletion breakpoints on the 
chromosome 3p using 250K SNP array (in 14 patients) and SNP 6.0 (in 2 
patients). 
 
 1.5.2  Cytogenetics and molecular genetic analysis of Beckwith Wiedemann 
syndrome (BWS) 
 
To define and characterise the region of chromosome 11p15 involved in 
Beckwith-Wiedemann syndrome (BWS), I have carried out a high resolution 
250K SNP array analysis on seven patients and SNP6.0 on one patient with 
features of BWS. Conventional and molecular cytogenetic techniques were 
also applied in two of the cases with chromosome rearrangements.  
 
 1.5.3  Analysis of copy number changes in primary tumours of clear cell renal cell 
carcinoma (cRCC) and renal cell carcinoma (RCC) cell lines using 250K 
SNP Array 
 
 
This study is aim to identify copy number changes and characterise 
chromosomal changes in primary tumours of clear cell renal cell carcinoma 
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from sporadic, VHL disease and renal cell carcinoma cell lines using 250K 
SNP Array.  
 
 1.5.4 Identification of copy number changes in sporadic clear cell renal cell 
carcinoma (cRCC) using high resolution array SNP6.0 
 
The main aim of this study is to precisely characterise and identify copy 
number changes associated with sporadic clear cell renal cell carcinoma 
(cRCC). Therefore, I took advantage of the latest microarray technology, 
Affymetrix array SNP6.0, to study copy number changes of 37 samples of 
sporadic cRCC. The data was then compared with the results of sporadic 
cRCC obtained using the 250K SNP array.  
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2 General methods 
2.1  250K SP array (Sty1) 
The experiment was carried out following the manufacturer’s protocol (Affymetrix, USA) 
(summarized in Figure 2.1) to minimize possible sources of contamination that would 
reduce genotyping accuracy, call rate and consequently genetic power.  
 
 Genomic DNA samples from: 
• 3p25-p26 deletion syndrome                                    
• Beckwith-Wiedemann syndrome (BWS) 
• Clear cell renal cell carcinoma (cRCC) primary  
tumours and RCC cell lines 
 
Digestion 
 
Ligation 
 
Polymerase chain reaction (PCR) 
 
Fragmentation 
 
Hybridisation 
 
Washing, staining and scanning 
 
Data analysis 
 
Figure 2.1: Steps involved in 250K SNP array 
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All the samples used for this study follows the guidelines and requirements specified by 
the manufacturer (Affymetrix, USA). Please refer appendix A1. 
 
2.1.1  Sample preparation  
 
Location: Pre-PCR clean area  
 
The samples were thoroughly mixed by vortexing at high speed for 3 seconds and spun 
down at 2000 rpm for 30 seconds. The concentration of each sample was determined using 
Nanodrop 1000 spectrophotometer (Thermo Scientific, USA). Based on OD 
measurements, the samples were diluted to 50ng/ul using DNase/RNase free molecular 
grade water. The diluted DNA was then thoroughly mixed by vortexing at maximum speed 
for 3 seconds. 5 ul DNA was aliquoted to the corresponding 96-well reaction plate which 
was placed in a double cooling chamber on ice. If the next step was not proceeded to 
directly, the samples were stored in -20°C.  
 
2.1.2 Restriction enzyme digestion  
Location: Pre-PCR clean area 
Before starting this step, the reagents, equipment and consumables required were prepared 
as follows:  
• Genomic DNA was thawed on ice if frozen. When thawed, the centre of the plate 
was vortexed at high speed for 3 seconds, spun down at 2000 rpm for 30 seconds 
and placed back on ice.  
• BSA (Bovine Serum Albumin) and NE Buffer 3 (New England Biolab, UK) were 
thawed on ice. When thawed, they were vortexed at high speed for 3 seconds, then 
spun for 3 seconds and placed on ice.  
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• 2 mL of AccuGENE® water was placed on ice. 
• The thermocycler was on to preheat the lid at room temperature.  
• A 2.0 mL Eppendorf tube was labeled Dig MM and placed on ice. 
 
2.1.2.1 Preparation of the digestion master mix 
 
All the reagents required were kept on ice. For 1 sample, 11.55 ul AccuGENE water, 2 ul 
NE Buffer 3 and 0.2 ul BSA (10X;1 mg/ml) were added to the 2.0 mL eppendorf tube. Sty1 
enzyme (10 U/ul) was removed from the freezer, immediately placed on ice and then spun 
for 3 seconds.  1 ul of the enzyme was then added to the master mix. The master mix was 
then vortexed at high speed for 3 seconds, spun for 3 seconds and then placed on ice. Any 
remaining enzyme was then returned to the freezer. When preparing multiple samples, 5% 
extra of each component were added. 
 
2.1.2.2 Addition of digestion master mix to samples 
This step was handled on ice. 14.75 µL of Digestion Master Mix was added to each DNA 
sample making the total volume in each well 19.75 µL. The plate was sealed tightly using 
96-well Clear Adhesive Films (Applied Biosystems, USA) and vortexed at the centre at 
high speed for 3 seconds. It was then spun down at 2,000 rpm for 30 seconds and loaded 
onto the preheated thermal cycler and the 500K Digest program was run as follows: 
120 minutes 37°C 
20 minutes 65°C  
Hold 4°C 
 
The plate was then removed and spun down at 2000 rpm for 30 seconds and the samples 
were stored in -20°C if not proceeding directly to the next step. 
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2.1.3 Ligation  
Location: Pre-PCR clean area 
Before starting, the reagents, equipment and consumables required for this step were 
prepared as follows: 
Adaptor Sty (50 µM; 1 vial) (Affymetrix, USA) and T4 DNA Ligase Buffer (10X; 1 vial) 
(Affymetrix, USA) were thawed on ice. They were then vortexed at high speed for 3 
seconds then pulse spun for 3 seconds and placed back on ice. 
If frozen, the Digestion Stage plate was thawed on ice. It was then vortexed at the centre at 
high speed for 3 seconds, spun down at 2000 rpm for 30 seconds and placed back on ice. 
The thermal cycler was powered on to preheat the lid. 
A 2.0 mL eppendorf tube was labeled Lig MM and placed on ice. 
 
2.1.3.1 Preparation of ligation master mix 
Keeping all reagents and tubes on ice, 0.75 ul Adaptor Sty1 (50 uM) and 2.5 ul T4 DNA 
Ligase Buffer (10X) were added to the 2.0 mL eppendorf tube labeled Lig MM.  T4 DNA 
Ligase (400 U/ul) was removed from the freezer and immediately placed on ice. It was then 
pulse spun for 3 seconds and immediately 2 ul of the enzyme was added to the master mix. 
The master mix was then vortexed at high speed for 3 seconds, pulse spun for 3 seconds 
and placed in the cooling chamber. Any remaining enzyme was placed back in the -20C 
freezer. 
2.1.3.2 Addition of ligation master mix to samples 
The addition was done on ice. The seal of the Digestion Stage plate was carefully removed 
and 5.25 µL of Ligation Master Mix was aliquoted to each reaction. The plate was then 
tightly sealed again using 96-well Clear Adhesive Films (Applied Biosystems, USA), 
vortexed at the centre at high speed for 3 seconds then spun down at 2000 rpm for 30 
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seconds. The plate was loaded onto the preheated thermal cycler and the 500K Ligate 
program was run as follows: 
180 minutes 16°C 
20 minutes 70°C 
Hold 4°C 
 
2.1.3.3 Dilution of the samples 
10 mL of the AccuGENE® water was placed on ice for 20 minutes prior to use. When the 
program was finished, the ligation plate was removed from the thermal cycler, spun down 
at 2000 rpm for 30 seconds and placed on ice. The seal of the plate was carefully removed 
and 75 µL of water was added to each reaction. The plate was then tightly sealed again 
using 96-well Clear Adhesive Films (Applied Biosystems, USA), vortexed at the centre at 
high speed for 3 seconds and then spun down at 2000 rpm for 30 seconds. If not 
proceeding directly, the samples were stored in -20°C. 
 
2.1.4 Polymerase Chain Reaction (PCR)  
Location: Pre-PCR clean area 
The following reagents, equipment and consumables were prepared before starting this 
step: 
10X TITANIUM™ Taq PCR Buffer (Clontech, USA), dNTPs (Takara, USA), PCR 
Primer 002 (Affymetrix, USA), G-C Melt (5M) (Clontech, USA) were thawed on ice. 
Once thawed, they were vortexed at high speed for 3 seconds, pulse spun for 3 seconds 
and placed back on ice.  
15 mL of AccuGENE water was placed on ice. 
36 
 
The Ligation Stage plate was thawed on ice if frozen. It was then labelled Lig, vortexed at 
the centre at high speed for 3 seconds, spun down at 2000 rpm for 30 seconds and placed 
back on ice. 
The thermal cycler was powered on and preheated. 
Three 96-well reaction plates were labeled P1, P2, and P3 
A 50 mL Falcon tube was labeled PCR MM 
 
2.1.4.1 Addition of DA to the reaction plates  
Location: Pre-PCR clean area 
10 µL of sample from each well of the Ligation Stage plate was transferred to the 
corresponding row and well of each reaction plate (as shown in figure 2.2). The transfer 
was done on ice. Each plate were tightly sealed and left on ice. 
 
 
Figure 2.2: Transfer of ligation stage plate to the corresponding row and well of reactions plates 1, 
2 and 3.  
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2.1.4.2 Preparation of PCR master mix  
Location: Pre-PCR clean area 
Keeping the 50 mL Falcon tube on ice, all of the reagents (except for Taq DNA 
polymerase) were added in the order shown in table 2.1. The TITANIUM Taq DNA 
Polymerase was then removed from the freezer and immediately placed on ice. It was then 
pulse spun for 3 seconds and immediately added to the master mix. The master mix was 
vortexed at high speed for 3 seconds. For multiple samples, 5% excess of each reagent was 
added. Any remaining of Taq DNA polymerase was returned to the -20C freezer. 
 
 Table 2.1: PCR master mix 
Reagent 1 PCR 3 PCR Final conc. in sample 
AccuGENE water 39.5 ul 118.5 µL  
TITANIUM Taq PCR Buffer (10X) 10 ul 30 µL 1X 
GC-melt (5M) 20 ul 60 µL 5M 
dNTPs (2.5 mM) 14 ul 42 µL 350 uM 
PCR primer 002 (100 uM) 4.5 ul 13.5 µL 4.5 uM 
TITANIUM Taq DNA polymerase (50X) 2 ul 6 µL 1X 
Total 90 ul 270 µL  
Abbreviation: conc., concentration 
 
2.1.4.3 Addition of PCR master mix to samples  
Location: PCR staging area 
The reaction plates P1, P2 and P3 and PCR Master Mix were transferred to PCR staging 
area on ice. 90 µL of PCR Master Mix was added to each sample making the total volume 
in each well 100 µL. Each reaction plate was sealed tightly, vortexed at medium speed for 
2 seconds and spun at 2,000 rpm for 1 minute. 
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2.1.4.4 PCR reaction 
Location: Main lab 
Reaction plates P1, P2 and P3 were transferred to the Main Lab. Each plate was loaded 
onto a preheated thermal cycler MJ Tetrad PTC-225 and the program was run as follows:   
3 minutes 94°C 1 cycle 
30 minutes94°C 
30 minutes60°C        30 cycles 
15 seconds68°C 
7 minutes68°C 1 cycle 
Hold 4°C 
 
 
Each reaction plate was then removed from the thermal cycler and spun down at 2000 rpm 
for 30 seconds then placed on ice. Three fresh 96-well reaction plates were labelled P1Gel, 
P2Gel and P3Gel. 3 µL of 2X Gel Loading Dye was added to each well of the three plates. 
3 µL of each PCR product from plates P1, P2 and P3 was transferred to the corresponding 
plate, row and wells of plates P1Gel, P2Gel and P3Gel. Plates P1Gel, P2Gel and P3Gel 
were sealed and vortexed at medium speed for 3 seconds then spun down at 2000 rpm for 
30 seconds. 6 µL from each well of plates P1Gel, P2Gel and P3Gel was loaded onto 2% 
TBE gels and run at 120V for 40 minutes to 1 hour. The gels were examined to verify that 
the PCR product distribution is between 250 bp to 1100 bp (figure 2.3). If not proceeding 
directly to the next stage within 60 minutes, the plates were sealed and stored at −20 °C. 
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Figure 2.3: Typical example of PCR products run on 2% TBE agarose gel at 120V for 1 hour, with 
average size between 200 and 1,100 bp 
 
 
 2.1.5  PCR purification and elution  
Location: main lab 
Before starting this step, the following were done:  
The PCR product was thawed at room temperature if frozen. Once thawed, it was vortexed 
at the centre at medium speed for 3 seconds and spun down at 2000 rpm for 30 seconds. 
The manifold-QIAvac multiwell unit (Qiagen, USA) was set up as follows: 
a. the manifold was connected to a vacuum source QIAGEN Vacuum Regulator  (Qiagen, 
USA) able to maintain 600 mbar. 
b. a waste tray was placed inside the base of the manifold. 
 
8 µL of diluted EDTA (0.1M) was aliquoted into each well on each PCR product plate. 
They were then tightly sealed and vortexed at medium speed for 2 seconds and spun at 
2000 rpm for 1 minute. 
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Next, the samples from the same row and well of each PCR product plate were transferred 
and pooled to the corresponding row and well of the Clontech Clean-Up Plate (figure 2.4). 
 
 
Figure 2.4: Pooling of PCR products 
 
The vacuum was then turned on and maintained at 600 mbar until all of the wells were dry 
(approximately 1.5 to 2 hours). The PCR products were washed by adding 50 µL 
molecular biology grade water and the wells completely dry in approximately 20 minutes. 
This step was repeated 2 additional times for a total of 3 water washes. After the third 
wash, the manifold was tapped firmly on the bench to force any drops on the sides of the 
wells to move to the bottom and be pulled through the plate. The samples were allowed to 
dry completely which took 45 to 75 minutes in the third wash.  The vacuum was then 
turned off and was carefully removed from the manifold. The bottom of the plate was 
immediately blotted on a stack of clean, absorbent paper to remove any remaining liquid. 
Next, 45 µL RB Buffer (Clontech, USA) was added to each well of the plate. It was then 
tightly sealed and then loaded onto a plate shaker, e.g., Jitterbug (Boekel Scientific, model 
130000), for 10 minutes at room temperature. Approximately 45 µL of each eluted sample 
was then transferred from the Clontech Clean-Up Plate to the corresponding well of a fresh 
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96-well plate. If not proceeding immediately to the next stage the plate was sealed and 
stored at −20 °C.  
 
2.1.6  Quantification of purified PCR product and normalization 
2 µL of the purified PCR product was added to 198 µL molecular biology grade water 
(100-fold dilution) and mixed well. Nanodrop 1000 spectrophotometer (Thermo, USA) 
was utilized to determine the purified PCR product yield. Water was used as blank. The 
absorbance at 260 nm was read for each sample. The convention that 1 absorbance unit at 
260 nm equals 50 µg/mL (equivalent to 0.05 µg/µL) was applied for double-stranded PCR 
products. For accurate concentration measurement, three independent dilutions of each 
sample were made and Average Sample OD was obtained by average the 3 readings.  
Average Sample OD: 
Sample Concentration in µg/µL = Average Sample OD X (0.05 µg/µL) X 100 
A typical average sample OD is 0.5 to 0.7. This OD range is equivalent to a final PCR 
product concentration of 2.5 to 3.5 µg/µL. 
 
Next, the samples were normalized by adding appropriate volume of RB Buffer (Clontech, 
USA) by using the formula as shown below: 
X µL RB Buffer = 45 µL – (Y µL purified PCR product) 
Where: 
Y = The volume of purified PCR product that contains 90 µg 
The value of Y is calculated as: 
Y µL purified PCR product = (90 µg) ÷ (Z µg/µL) 
Z = the concentration of purified PCR product in µg/µL 
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Calculated volume of RB Buffer (the value of X) was added to each well of the reaction 
plate in the cooling chamber on ice.  The calculated volume of purified PCR product (the 
value of Y) was added to the corresponding well with RB Buffer. The total volume of each 
well was 45 µL. After normalization, each well contains 90 µg of purified PCR product in 
a volume of 45 µL (or 2 µg/µL).  The plate was then sealed with a clear adhesive film, 
vortexed at medium speed for 2 seconds and spun down at 2000 rpm for 1 minute. If not 
proceeding immediately to the next step, the plate was sealed and stored at –20 °C. 
 
2.1.7  Fragmentation  
Location:  main lab 
Before starting, reagents, equipments and consumables were prepared as follows: 
The thermal cycler block was preheated to 37 °C for 10 minutes prior to loading reactions. 
The Fragmentation Buffer (10X) (Affymetrix, USA) was thawed on ice. Once thawed, it 
was vortexed at medium speed for 3 seconds, pulse spun for 3 seconds and placed on ice. 
2 mL of the AccuGENE water was placed on ice. 
One 1.5 mL Eppendorf tube labeled Frag MM 
Plate of purified, normalized PCR product from the previous stage. 
Two strips of 12 tubes labeled Buffer and FR.   
 
5 µL of Fragmentation Buffer was added to each sample on ice. The label of the 
Fragmentation Reagent (Affymetrix, USA) tube was examined to define the concentration 
(U/ul). Based on the concentration, the Fragmentation Reagent was diluted to 0.05 U/µL 
by adding water and fragmentation buffer in a 1.5 ml tube labelled Frag MM placed on 
ice. The mix was then vortexed at medium speed for 2 seconds and placed back on ice. 
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Example of the dilution for two different concentrations of fragmentation reagent is shown 
in table 2.2.  
 
Table 2.2: Dilution of fragmentation reagent 
Reagent Fragmentation Reagent Concentration 
 2 U/ul 3 U/ul 
Water, molecular grade 525 ul 530 ul 
10X Fragmentation buffer 60 ul 60 ul 
Fragmentation Reagent 15 ul 10 ul 
Total (enough for 96 samples) 600 ul 600 ul 
 
The Fragmentation Reagent was removed from the freezer and immediately placed on ice. 
It was pulse spun for 3 seconds and immediately added to the mix, vortexed at high speed 
for 3 seconds then pulse spun for 3 seconds and immediately placed on ice. On ice, 5 µL of 
diluted Fragmentation Reagent was added to each sample and pipetted up and down 
several times to mix. The plate was tightly sealed, vortexed at medium speed for 2 seconds 
and spun briefly at 2000 rpm at 4°C. The plate was immediately loaded onto the preheated 
block of the thermal cycler (37 °C) and the 500K Fragment program was run as follows:  
35 minutes 37°C 
15 minutes 95°C 
Hold 4°C 
 
The plate was then removed from the thermal cycler, spun down at 2000 rpm for 30 
seconds and placed back on ice. 4 µL of each fragmented PCR product was diluted with 4 
µL gel loading dye. It was then loaded and run on a 4% TBE gel with the BioNexus All 
Purpose Hi-Lo Ladder at 120V for 30 minutes to 1 hour. If the gel matches the example 
shown in figure 2.5, the process was continued immediately to the next step.  
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Figure 2.5: Typical example of fragmented PCR products run on 4% TBE agarose gel at 120V for 
30 minutes to 1 hour. Average fragment size is < 180 bp. 
 
 
2.1.8  Labeling  
Location: Post-PCR clean area 
The following were done before starting this stage: 
The 5X TdT Buffer (Affymetrix, USA) and the GeneChip® DNA Labeling Reagent (30 
mM) (Affymetrix, USA) were thawed on ice. Once thawed, they were vortexed at medium 
speed for 3 seconds, pulse spun for 3 seconds and placed on ice. 
The thermal cycler was turned on and the block preheated to 37°C for at least 10 minutes 
before samples are loaded. 
One 1.5 mL centrifuge tube marked Label MM 
 
For 1 sample, 14 ul 5X TdT Buffer and 2 ul Labeling Reagent (30 mM) were added to the 
1.5 mL centrifuge tube on ice. The TdT enzyme (30 U/µL) was removed from the freezer 
and immediately spun for 3 seconds.  Immediately 3.5 ul of the enzyme was added to the 
master mix, vortexed at medium speed for 3 seconds and then pulse spun for 3 seconds. 
Next, 19.5 µL of Labeling Master Mix was aliquoted to each fragmented DNA samples 
from the previous step. The mixture was pipetted up and down one time.  The plate was 
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sealed tightly, vortexed at medium speed for 3 seconds and spun down at 2000 rpm for 30 
seconds. The plate was placed onto the preheated thermal cycler block, and the 500K 
Label program was run as follows:  
4 hours 37°C 
15 minutes 95°C 
Hold 4°C 
 
 
The plate was then removed from the thermal cycler and spun down at 2000 rpm for 30 
seconds. If not proceeding directly to the next stage, the samples were freeze at −20 °C. 
 
2.1.9  Hybridisation 
The following reagents, equipments and consumables were prepared prior hybridisation:  
The hybridisation oven was turned on and allowed to preheat for 1 hour. The temperature 
was set to 49 °C, the rpm was set to 60 and the rotation was turned on. 
Two heat blocks were turned on; one was preheated to 99 °C and the other to 49 °C. 
If the labelled samples from the previous stage were frozen, they were thawed on the 
bench top, then vortexed at high speed for 3 seconds, spun down at 2000 rpm for 30 
seconds and placed back on ice. 
The arrays were unwrapped and placed on the bench top, septa side up, to warm to room 
temperature for 10–15 minutes. 
Each array was marked with a meaningful designation (e.g., a number) to know which 
sample is loaded onto each array.  
 A 200 µL pipet tip was inserted into the upper right septum of each array. 
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1000 ml 12X MES stock solution was prepared by adding 70.4 g MES hydrate (Sigma-
Aldrich, USA) and 193.3 g MES Sodium Salt (Sigma-Aldrich, USA) to 800 mL molecular 
biology grade water. The reagents and the water were mixed together and volume was 
adjusted to 1,000 mL. The pH should be between 6.5 and 6.7. The solution was filtered 
through a 0.2 µm filter, stored in 2-8ºC and shield from light.  
 
Preparation of hybridisation master mix 
The reagents were added to a 50 mL centrifuge tube in the order as shown in table 2.3 and 
mixed well. For multiple samples, 5% excess was made.  
 
Table 2.3: Hybridisation cocktail master mix 
Reagent 1 array Final concentration in sample 
MES (12X;1.22M) 12 ul 0.056 M 
Denhardt’s solution (50X) 
(Sigma-Aldrich, USA) 
13 ul 2.50X 
EDTA (0.5M) 
(Ambion, USA) 
3 ul 5.77 mM 
HSDNA (10 mg/ml) 
(Promega, USA) 
3 ul 0.115 
Oligo Control Reagent, 0100 
(Affymetrix, USA) 
2 ul 1X 
Human Cot-1 DNA (1 mg/ml) 
(Invitrogen, USA) 
3 ul 11.55 ug/ml 
Tween-20 (3%) 
(Surfact-Amp, USA) 
1 ul 0.0115% 
DMSO (100%) 
(Sigma-Aldrich), USA) 
13 ul 5.0% 
TMACL (5 M) 
(Sigma-Aldrich, USA) 
140 ul 2.69M 
Total 190 ul  
 
Each of the labelled samples was transferred from the plate to a 1.5 mL eppendorf tube. 
190 µL of the Hybridisation Cocktail Master Mix was aliquoted into the labelled DNA 
samples. The hybridisation mix and labeled DNA were heated at 99°C for exactly 10 
minutes to denature. It was then cooled on crushed ice for 10 seconds, spun briefly at 2000 
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rpm in a microfuge to collect any condensate. The tubes were then placed in a heat block 
at 49°C for 1 minute. 200 µL denatured hybridisation cocktail was injected into the array 
and each septa was then covered with a Tough-Spot (figure 2.6). The arrays were then 
hybridised at 49°C for 16 to 18 hours at 60 rpm. 
 
 
 
 
 
 
 
 
 
Figure 2.6: Loading samples onto arrays 
 
2.1.10  Washing, staining and scanning arrays 
The automated fluidics station used for washing and staining the arrays was the 
GeneChip® Fluidics Station 450 (Affymetrix, USA). The arrays were scanned using 
GeneChip® Scanner 3000 7G (Affymetrix, USA). The scanned data were collected and 
extracted by the Affymetrix GeneChip Operating Software (GCOS) v 1.4. 
 
 
 
 
 
Septa covered 
with tough-spots 
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2.1.10.1  Preparation of reagents required for washing and staining 
Wash A: Non-stringent wash buffer (6X SSPE, 0.01% Tween 20) 
For 1000 mL, 300 mL of 20X SSPE (BioWhittaker Molecular Applications/Cambrex, 
USA), 1.0 mL of 10% Tween-20 and 699 mL of water were added together. The solution 
was filtered through a 0.2 µm filter and stored at room temperature. 
 
Wash B: Stringent Wash Buffer (0.6X SSPE, 0.01% Tween 20) 
For 1000 mL, 30 mL of 20X SSPE, 1.0 mL of 10% Tween-20 and 969 mL of water were 
added together. The solution was filtered through a 0.2 µm filter and stored at room 
temperature.  
 
0.5 mg/mL Anti-Streptavidin Antibody 
0.5 mg of Anti-Streptavidin Antibody was resuspend in 1 mL of water and stored at 4°C. 
 
12X MES solution 
The solution was prepared following the method mentioned previously in section 2.1.9. 
 
Stain Buffer 
Stain buffer was prepared by adding 800.04 ul H2O, 360 ul SSPE (20X), 3.96 ul Tween 20 
(3%) and 24 ul Denhardt’s. The solution was mixed. 
 
Streptavidin Phycoerythrin (SAPE) (Sigma-Aldrich, USA) Stain Solution 
6.0 ul Streptavidin Phycoerythrin (SAPE) was added to 594 ul Stain buffer and stored in the 
dark at 4°C. The solution was always prepared immediately before use. A vial containing 
SAPE Stain Solution must be placed in sample holder 1 for each module used. 
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0.5 mg/mL biotinylated antibody solution mix  
6 µL of 5 µg/mL biotinylated antibody (Vector Laboratories, USA) was added to 594 µL 
Stain buffer.  A vial containing Antibody Stain Solution must be placed in sample holder 
2 for each module used. 
 
1X Array Holding Buffer: 
The solution was prepared by adding together 8.3 ml MES stock buffer (12X), 18.5 ml 5 
M NaCl, 0.1 ml Tween-20 (10%) and 73.1 ml water. It was mixed and stored at 2°C to 
8°C, shield from light. A vial containing 820 ul of Array Holding Buffer must be placed in 
sample holder 3 for each module used. 
 
2.1.10.2  Experiment and fluidics station setup 
The following instructions were followed for GeneChip® Operating Software (GCOS) 1.4 
client (1.3 server). 
 
STEP 1: REGISTERING A NEW EXPERIMENT IN GCOS 
 From the File menu click New Experiment. 
The New Experiment window appears in the display pane (figure 2.7). 
• The top half of the display pane refers to the sample and then bottom half refers to the 
experiment. 
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Figure 2.7: GCOS sample entry pane 
 
Enter information into the appropriate boxes. 
• Fields that are highlighted in bold require an entry. 
• Drop-down menus are available for Sample/Project information (default information can 
be used or new information can be entered). 
• The Experiment Name must be unique. 
• Appropriate library files must be installed for a probe array to appear in the drop-down 
menu. 
 
From the File menu click Save As, or click the Save icon on the tool bar to register the 
experiment into the database. 
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STEP 2: PREPARING THE FLUIDICS STATION 
1. Turn on the Fluidics Station using the toggle switch on the lower left side of the 
machine. 
2. Select Run → Fluidics from the menu bar in GCOS. 
The Fluidics Station dialog box appears with a drop-down list for selecting the experiment 
name for each of the fluidics station modules. A second drop-down list is accessed for 
choosing the Protocol for each of the fluidics station modules. Use the radio buttons to 
access each module. 
 
Priming the Fluidics Station 
Priming ensures the lines of the fluidics station are filled with the appropriate buffers and 
the fluidics station is ready to run fluidics station protocols. 
Priming should be done: 
• when the fluidics station is first started. 
• when wash solutions are changed. 
• before washing, if a shutdown has been performed. 
• if the LCD window instructs the user to prime. 
1. To prime the fluidics station, select Protocol in the Fluidics Station dialog box. 
2. Choose Prime_450 for the respective modules in the Protocol drop-down list. 
3. Change the intake buffer reservoir A to Non-Stringent Wash Buffer, and intake buffer 
reservoir B to Stringent Wash Buffer. 
4. Click Run for each module to begin priming. 
5. Follow LCD instructions. 
Probe Array Wash and Stain 
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After 16 to 18 hours of hybridisation, the hybridisation cocktail was removed from the 
probe array and set aside in a microcentrifuge vial. It was stored on ice during the 
procedure or at –80°C for long-term storage. The probe array was filled completely with 
270 µL of Array Holding Buffer. The following instructions were followed for washing 
and staining the arrays using the Fluidics Station 450.  
 
Using the Fluidics Station 450 
1. In the Fluidics Station dialog box on the workstation, select the correct experiment name 
from the drop-down Experiment list. The Probe Array Type appears automatically. 
2. In the Protocol drop-down list, select Mapping500Kv1_450, to control the washing and 
staining of the probe array. 
3. Choose Run in the Fluidics Station dialog box to begin the washing and staining. Follow 
the instructions in the LCD window on the fluidics station. 
4. Insert the appropriate probe array into the designated module of the fluidics station 
while the cartridge lever is in the Down or Eject position. When finished, verify that the 
cartridge lever is returned to the Up or Engaged position. 
5. Remove any microcentrifuge vials remaining in the sample holders of the fluidics 
station module(s) being used. 
6. When prompted to “Load Vials 1-2-3,” place the three vials into the sample holders 1, 2 
and 3 on the fluidics station. 
• Place one vial containing 600 µL Streptavidin Phycoerythrin (SAPE) stain solution mix 
in sample holder 1. 
• Place one vial containing 600 µL anti-streptavidin biotinylated antibody stain solution in 
sample holder 2. 
• Place one vial containing 820 µL Array Holding Buffer in sample holder 3. 
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• Press down on the needle lever to snap needles into position and to start the run. 
Once these steps are complete, the fluidics protocols begin. The Fluidics Station dialog 
box at the workstation terminal and the LCD window displays the status of the washing 
and staining steps. 
7. When staining is finished, remove the microcentrifuge vials containing stain and replace 
with three empty microcentrifuge vials as prompted. 
8. Remove the probe arrays from the fluidics station modules by first pressing down the 
cartridge lever to the eject position. 
9. Check the probe array window for large bubbles or air pockets.  
• If bubbles are present, the probe array should be filled with Array Holding Buffer 
manually, using a pipette. Take out one half of the solution and then manually fill the 
probe array with Array Holding Buffer. 
• If the probe array has no large bubbles, it is ready to scan on the GeneChip® Scanner 
3000 7G. Pull up on the cartridge lever to engage wash block and proceed to Probe Array 
Scan. 
If the arrays cannot be scanned promptly, keep the probe arrays at 4°C and in the dark until 
ready for scanning. Scan must be preformed within 24 hours. 
The fluidics station was shut down after the washing and staining of the probe arrays 
completed (appendix A2). 
 
2.1.10.3  Probe array scan 
Before the probe array was scanned, the following were done: 
The GeneChip Scanner 3000 7G laser was turned on to warmed up the laser at least 10 
minutes prior to scanning. 
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Tough-Spots®, label spots was applied to each of the two septa on the probe array 
cartridge to prevent leaking of fluids from the cartridge during scanning. Excess fluid was 
cleaned from around the septa. 
If necessary, the glass surface of the probe array was clean with a non-abrasive towel or 
tissue before scanning. 
If the probe array was stored at 4°C, it was allowed to warm to room temperature before 
scanning. 
 
Scanning the probe array 
1. Select Run → Scanner from the menu bar. Alternatively, click the Start Scan icon in the 
tool bar. The Scanner dialog box appears with a drop-down list of all unscanned 
experiments. 
2. Select the experiment name that corresponds to the probe array being scanned. A 
previously run experiment can also be selected by using the Include Scanned Experiments 
option box. After selecting this option, previously scanned experiments appear in the drop-
down list. 
3. Click the Load/Eject button and place the array in the scanner. Only one scan is required 
for the GeneChip Scanner 3000 7G. 
4. Once the experiment has been selected, click the Start button. A dialog box prompts to 
load the array into the scanner. 
5. Pixel resolution and wavelength for the GeneChip Scanner 3000 7G are preset and 
cannot be changed. 
6. Open the sample door of the scanner and insert the probe array into the holder. The door 
of the GeneChip Scanner 3000 7G closes automatically. 
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7. Click OK in the Start Scanner dialog box. The scanner begins scanning the probe array. 
When Scan in Progress is selected from the View menu, the probe array image appears on 
the screen as the scan progresses. 
 
2.1.11: Data analysis 
Data analysis was done using Genotyping Console (GTC) 3.0.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
2.2  SP Array 6.0  
The genomic DNA general requirement for SNP array 6.0 is the same as in 250K SNP 
array (refer to Appendix A1). The experiment was carried out following the 
manufacturer’s protocol (Affymetrix, USA) (as summarized in section 2, figure 2.1).  
 
2.2.1  Sample preparation 
The genomic DNA and Ref 103 were thawed on the bench top at room temperature. Once 
thawed, they were placed in the cooling chamber on ice. OD measurement of each sample 
was taken using Nanodrop spectrophotometer.  The convention that 1 absorbance unit at 
260 nm equals 50 µg/mL for double-stranded DNA.was applied.  This convention assumes 
a path length of 1 cm. Based on OD measurements, each sample was diluted in a separate 
well of the 96-well plate to 50 ng/µL using reduced EDTA TE buffer (10 mM Tris, 0.1 
mM EDTA, pH 8.0). The plate was sealed, vortexed at high speed for 3 seconds then spun 
down for 30 seconds. It was then placed back on the top half of the cooling chamber. 
 
2.2.2:  Aliquoting the prepared genomic DNA (gDNA) and controls 
A 96-well plate was marked as shown in Figure 2.8 (a blue marker was used for Nsp (N) 
and a red marker for Sty (S) and placed on the bottom half of the cooling chamber.  
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Figure 2.8: Setup for aliquoting diluted gDNA and controls to a 96-well plate labeled for Nsp and 
Sty digest and ligation 
 
 
Two 5 µL aliquots of the first sample were transferred to wells A1 and A12 of the 
digest/ligate plate (figure 2.8). The remaining samples were transferred in the same 
manner into the appropriate wells. The Ref 103 (positive control) was vortexed for 3 
seconds then spun down for 30 seconds. 5 ul of the control sample was transferred to wells 
G1 and G12. 5 ul of water which served as negative control was transferred into wells H1 
and H12. The plate was tightly sealed. If the next step was not continued immediately, it 
was stored in -20°C.   
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2.2.3  Nsp and Sty restriction enzyme digest 
Before starting this step, the following reagents, equipment and consumables were 
prepared: 
NE Buffer 2, NE Buffer 3 and BSA were thawed on ice. They were then vortexed 3 times, 
1 second each time, pulse spun for 3 seconds and placed in the cooling chamber on ice. 
If the plate of genomic DNA and controls were frozen, it was thawed in a cooling chamber 
on ice. Once thawed, they were vortexed at high speed for 3 seconds and spun down at 
2000 rpm for 30 seconds. 
The thermal cycler was powered on to preheat the lid. The block was left at room 
temperature. 
A 1.5 mL Eppendorf tubes was labeled SP and another one labelled STY. 
 
Preparation of the Nsp Digest Master Mix: 
Usually 8 samples were processed at one time. Therefore, the preparation of the master 
mix was made for 8 samples+15% extra. All the reagents and tubes were placed on ice 
while preparing the master mix. 106.3 ul AccuGene water, 18.4 ul NE Buffer (10X), 1.8 ul 
BSA (100X;10 mg/ml) were added together. The NspI enzyme (10U/ul) was removed 
from the freezer and pulse spun for 3 seconds.  9.2 ul of the enzyme was immediately 
added to the master mix and vortexed at high speed 3 times, 1 second each time. It was 
pulse spun for 3 seconds and placed in the cooling chamber. The tube was labeled SP. 
14.75 µL of Nsp Digest Master Mix was then added to each sample and control for Nsp 
digest.  
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Preparation of the Sty Digest Master Mix: 
The volumes and the reagents used for the preparation of the master mix was the same as 
Nsp Digest Master Mix, except for the enzyme.  The StyI (10U/ul) was added to the 
solution and the tube was labeled STY.  14.75 µL of Sty Digest Master Mix was added to 
each sample and control for Sty1. The total volume in each well is now 19.75 µL. The 
plate was then sealed tightly. Next, the plate was vortexed at high speed for 3 seconds then 
spun down at 2000 rpm for 30 seconds. It was then loaded onto the thermal cycler and the 
Cyto Digest program was run as follows: 
120 minutes 37°C 
20 minutes 65°C 
Hold 4°C 
 
Then, the plate was removed and spun down at 2000 rpm for 30 seconds. The plate was 
stored at –20°C if not proceeding directly to the next step, 
 
2.2.4 Nsp and Sty Ligation  
Location: Pre-PCR clean area:  
The following were prepared before starting this step:  
Adaptor Nsp, Adaptor Sty and T4 DNA Ligase Buffer were thawed on ice, then vortexed 
at high speed 3 times, 1 second each time and pulse spun for 3 seconds. 
The digested samples were thawed on ice. They were then vortexed at high speed for 3 
seconds and spun down at 2000 rpm for 30 seconds. 
One 1.5 mL Eppendorf tube was labeled SP and another was labelled STY. 
The thermal cycler was powered on to preheat the lid and the block was left at room 
temperature. 
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Preparation of the Nsp Ligation Master Mix: 
The preparation of the master mix was done on ice. For 8 samples+15% extra, 23.0 ul T4 
DNA Ligase Buffer (10X) and 6.90 ul Adaptor Nsp were added together in the 1.5 mL 
eppendorf tube labeled SP. T4 DNA Ligase (400 U/ul) was removed from the freezer and 
immediately pulse spun for 3 seconds.  18.4 ul of the enzyme was immediately added to 
the master mix. The solution was vortexed at high speed 3 times, 1 second each time, pulse 
spun for 3 seconds and placed on ice. 5.25 µL of Nsp Ligation Master Mix was then added 
to each Nsp digested sample and control. 
 
Preparation of the Sty Ligation Master Mix: 
The preparation of the master mix was done on ice. For 8 samples+15% extra, 23.0 ul T4 
DNA Ligase Buffer (10X) and 6.90 ul Adaptor Sty (50 uM) were added together in the 1.5 
mL eppendorf tube labeled STY. T4 DNA Ligase (400 U/ul) was removed from the freezer 
and immediately pulse spun for 3 seconds.  18.4 ul of the enzyme was immediately added 
to the master mix. The solution was vortexed at high speed 3 times, 1 second each time, 
pulse spun for 3 seconds and placed on ice. 5.25 µL of Sty Ligation Master Mix was then 
added to each Sty digested sample and control.  
 
The plate was then sealed tightly. It was then vortexed at high speed for 3 seconds, spun 
down at 2000 rpm for 30 seconds and loaded onto the pre-heated thermal cycler and the 
Cyto Ligate program was run as follows: 
180 minutes 16°C 
20 minutes 70°C 
Hold 4°C 
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Dilution of the Ligated Samples: 
Before the dilution was done, the water was placed on ice 20 minutes prior to use. When 
the Cyto Ligate program is finished, the plate was removed and spun down at 2000 rpm for 
30 seconds and placed in a cooling chamber on ice. 75 µL of water was added to each 
reaction. The plate was then sealed tightly, vortexed at high speed for 3 seconds then spun 
at 2000 rpm for 30 seconds. If not proceeding directly to the next step, the plate was stored 
at –20 °C. 
 
2.2.5  Nsp and Sty PCR  
Location: Pre-PCR clean area 
The following were done before starting this step:  
 A double cooling chamber was placed on ice. 
 A 50 mL centrifuge tubes was labelled PCR. 
The thermal cycler in the Post-PCR Area was power on to preheat the lid. The blocks were 
left at room temperature. 
Water (AccuGENE) and GC-Melt were placed on ice. 
TITANIUM Taq, PCR Buffer, dNTPs and PCR Primer 002 (Affymetrix, USA) were 
thawed on ice. They were then vortexed at high speed 3 times, 1 second each time, pulse 
spun for 3 seconds and placed on ice or in the cooling chamber. 
If the diluted ligated samples were frozen, they were thawed in a cooling chamber on ice, 
vortexed at high speed for 3 seconds then spun down at 2000 rpm for 30 seconds. It was 
placed in the top half of the cooling chamber.  
A fresh 96-well plate was labelled as shown in figure 2.9 (blue for Nsp; red for Sty). The 
plate was placed in the lower half of the cooling chamber. 
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Figure 2.9: Labeling the 96-well plate for PCR. 
 
10 µL of each Nsp ligated sample was transferred to the corresponding four wells of the 
PCR plate. 10 µL of each Sty ligated sample was transferred to the corresponding three 
wells of the PCR plate. The remaining ligated Nsp and Sty samples in the plate were 
sealed, labeled and stored at –20 °C.  
 
Keeping the 50 mL centrifuge tube in the cooling chamber, PCR master mix was prepared 
for 8 samples+15% extra by adding 2544 ul AccuGene water, 644 ul TITANIUM Taq 
PCR Buffer (10X), 1288 ul GC-Melt (5M), 902 ul dNTP (2.5 mM each), 290 ul PCR 
primer 002 (100 uM). The TITANIUM Taq DNA polymerase (50X) was removed from 
the freezer and immediately pulse spun for 3 seconds. Immediately 129 ul of the enzyme 
was added to the master mix. The mix was then vortexed at high speed 3 times, 1 second 
each time. 90 µL PCR Master Mix was added to each sample and control on the PCR 
plate.  
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The plate was then sealed tightly, vortexed at high speed for 3 seconds then spun down at 
2000 rpm for 30 seconds. It was then loaded onto the thermal cycler with preheated lid and 
the Cyto PCR program was run as follows:  
3 minutes 94°C 1 cycle 
30 seconds 94°C 
30 seconds 60°C       30 cycles 
15 seconds 68°C 
7 minutes 68°C 1 cycle 
Hold 4°C 
 
 
The plate was then removed from the thermal cycler and spun down at 2000 rpm for 30 
seconds and placed in a cooling chamber on ice.  
 
A fresh 96-well plate was labeled as gel plate. 3 µL of 2X Gel Loading Dye was aliquot to 
each well to be used. 10 µL BioNexus Hi-Lo Ladder was loaded to the first lane of the gel. 
3 µL of Nsp PCR product was transferred from each well in one column only to the 
corresponding wells of the gel plate. The step was repeated for Sty PCR product. The plate 
was sealed, vortexed and then spun down at 2000 rpm for 30 seconds. The total volume 
from each well of the gel plate was loaded onto a 2% TBE gel. The gel was run at 120V 
for 40 minutes to 1 hour. The PCR product distribution was verified between ~250 bp to 
1100 bp (figure 2.10). If not proceeding directly to the next stage, the plate was sealed with 
PCR product and stored at –20 °C. 
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Figure 2.10: Example of PCR products run on 2% TBE agarose gel at 120V for 1 hour. Average 
product distribution is between ~200 to 1100 bp. 
 
 
 
2.2.6  PCR product purification  
Location: Post PCR Area 
If frozen, the PCR products were thawed in a plate holder on the bench top to room 
temperature. The plate was then vortexed at high speed for 3 seconds then spun down at 
2000 rpm for 30 seconds. Seven aliquots of each sample were transferred to the 
appropriately marked 2.0 mL microcentrifuge tube (figure2.11). The PCR plate was then 
examined to ensure that the total volume in each well has been transferred and pooled. 
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Figure 2.11: Pooling PCR products 
 
The magnetic bead (Agencourt Bioscience, Beverly, Massachusetts, USA) stock was 
thoroughly mix by shaking the bottle vigorously. The bottom of the bottle was examined 
to ensure that the solution appears homogenous. Magnetic beads were poured into a 50 mL 
conical tube. 1 mL of magnetic beads was aliquot to each pooled sample. Each tube was 
securely capped and mixed well by inverting 10 times. It was then incubated at room 
temperature for 10 minutes to allow the DNA binds to the magnetic beads. The tubes were 
then loaded with cap hinge facing out onto the microcentrifuge and spun for 3 minutes at 
maximum speed (16,100 rcf). They were then placed on the magnetic stand (Invitrogen 
Corporation, Carlsbad, CA, USA). Leaving the tubes in the rack, the supernatant was 
pipetted off without disturbing the bead pellet and discard. 
 
Next, 1.5 mL of 75% EtOH was added to each tube. The tubes were capped and loaded 
into the foam tube adaptor, fully inserted into the foam to ensure they are secured and 
spaced adequately to balance. The tubes were vortexed at 75% power for 2 minutes, then 
centrifuge for 3 minutes at maximum speed (hinges facing out; 16,100 rcf). They were 
66 
 
then placed on the magnetic stand and the supernatant was pipetted off without disturbing 
the bead pellet and discard. The tubes were then spun for 30 seconds at maximum speed 
(hinges facing out; 16,100 rcf) and placed back on the magnetic stand. Remaining drops of 
ethanol was removed from the bottom of each tube. The tubes were left uncapped at room 
temperature for 15 minutes to allow the remaining ethanol to evaporate. 
 
55 µL of Buffer EB (Qiagen, USA) was added to each tube and they were then capped and 
loaded into the foam tube adaptor. The tubes were then vortexed at 75% power for 10 
minutes to resuspend the magnetic beads. Each tube was examined to ensure that the beads 
were resuspended in homogeneous slurry. If the beads were not fully resuspended, the tube 
was flicked to dislodge the pellet and vortexed an additional 2 minutes. It was then re-
examined. The tubes were centrifuged for 5 minutes at maximum speed (hinges facing out; 
16,100 rcf) and placed on the magnetic stand for 5 minutes. When all the beads had been 
pulled to the side in each tube, 47 µL of eluted sample was transferred to the appropriate 
well on a fresh 96-well plate. The plate was sealed tightly. 
 
2.2.7  Quantitation 
18 µL of water was added to the corresponding wells of a 96-well plate. 2 µL of each 
purified sample was transferred to the corresponding well of the 96-well plate and pipette 
up and down a few times. The result was a 10-fold dilution. The NanoDrop 1000 
spectrophotometer (Thermo, USA) was blanked with water. 2 µL of the diluted sample 
was taken and the OD of each sample at 260, 280 and 320 nm was measured. OD280 and 
OD320 were used as controls. The undiluted concentration for each sample was calculated 
as follows: 
Undiluted sample concentration in µg/µL = OD X 10 
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An acceptable OD should fall within 0.9 to 1.4. 
DNA yield equivalent = 4.5 to 7.0 µg/µL 
This OD range is based on the use of a conventional UV spectrophotometer plate reader 
and assumes a path length of 1 cm. 
• The OD260/OD280 ratio should be between 1.8 and 2.0. 
• The OD320 measurement should be very close to zero (≤ 0.1). 
If not proceeding immediately to the next step, the plate was sealed and stored at –20 °C. 
 
2.2.8  Fragmentation  
Location: post-PCR area 
Equipment, reagents and consumables required in this step were prepared as follows: 
A cooling chamber and the water were placed on ice. 
The Fragmentation Buffer (10X) (Affymetrix, USA) was thawed on ice. It was then 
vortexed 3 times, 1 second each time, pulse spun for 3 seconds and placed in the cooling 
chamber. 
The plate of purified, quantitated samples was placed in the cooling chamber. 
A 1.5 mL eppendorf tube was labelled Frag and placed in the cooling chamber. 
The thermal cycler block was powered on and the block preheated to 37 °C. 
5 µL of Fragmentation Buffer was added to each sample on ice. 
 
Preparation of the fragmentation master mix: 
The concentration of the Fragmentation Reagent written on the tube label was identified 
and recorded. For 8 to 16 samples, the volume of reagents used is as shown in table 2.4. 
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Table 2.4: Fragmentation master mix 
 
 
The appropriate volume of water and fragmentation buffer were added to the Frag tube on 
ice. It was allowed to cool on ice for 5 minutes. The fragmentation reagent (enzyme) was 
removed from the freezer and immediately pulse spun for 3 seconds. Immediately the 
appropriate volume of fragmentation reagent was then added (refer to table 2.4). The 
master mix was vortexed at high speed 3 times, 1 second each time, pulse spun for 3 
seconds and immediately placed on ice. 5 µL of fragmentation master mix were transferred 
to each sample - mixing was not allowed at this stage. The plate was then sealed tightly, 
vortexed at high speed for 3 seconds then spun down for 30 seconds. The samples were 
immediately loaded onto the pre-heated block of the thermal cycler (37°C) and the Cyto 
Fragment program was run as follows:   
35 minutes 37°C 
15 minutes 95°C 
Hold 4°C 
 
 
The samples were then removed from the thermal cycler, spun down for 30 seconds and 
placed in a cooling chamber on ice. 2.0 µL of each sample was removed and placed in a 
96-well plate. 4 µL gel loading dye was added to each sample. 10 µL BioNexus All 
Purpose Hi-Lo Ladder was loaded to the first and last lanes. The samples were loaded and 
run on a 4% TBE gel at 120V for 30 minutes to 1 hour. The gel was inspected and 
compared against the example shown in figure 2.12. 
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 Figure 2.12: Typical example of fragmented PCR products run on 4% TBE agarose gel at 120V 
for 30 minutes to 1 hour. Average fragment size is < 180 bp. 
 
 
2.2.9  Labeling  
Location: Post-PCR area 
The equipment, reagents and consumables required for this step were prepared as follows:  
5X TdT Buffer (Affymetrix, USA) and DNA Labeling Reagent (Affymetrix, USA) were 
thawed on ice. When thawed, each reagent was vortexed at high speed 3 times, 1 second 
each time, pulse spun for 3 seconds then place in the cooling chamber. 
The thermal cycler block was heated to 37 °C before samples were loaded. 
A cooling chamber was placed on ice. 
A 1.5 mL centrifuge tube was labeled LBL and placed in the cooling chamber. 
 
All reagents and tubes were kept on ice while preparing the Labeling Master Mix. For 8 
samples+15% extra, 128.8 ul 5X TdT Buffer and 18.4 ul DNA Labeling Reagent were 
added to the 1.5 mL centrifuge tube on ice. The TdT enzyme (30 U/ul) was removed from 
the freezer and immediately pulse spun for 3 seconds then immediately placed back in the 
cooler. 32.2 ul TdT enzyme was added to the master mix, vortexed at high speed 3 times, 1 
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second each time, pulse spun for 3 seconds. 20 µL of Labeling Master Mix was aliquot to 
each sample and pipetted up and down one time to ensure that all of the mix were added to 
the samples. The plate was sealed tightly, vortexed at high speed for 3 seconds then spun 
down for 30 seconds. It was then placed on the pre-heated thermal cycler block and the 
Cyto Label program (table 28) was run as follows:  
4 hour 37°C 
15 minutes 95°C 
Hold 4°C 
 
The plate was then removed from the thermal cycler and spun down for 30 seconds. If not 
proceeding directly to the next stage, the samples were stored at –20°C. 
 
2.2.10  Target hybridisation 
The equipment, reagents and consumables required for this step were prepared as follows:  
 The labeled samples from the previous stage were allowed to thaw on the bench top at 
room temperature if frozen. It was then vortexed at high speed for 3 seconds then spun 
down for 30 seconds and placed in a cooling chamber on ice. 
The oven was turned on and the temperature set to 50°C. The rpm was set to 60. The 
rotation was turned on and allowed to preheat for 1 hour before loading arrays. 
 The thermal cycler was powered on to preheat the lid. The block was left at room 
temperature. 
The arrays were unwrapped and placed on the bench top, septa-side up. 
The front or back of each array was marked with a designation that will identify which 
sample was loaded onto each array. 
The arrays were allowed to warm to room temperature on the bench top 10 to 15 minutes. 
A 200 µL pipet tip was inserted into the upper right septum of each array. 
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500 mL 12X MES stock solution (1.25 M MES, 0.89 M [Na+] ) was prepared. The recipe 
is the same as in the section 2.1.9. 
Preparation of hybridisation master mix for 8 samples+15% extra was done by adding 
110.4 ul MES (12X;1.25 M), 119.6 ul Denhardt’s solution (50X), 27.6 ul EDTA (0.5 M), 
27.6 ul Herring Sperm DNA (10 mg/ml), 18.4 ul Oligo Control Reagent 0100, 27.6 ul 
Human Cot-1 DNA (1 mg/ml), 9.2 ul Tween-20, 119.6 ul Dimethyl sulfoxide (DMSO) 
(100%), 1288.0 ul 5 M Tetramethylammonium Chloride (TMACL). The solution was 
mixed and placed on ice. 
 
190 µL of Hybridisation Master Mix was added to each sample. The plate was then sealed 
tightly, vortexed for 30 seconds then spun down for 30 seconds and placed onto the 
thermal cycler. The Cyto Hyb program was run as follows:  
10 minutes 95°C 
Hold 49°C 
 
  
The lid of the thermal cycler was opened when the temperature reached 49°C. 200 µL of 
the first sample were removed and immediately injected into an array. The septa on the 
array were covered with a Tough-Spot. It was pressed firmly to ensure a tight seal to 
prevent evaporation and leakage. When 4 arrays were loaded and the septa were covered, 
the arrays were loaded into an oven tray evenly spaced. The tray was then immediately 
placed into the hybridisation oven. It was not allowed to sit at room temperature for more 
than approximately 1 minute. The oven was ensured balanced and the trays were rotating 
at 60 rpm. This process was repeated until all samples were loaded onto arrays and were 
placed in a hybridisation oven. The arrays were allowed to rotate at 50 °C, 60 rpm for 16 
to 18 hours. 
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2.2.11 Washing, staining and scanning arrays 
The Fluidics Station 450 was used to wash and stain the arrays. It is operated using either 
GCOS or Affymetrix GeneChip® Command Console (AGCC) software. 
Detail information on these applications can be found in Affymetrix GeneChip® 
Command Console™ User’s Guide  
(http://www.affymetrix.com/support/technical/byproduct.affx?product=commandconsole) 
Before washing and staining were performed, the fluidics station was primed using AGCC 
software.  
 
Prime the Fluidics Station 
The Fluidics Station 450 was used to wash and stain the arrays. 
To prime the Fluidics Station: 
1. The Fluidics Station turned on. 
2. The Fluidics Station was primed by: 
• Select protocol Prime_450 for each module 
• Intake buffer reservoir: use on-Stringent Wash Buffer 
• Intake buffer reservoir B: use Stringent Wash Buffer 
 
After 16 to 18 hours of hybridisation, the arrays were removed from the oven. The 
hybridisation cocktail from each array was extracted and transferred to the corresponding 
well of a 96-well plate. It can be stored on ice during the procedure or at –80 °C for long-
term storage. Each array was filled completely with 270 µL of 1X Array Holding Buffer. 
The arrays were allowed to equilibrate to room temperature before washing and staining. 
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Buffers and solutions required for washing and staining are the same as used in 250K array 
in section 2.1.10.  
 
To wash and stain the array using fluidics station 450 for AGCC: 
1. Sample name was selected in AGCC. 
2. The protocol GenomeWideSP6_450 was selected. 
3. The protocol was then started and the instructions in the LCD were followed on the 
fluidics station. 
Details on how to handle the arrays on the fluidics station can be found in the appropriate 
Fluidics Station User’s Guide, or Quick Reference Card (P/N 08-0093 for the Fluidics 
Station450) 
(https://www.affymetrix.com/support/downloads/quick_reference_cards/fs450_agcc_qrc.p
df). 
4. An array was inserted into the designated module of the fluidics station while the 
cartridge lever was in the Down or Eject position. 
5. When finished, the cartridge lever was returned to the Up or Engaged position. 
6. Any vials remaining in the positions of the fluidics station module(s) being used were 
removed.  
7. When prompted to “Load Vials 1-2-3,” the three vials were placed into positions 1, 2 
and 3 on the fluidics station. 
a. One vial containing 600 µL Streptavidin Phycoerythrin (SAPE) stain solution mix was 
placed in position 1. 
b. One vial containing 600 µL anti-streptavidin biotinylated antibody stain solution was 
placed in position 2. 
c. One vial containing 1 mL Array Holding Buffer was placed in position 3. 
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d. the needle lever was pressed down to snap needles into position and to start the run. 
 
Once these steps are complete, the fluidics protocol begins. The Fluidics Station dialog 
box at the workstation terminal and the LCD window displays the status of the washing 
and staining steps. 
 
8. When staining was finished, the microcentrifuge vials containing stain were removed 
and replace with three empty vials as prompted. 
9. The arrays were removed from the fluidics station by first pressing down the cartridge 
lever to the eject position. 
10. Presence of large bubbles or air pockets was checked by looking at the array window. 
If there were bubbles, these steps were taken: 
1) One-half of the solution was manually removed, then  
2) The array was manually filled with Array Holding Buffer. 
11. If there were no bubbles, the array is ready for scanning.  
If the arrays cannot be scanned promptly, they were store at 4°C in the dark until ready for 
scanning. Scan must be performed within 24 hours. 
12. When finished washing and staining, the fluidics station was shut down following the 
procedure in appendix A2. 
 
Scanning Arrays 
The GeneChip Scanner 3000 7G was used in this experiment. It is controlled by GCOS or 
AGCC software. The scanner has to be turned on at least 10 minutes before use. If the 
arrays were stored at 4°C, they were allowed to warm to room temperature before 
scanning. The glass surface of the array was cleaned with a non-abrasive towel or tissue 
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before scanning. Any excess fluid from around the septa on the back of the array cartridge 
was cleaned. Both septa were carefully covered with Tough Spots. The spots were pressed 
firmly to ensure they remain flat. An array was inserted into the scanner and tests the 
autofocus to ensure the spots do not interfere with the focus. If a focus error message was 
observed, the spot was removed and a new spot was applied. The arrays were scan by 
following these steps: 
1. The sample name that corresponds to the array being scanned was selected from AGCC. 
2. Following the AGCC instructions as appropriate, the array was loaded into the scanner 
and the scan begin. 
 
2.2.12 Data analysis 
Data analysis was done using Genotyping Console (GTC) 3.0.2 
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2.3  Multiplex ligation-dependent probe amplification (MLPA) 
This protocol is based by the procedure recommended by MRC-Holland. It has five parts: 
-DNA denaturation and hybridisation of SALSA probes to DNA 
-ligation reaction 
-PCR of ligation products 
-separation by capillary electrophoresis 
-data analysis 
 
2.3.1   DNA denaturation and hybridisation of the SALSA probes 
A set of 0.2 ml thin-walled PCR tubes were labeled with patient’s initials or lab          
number on the lid or on the side of the tube. Each DNA sample (50-250 ng) was diluted 
with TE to 2.5 ul in a 0.2 ml labelled tube (for example, 0.5 ul of a 500 ng/ul DNA sample 
and 2 ul TE). A drop of mineral oil was added to each tube. The tubes were then loaded 
onto a PCR machine with a heated lid and the MLPA program was started as follows: 
5 minutes 98°C 
25°C pause 
1 minute 95°C 
60°C pause 
 
SALSA probe mix and MLPA buffer tubes were taken out of the freezer to thaw. For one 
sample, 0.75 ul SALSA probe mix and 0.75 ul MLPA buffer was added together.  The 
solution was pipetted up and down to mix. 1.5 ul of the mix was added to PCR tube whilst 
still at 25ºC on the PCR block and pipetted up and down gently to mix. Lids were closed 
firmly and proceed to next step of the program – incubation for 1 minute at 95ºC then 16 
hours at 60ºC. 
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2.3.2   Ligation reaction 
A master mix for the ligase reaction was prepared less than 1 hour before use. For 1 
reaction, 1.5 ul ligase-65 buffer A was added with  1.5 ul ligase 65 buffer, 0.5 ligase 65 
and 12.5 ul water. Temperature of the PCR machine was reduced to 54ºC by proceeding to 
the next step of the PCR program. The ligation reaction program was started as follows: 
15 minutes 54ºC 
5 minutes 98ºC 
4ºC pause 
 
Whilst at 54ºC, 15 ul of the ligase 65 mix was added to each sample whilst still on the 
block and mixed by repeated pipetting. This was done as quickly as possible. The tubes 
were close firmly. It was then incubated for 10-15 minutes at 54ºC then heated for 5 
minute at 98ºC to deactivate the ligase enzyme. Following 98ºC ligase inactivation 
treatment, samples can be stored at 4ºC for up to 1 week or for longer at –20ºC. 
 
2.3.3   Polymerase chain reaction (PCR) 
A second set of 0.2 ml thin walled PCR tubes were labeled as previously. PCR Buffer 
master mix was prepared by adding 2 ul 10X SALSA PCR Buffer and 13 ul water. 15 ul of 
the master mix was transferred into the labeled 0.2 ml thin walled PCR tubes. 5 ul of each 
of the MLPA ligation reaction was transferred to the correctly labeled tube.The tubes were 
then loaded onto the PCR machine with heated lid and heat to 60ºC by proceeding to the 
next step of the MLPA program. The PCR program applied was as follows:  
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60ºC pause 
30 seconds 95ºC 
30 seconds 60ºC      33 cycles 
60 seconds 72ºC 
20 minutes 72ºC 
4ºC pause 
 
Next, Polymerase master mix was prepared by adding 1 ul SALSA PCR primers, 1 ul 
SALSA enzyme dilution buffer, 0.25 ul SALSA polymerase and 2.75 ul water. While at 
60ºC 5 ul polymerase mix was added to each tube and mix by pipetting up and down. The 
lids were then closed firmly. The PCR cycles was run by proceeding to the next step of the 
MLPA program. The PCR products may be stored for 1 week at 40ºC or indefinitely at –
20ºC. 
 
2.3.4   Separation of amplification products by capillary electrophoresis 
0.2 ml tubes were labelled with sample/lab name. 90 ul of water was added into each tube. 
10 ul of the PCR product was then transferred into the tube to make a dilution of 1:10. Hi-
Di (Applied Biosystem, USA) master mix was prepared by adding 500 ul Hi-Di formamide 
and 4 ul LIZ-500 (Applied Biosystem, USA). 1 ul of the diluted PCR products were then 
pipette out into the well of the plate. Only the uneven rows of the plate were used. 10 ul of 
Hi-Di mix was added into the PCR products in the well. The plate was then sealed and 
pulse spin for 30 seconds. It was then loaded into a thermal cycler to denature the DNA. 
The program used was 96ºC for 5 minutes with no heated lid.  
 
The plate was then immediately snap-chilled and ready to be loaded on capillary 
electrophoresis for fragment analysis. The amplified products were separated by capillary 
electrophoresis equipped with fragment analysis software. Relative amounts of probe 
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amplification products as compared to a control DNA sample reflect the relative copy 
number of target sequences. Intensity peaks or electropherograms were produced and 
analysed to determine genomic deletion or amplification.  
 
 
2.3.5    Data analysis 
 
SoftGenetics GeneMarker v1.85 (ABI) software was used to analyse MLPA worksheets 
ran on the capillary electrophoresis system. The analysis was done according to the steps 
described in the website http://www.softgenetics.com/GeneMarkerMLPA.html 
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3 Array CGH analysis of 3p25-p26 deletion (3p- syndrome) 
 
3.1 Introduction 
 
Distal 3p25-p26 deletion (3p- syndrome) is a rare contiguous gene disorder and less than 
30 cases have been reported since it was first described by Verjaal and de Nef  (Verjaal 
and De Nef, 1978; Merrild et al., 1981; Schwyzer et al., 1987; Narahara et al., 1990; 
Nienhaus et al., 1992; Mowrey et al., 1993; Phipps et al., 1994; Knight et al., 1995; 
Drumheller et al., 1996; McClure et al., 1996; Angeloni et al., 1999; Benini et al., 1999; 
Green et al., 2000; Kariya et al., 2000; Cargile et al., 2002; Endris et al., 2002; Fernandez 
et al., 2004; Higgins et al., 2004; Malmgren et al., 2007). Characteristic feature of distal 
3p- syndrome include low birth weight, microcephaly, trigonocephaly, hypotonia, 
psychomotor and growth retardation, ptosis, telecanthus, downslanting palpebral fissures 
and microagnathia. In addition, postaxial polydactyly, renal anomalies, cleft palate, 
congenital heart defects especially atrioventricular septal defects (AVSDs), preauricular 
pits, sacral dimple and gastrointestinal anomalies occur variably. Although intellectual 
deficits are almost invariably associated with cytogenetically visible 3p deletions, rare 
patients with a 3p25-p26 deletion and normal intelligence or only mild abnormalities have 
been described (Knight et al., 1995; Jervis et al., 2002; Sklower-Brooks et al., 2002; 
Takagishi et al., 2006).  
 
The two main aims of my studies were to investigate phenotype-genotype correlations and 
to accurately map the deletion breakpoints on the chromosome 3p.  Previous studies had 
used microsatellite markers and molecular cytogenetic methods to accomplish this. Thus in 
a study of five patients, it was found that congenital heart defects were present only in the 
81 
 
three patients with the most centromeric deletions (Phipps et al., 1993). Further mapping 
studies suggested that the 3p25 congenital heart disease (CHD) susceptibility locus 
mapped between D3S1263 and D3S3594, a distance of 3.7 cM (Green et al., 2000). 
Subsequently Malmgren et al., (2007) further refined the CHD gene localization interval to 
a 450 kb region and following a report that three of  50 subjects with sporadic AVSD had a 
CRELD1 missense substitution, CRELD1 was proposed as a candidate 3p25 CHD gene 
(Robinson et al., 2003). However, CRELD1 maps outside the 3p- CHD target intervals 
identified by both Green et al., (2000) and Malmgren et al., (2007) and in a previous study 
from Birmingham there was no evidence of pathogenic CRELD1 mutations in 49 sporadic 
AVSD cases (Zatyka et al., 2005). A number of genes have been implicated in the 
pathogenesis of mental retardation associated with 3p- syndrome including: CHL1(CALL) 
(at 213 kb from p-telomere), ITPR1 (4,700 kb), and SRGAP3 (9,000 kb) (Angeloni et al., 
1999; Endris et al., 2002; Higgins et al., 2004). In addition, Fernandez et al., (2004) 
reported a balanced t(3;10)(p26;q26) translocation associated developmental delay (full 
scale IQ of 73) and some features of 3p deletion syndrome (short stature, downslanting 
palpebral fissures and ptosis) that disrupted CT4.  
 
3.2    Materials and methods 
3.2.1 Patients 
Sixteen cases of 3p25-p26 deletion were studied. The clinical details of 10 patients were 
reported previously (Green et al., 2000; Zatyka et al., 2005). Four of these cases (P1, P2 
and P4, P5) had a congenital heart defect and all had mental retardation. Three of the four 
new cases (P13, P14, and P15) showed characteristic features of 3p- syndrome 
(microcephaly, developmental delay, mental retardation, ptosis, micrognathia) and in 
addition P15 also had congenital heart disease (AVSD). One patient, P16, was ascertained 
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incidentally via recurrent miscarriages and did not show any features of 3p- syndrome (in 
particular there was no evidence of mental retardation). Following the publication of Shuib 
et al (2009), two further cases were ascertained (P17 and P18). P17 had an unbalanced 3,7 
translocation (karyotype 46,XX,der(3)t(3;7)(p25.3;p21.3)). P18 was presented with a 
tetralogy of fallot and has abnormal karyotype 47,XXY add(3)p25.3.ish 
add(3)(D3S4559)mat. 
 
Information on clinical phenotype was obtained from the referring clinicians and hospital 
records. The studies were approved by the South Birmingham Research Ethics Committee 
and informed consent was obtained (from parents except for the one case without mental 
retardation).  
 
3.2.2  Array analysis 
250K Sty1 SNP mapping arrays were applied in 14 (P1-P16) cases and SNP 6.0 arrays in 
two cases, P17 and P18.  The methods applied are described in detail in sections 2.1 and 
2.2.  
For 250K SNP arrays, genotypes were generated using the BRLMM algorithm using 
default settings. Copy number analysis was performed with Affymetrix Genotyping 
Console 2.0 (GTC v2.0) using the CNAT v4.0 algorithm. Deletion intervals were 
automatically called by Hidden Markov Model (HMM) generated Copy Number (CN) 
state intervals with genomic smoothing set at 100 kb. In addition to this automated calling 
estimate I also derived an estimate of the breakpoint by analyzing the unsmoothed 
Affymetrix genotyping console log2 ratios with the Nexus 3.1 copy number analysis 
software (Biodiscovery, El Segundo, CA). This utilizes a rank segmentation algorithm. 
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The deletion breakpoint estimates (approximated to the nearest 50 kb) from both analyses 
are presented but the discussion is based on the Nexus estimates. 
 
The SNP Array 6.0 platform offers the genotype calling algorithm "Birdseed" to determine 
the genotypes of 909,622 SNPs (Affymetrix, Inc. http://www.affymetrix.com/index.affx). 
The Birdseed algorithm performs a multiple-chip analysis to estimate signal intensity for 
each allele of each SNP, fitting probe-specific effects to increase precision, and then makes 
genotype calls by fitting a Gaussian mixture model in the two-dimensional A-signal vs. B-
signal space, using SNP-specific models to improve accuracy. In addition, this array also 
contains 945,826 copy number probes designed to interrogate CNVs in the genome; 
115,000 of these probes interrogate previously identified CNVs while the remaining 
831,000 are distributed across the genome for improved CNV detection (Affymetrix, Inc. 
http://www.affymetrix.com/index.affx). Copy number analysis was performed with 
Affymetrix Genotyping Console v3.0.2 (GTC v3.0.2)  
 
3.2.3  MLPA analysis 
MLPA was applied using a SALSA P016B VHL kits (MRCHolland, Amsterdam, The 
Netherlands) that contains specific probes to detect deletions of four genes: FACD2 (at 
10043.1 kb from pter), VHL (10158.3 kb), IRAK2 (10181.6 kb), and GHRL (10302.4 kb) 
on chromosome 3p25. The analysis was performed according to the manufacturer’s 
instructions (for full details see section 2.3). The ligation products were amplified on a 
Tetrad thermal cycler (Peltier 225 from MJR). PCR products were then separated by 
capillary electrophoresis on a Beckman Coulter CEQ 8000 genetic analyser. 
Electropherograms were analysed using Beckman Coulter Fragment Analysis software all 
from Beckman Coulter. DNA dosage was estimated using an in house developed Excel 
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dosage calculator using peak heights. All results which fell outside of a predetermined 
dosage range were highlighted. Deletions were indicated by a relative dosage value of 0.5 
and duplications by 1.5. 
 
3.3    Results 
3.3.1 Array analysis results and correlation with MLPA copy number analysis 
 
The reference set for 250K Sty1 mapping arrays was 48 samples from the HapMap project 
(www.hapmap.org/downloads/raw_data/affy500k/) and 270 HapMap individuals of 
various populations for SNP 6.0 (Goldstein and Cavalleri, 2005). Six normal controls were 
used for MLPA. The average genotype call rate for the 14 samples of 250K Sty was 
97.70±1.95% and 96.11±1.82 for the two samples of SNP6.0 (P17 and P18). Analysis of 
3p copy number status on the 14 samples was performed with Affymetrix Genotyping 
Console v2.0 and Nexus 3.1 copy number analysis software (Table 3.1, figure 3.1 and 
figure 3.2) while  Affymetrix Genotyping Console v3.0.2 was used for the two samples of 
SNP6.0 (figure 3.3). Microarray and the MLPA copy number analysis results were 
concordant (see table 3.1). 
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Table 3.1: Clinical and molecular cytogenetics features of 3p- syndrome patients studied 
 
                 Clinical features 
 
 
 
 
 
 
Chrom.  
region  
affected 
 
Deletion 
size by 
Affymetrix 
Genotyping 
Console 
v2.0 or 
v3.0.2 
(Mb)* 
Deletion 
breakpoints 
by exus 
3.1 copy 
number 
analysis 
software  
(El 
Segundo, 
CA)* 
 
 
 
 
 
 
 
 
MLPA probes 
deleted 
 
 
 
 
 
 
 
Deletion 
type 
 
 
       Congenital  
          heart  
           disease 
 
 
 
 
 
Mental 
 retardation 
P1 Yes Yes 3p25.2-pter 12.65 0-12.55 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P2 Yes Yes 3p25.2-pter 12.25 0-12.20 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P4 Yes Yes 3p25.2-pter 12.05 0-12.05 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P5 Yes Yes 3p25.3-pter 11.35 0-11.30 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P6 No Yes 3p25.3-pter 11.15 0-11.10 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P7 No Yes 3p25.3-pter 11.10 0-11.05 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P8 No Yes 3p25.3-pter 10.20 0-10.31 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P9 No Yes 3p25.3-pter 9.95 0-10.01  terminal 
P10 No Yes 3p25.3-pter 9.55 0-9.50  terminal 
P11 No Yes 3p25.3-pter 9.60 0-9.55  terminal 
P13 No Yes 3p25.3-pter 10.90 0-10.90 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P14 No Yes 3p25.3-p26.1 6.30 4.40-10.65 FANCD2,VHL,
IRAK2,GHRL 
interstitial 
P15 Yes Yes 3p25.3-pter 11.50 0-11.55 FANCD2,VHL,
IRAK2,GHRL 
terminal 
P16 No No 3p26.1-pter 8.60 0-8.55  terminal 
P17 Yes NA 3p26.1-pter 7.67 ND  terminal 
P18 NA NA 3p26.1-pter 8.53 ND  terminal 
 
The size of the deleted region was estimated by Affymetrix Genotyping Console 2.0 (GTC v2.0) or 
GTCv3.0.2 using the CNAT v4.0 algorithm and Birdseed v1 algorithm respectively. In addition to 
this automated calling estimate, primary unsmoothed log 2 ratios of 250K Sty data were imported 
into Nexus 3.1 and analysed using the Rank Segmentation algorithm and estimates of the deletion 
breakpoints obtained. 
 
Abreviations: pter, p terminal; Mb, megabase; ND, not done; NA, not available 
 
*both the deletion size and Nexus deletion breakpoints were approximated to the nearest 50kb. 
MLPA results reported for probes at FANCD2 (at 10043.1 kb from pter), VHL (10158.3 kb), 
IRAK2 (10181.6 kb) and GHRL (10302.4 kb)  
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Figure 3.1: Mapping of the extent of deletions at chr 3p25-p26 in the 14 patients studied. Relative 
genomic locations of 3p deletions is shown using Nexus 3.1 software (El Segundo, CA), calculated 
from unsmoothed log2 ratios generated in Genotyping Console v2.0 using the Rank Segmentation 
algorithm with default settings. The consensus region of overlap is a 4.2 Mb region (shown as an 
aggregate bar at 100%) containing 7 HGNC mapped genes. The percentage penetrance for all cases 
within the area of analysis is illustrated by the solid red area. The open boxes and solid bars below 
the percentage penetrance represent genes within the area of analysis. The horizontal pink lines 
represent copy number variants within the area of analysis. The horizontal red lines at the bottom 
of the figure represent the extent of deletion within the area of analysis for each individual case. 
Please refer to table 3.1 for the genomic coordinates and deletion size for each individual case. 
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Figure 3.2: Sample P11 chromosome 3 unsmoothed log2 ratios imported into Nexus 3.1 and 
analysed using the Rank Segmentation algorithm. The horizontal red line at the bottom of the 
ideogram represents the extent of deletion within the area of analysis. Probe-level view of the 
focused chromosome 3p25.3-pter array indicating the boundaries of the breakpoint in the 3p25.3-
pter is shown in the lower panel. Blue dots depict single SNP signal intensity while horizontal 
black segmentation bar present an average value of SNP signal intensity. The deletion 3p25.3-pter 
is observed as a reduction in copy number (-0.5=heterozygous deletion, 0= diploid DNA copy 
number) as denoted by the black segmentation bar.  The proximal breakpoint denoted by the black 
segmentation bar is called at 9.56 Mb.  
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Figure 3.3: Sample P17 (upper panel) and P18 (lower panel) chromosome 3 log2 ratio analysed 
using the Birdseed v1 algorithm for SNP 6.0 arrays. Blue and green dots depict single SNP signal 
intensity in P17 and P18 respectively.  The horizontal red bars represent the extent of deletion 
within the area of analysis for each individual case. The proximal breakpoint in P17 and P18 is 
called at 7.67 Mb and 8.53 Mb respectively. Ideogram of chromosome and genes within the area of 
analysis are displayed at the bottom of the figure.    
 
 
3.3.2 Array-based 3p25-p26 deletion analysis and genotype–phenotype correlations 
Deletions ranged from ~6.3 Mb (P14) to 12.65 Mb (P1) (see Table 3.1). Fifteen of 16 
deletions were terminal and the only interstitial deletion (P14) was also the smallest. No 
clear breakpoint hotspots were detected. Ten patients (P1–P8 and P13–P15) were 
hemizygous for VHL, however to date none of these children have yet been reported to 
have features of von Hippel–Lindau disease. Array based analysis refined the 3p deletion 
breakpoints in the four previously reported patients with CHD to between 11.3 and 12.55 
Mb. In addition, a new 3p- syndrome patient (P15) with CHD was investigated and found 
to have a terminal deletion with a breakpoint at 11.55 Mb. The most centromeric 
breakpoint in the nine patients without CHD (P6–P14) was ~11.1 Mb and thus there was 
P17 
P18 
89 
 
an ~200 kb interval in the breakpoints between P5 and P6 (with and without CHD 
respectively). All but one of the 16 patients with cytogenetically visible distal 3p deletions 
for whom detailed psychomotor status was available had psychomotor retardation. 
 
The exception (P16) had the smallest terminal deletion with a breakpoint at ~8.6 Mb from 
pter. The smallest terminal deletion associated with psychomotor delay was detected in 
P10 and this suggested that the critical interval for mental retardation associated with distal 
3p deletions was ~950 kb interval between the breakpoints in P16 and P10. This interval 
was deleted in the one patient with an interstitial deletion (P14) who also had 
developmental delay. 
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3.4    Discussion 
This is the first report of high resolution (~238,000 probes, mean inter-probe distance 
within ~12.0 kb for 14 patients and more than 1.8 million markers, mean inter-probe 
distance within 680 bases for 2 patients) array-based analysis of a cohort of distal 3p 
deletion syndrome patients. The results of 14 patients have been published (Shuib et al., 
2009). Previously Affymetrix 250K oligonucleotide arrays have been used successfully to 
map constitutional deletions (Ballif et al., 2007; Kirov et al., 2008) and the results of 
MLPA and array analyses were concordant in this study. The SNP6.0 arrays have been 
applied for studies of common diseases such as diabetes and heart disease (McPherson et 
al., 2007; Saxena et al., 2007; Zeggini et al., 2007), detection of UPD and characterisation 
of chromosome breakpoint in chronic lymphocytic leukemia (Hagenkord et al., 2010) and 
identification of copy number alterations and LOH in tumours (Gorringe et al., 2009; 
Greenman et al., 2010). The arrays were also successfully applied on fresh frozen tissue 
(Tuefferd et al., 2008) as well as archived samples (Tuefferd et al., 2008; Bucasas et al., 
2009). 
 
The majority of distal 3p deletions are terminal deletions and only one interstitial deletion 
was detected. Although a patient analysed by Dijkhuizen et al., (2006) had a complex 3p 
abnormality in which an ~4 Mb distal deletion was accompanied by a more proximal 
duplication, all of the patients in my study appeared to have ‘‘pure’’ deletions. In contrast 
to disorders such as Jacobsen syndrome (Tunnacliffe et al., 1999; Jones et al., 2000), there 
was no close clustering of terminal deletion breakpoints (although the breakpoints in P6 
and P7 mapped within an ~50 kb interval) in my study.  
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I found that the candidate interval for a 3p25 CHD susceptibility locus mapped to an ~200 
kb interval. Two known genes contained in the region are HRH1 and ATG7. The histamine 
receptor H1 (HRH1) gene encodes a G protein-coupled receptor that mediates diverse 
neuronal and peripheral actions of histamine. The H1 receptor is expressed by various 
peripheral tissues, such as smooth muscle, and by neurons in the brain, where histamine 
may be involved in the control of wakefulness, mood, and hormone secretion. 
ATG7/APG7L is the human homolog of yeast Apg7, an ubiquitin-activating enzyme E1-
like protein essential for the Apg12 conjugation system that mediates membrane fusion in 
autophagy (Tanida et al., 2001). To date neither of these genes has been linked to 
cardiovascular development and several known genes such as ATP2B2, FBL2, TIMP4, 
and SEC13R, which are expressed in the heart, were shown to map outside the target 
interval. Potential complicating factors in the mapping of a 3p25 CHD locus using 3p 
deletions include (a) that some patients with more telomeric deletions might be non-
penetrant and (b) that genes that are outside of the CHD critical interval might have altered 
expression as a result of deleted regulatory regions. The latter possibility is difficult to 
exclude since regulatory regions may exert long-range influences over gene expression 
(Crolla and Van Heyningen, 2002; Velagaleti et al., 2005). Although CRELD1 has been 
suggested as a 3p25 AVSD susceptibility locus (Robinson et al., 2003), it maps ~1Mb 
distal to the ~200kb target interval that I found and CRELD1 was deleted in four patients 
without CHD (Zatyka et al., 2005). Although such cases might be non-penetrant, to date 
all 3p- patients with CHD have had the most centromeric breakpoints and so there is no 
direct evidence for non-penetrance (although this possibility cannot be exclude formally) 
(Malmgren et al., 2007). Analysis of further 3p- patients with and without CHD would be 
helpful in confirming this interpretation.  
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Another potential strategy for identifying the precise 3p25 AVSD gene would be to 
undertake mutation analysis of candidate genes in sporadic AVSD cases. Similar studies of 
CRELD1 identified missense substitutions (not present in >200 control chromosomes) in 
~4% of sporadic AVSD patients (Robinson et al., 2003; Zatyka et al., 2005). However the 
relevance of these rare substitutions to AVSD pathogenesis is unclear. One intriguing 
possibility is that CHD in 3p- cases might result from deletion of two genes (e.g. CRELD1 
and a gene within the more centromeric target interval). Such a model, although consistent 
with the 3p deletion mapping data would imply that a single mutation in either gene would 
not be sufficient to cause AVSD and so analysis of sporadic AVSD cases would not 
unequivocally identify a single 3p25 AVSD susceptibility gene.  
 
Previously a number of genes (e.g., CHL1 (CALL), CT4, LRR1, SRGAP3/MEGAP, 
and ITPR1) have been suggested to be responsible for psychomotor retardation in 3p- 
syndrome. In addition, a locus for non-syndromic autosomal recessive mental retardation 
(MRTA-OMIM 607417) was mapped to 4.2 Mb in 3p26.3-p26.1 between loci D3S3630 
and D3S1304 containing nine known genes (Higgins et al., 2004). Although most patients 
with a cytogenetically visible 3p deletion have psychomotor retardation, a few rare 
individuals with normal intelligence have been described (Knight et al., 1995; Endris et al., 
2002; Takagishi et al., 2006).  
 
P16 is a phenotypically normal patient with a terminal deletion of ~8.6 Mb. The deleted 
region contains 16 known genes which included ITPR1, CT4, CHL1, LRR1, 
SETMAR, IL5RA, and TRT1. Takagishi et al (2006) reported a mother and daughter with 
a cytogenetically visible deletion of 3pter. The mother showed only a mild phenotype 
(simple-formed ears, a high arched palate, fourth and fifth toe clinodactyly, and a history 
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of moderate scoliosis) while, at age 15 months, the daughter had mild hypotonia and joint 
laxity, fourth and fifth toe clinodactyly but no developmental delay. A terminal deletion 
with a breakpoint between ~8.65 and 10.16 Mb was detected. Patients P1-P15 had marked 
intellectual disability and so, assuming the most parsimonious explanation of complete 
penetrance for deletion of a psychomotor retardation gene, candidate genes for terminal 
3p- associated mental retardation should map centromeric to the P16 deletion breakpoint 
(~8.6 Mb) and telomeric to the breakpoint in P10. SRGAP3(MEGAP) (a GTPase-activating 
protein that acts towards Rac1 and Cdc42 in vitro and in vivo and regulates cell migration 
by affecting actin and microtubule cytoskeleton dynamics (Yang et al., 2006), maps ~9Mb 
from the telomere and so is retained in P16 and is possibly retained in the family reported 
by Takagishi et al (2006). Endris et al (2002) reported that SRGAP3 was disrupted in a 
patient with a constitutional translocation associated with hypotonia and severe mental 
retardation and SRGAP3 was deleted in all our patients with mental retardation and the 
three patients reported by Malmgren et al (2007). Two patients further with a relatively 
mild phenotype have also been reported. Thus Shrimpton et al (2006) described an 
unbalanced der(3)t(3;8)(p26;q24.3) translocation associated with a terminal 3p deletion 
and 8q duplication in a boy with a mild cognitive deficit (IQ score of 97). The 3p deletion 
breakpoint mapped distal to SRGAP3 (between 6.89 and 8.16 Mb). Rivera et al., (2006) 
reported a 3p26 to 3pter deletion in a 14-year old boy with a full scale IQ of 95 but an 
unusual cognitive and behavioral profile. However the deletion has not been characterized 
in detail.  
 
The findings of my study are consistent with the hypothesis that SRGAP3 (MEGAP) is a 
prime candidate for 3p- syndrome psychomotor retardation. A number of genes previously 
implicated in  3p- associated mental retardation are deleted in P16 and the family of 
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Takagishi et al (2006) (CHL1/CALL at 2.14 Mb, CT4 at 3.06 Mb, LRR1 at 3.86 Mb, 
and ITPR1 at 4.51Mb). Of these candidate genes the most convincing case has been made 
for CT4 (contactin 4) that encodes a GPI-anchored neuronal membrane protein that 
functions as a cell adhesion molecule. Dijkhuizen et al (2006) reported a patient with 
severe mental retardation (IQ score 30), upslanted palpebral fissures, a small nose with a 
short philtrum, macrostomia with prominent everted lips, small cup-shaped ears and small 
hands (metacarpal and phalanges lengths were particularly small). Array-CGH 
demonstrated a complex rearrangement with a 4.0-Mb deletion (3p26.2-3pter), 1.3-Mb 
amplification (3p26.1-3p26.2) and 6.0-Mb duplication (3p25.3-3p26.1) (all on the same 
chromosome 3 homologue), CT4 and CRB were deleted and duplicated in this patient 
and it is difficult to evaluate detailed genotype–phenotype correlations in this case. 
Although Cargile et al (2002) reported on a child with features of 3p- syndrome (ptosis, 
microcephaly, growth retardation, and developmental delay) and an interstitial deletion 
mapping somewhere betweenD3S3630 (at 2.67Mb) and D3S1304Mb (at 6.89Mb) the 
deletion was characterized by FISH studies and it is possible that a high resolution 
microarray analysis might have discovered additional abnormalities. Fernandez et al 
(2004) reported a balanced t(3;10)(p26;q26) translocation associated with borderline 
intellectual disability (full scaleIQ of 73) and some features of 3p- syndrome (short stature, 
downslanting palpebral fissures and ptosis) that mapped within the first intron of CT4 
and was predicted to disrupt the 5’ UTR of the mature mRNA of one of three of CT4 
isoforms that is highly expressed in human brain leading to the suggestion that deletion of 
CT4 was causally associated with the pathogenesis of the 3p- syndrome phenotype. 
However this conclusion is at odds with our results and those of Takagishi et al (2006). In 
addition, Roohi et al (2009) reported on two patients with autistic spectrum disorder with 
germline deletions involving CT4. Neither demonstrated phenotypic features of a 3p- 
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syndrome and the copy number variant was inherited from a normal phenotype father. This 
could suggest that loss of CT4 is not sufficient to cause a 3p- syndrome phenotype but, 
in combination with other autistic susceptibility alleles, could contribute to autistic 
spectrum disorder. If this hypothesis is correct, then the translocation reported by 
Fernandez et al (2004) may have been associated with a 3p- phenotype because of position 
effects of the translocation on other genes, unmasking of recessive alleles or through an 
oligogenic effect whereby the phenotypic effects of loss of CT4 depended on loci 
outside of 3p25-p26.  
 
In summary, currently most evidence is in favour of SRGAP3 being the major determinant 
of mental retardation in 3p- syndrome. However, the interpretation of genotype–phenotype 
studies for distal 3p deletions is complex (Barber, 2008), and analysis of such cases on 
genome-wide high density arrays will provide better characterisation of the deletions in 
individual cases and exclude the possibility of coexistent unrecognised copy number 
abnormalities.  
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4  Cytogenetics and molecular genetic analysis of Beckwith-Wiedemann 
syndrome (BWS) 
 
4.1  Introduction 
Most genes are expressed equally from the paternal and maternal alleles ie. biallelic gene 
expression is the usual physiological state. However, a minority of genes, probably 
numbering about 100 in humans and in mice are imprinted genes and show differences in 
expression according to the parental origin of the allele. This parent-of-origin genomic 
imprinting phenomenon is heritable at a cellular level and, when complete, only one of the 
alleles is expressed ie. monoallelic gene expression. Imprinted genes often have a critical 
role in prenatal growth and development (Charalambous et al., 2007). The process of 
genomic imprinting is initiated during the formation of germ cells. Thus imprints are 
erased and re-established based on the sex of the transmitting parent (Barlow, 1994). The 
establishment and maintenance of genomic imprinting involves a number of epigenetic 
mechanisms including differential DNA methylation, allele-specific RNA transcription, 
antisense transcripts, histone modifications as well as differences in replication timing 
(Weksberg et al., 2003).  
 
The first evidence for genomic imprinting was provided by classical mouse experiments 
using the technique of pronuclear transplantation (McGrath and Solter, 1984). Mouse 
embryos that were diploid but with the nuclear material derived solely from the maternal 
(gynogenetic) or paternal (androgenetic) genomes were created but failed to develop post-
implantation. In gynogenotes, development of the extraembryonic tissues was poor 
although the embryo was present. In contrast, embryonic development in androgenotes 
was considerably retarded but substantial growth of the trophoblast and yolk sac was 
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evident (McGrath and Solter, 1984; Barton et al., 1984). These experiments demonstrated 
that diploidy alone is not sufficient for normal embryonic development and the presence of 
both of maternal and paternal genomes is required. In addition, they also showed that the 
maternal genome appears to be biased towards fetal development whereas the paternal 
genome contributes more towards the development of extra embryonic structures 
(McGrath and Solter, 1984). Evidence for the differential contribution of maternal and 
paternal genomes is also clearly demonstrated by the reciprocal phenotypes observed in 
ovarian teratomas and complete hydatidiform moles in humans. These occurred from 
parthenogenotes and androgenotes, respectively. Ovarian teratomas are composed of a 
disorganised mass of differentiated embryonic tissues but do not contain any placental 
tissue (Linder et al., 1975). Complete hydatidiform moles are characterised by extensive 
growth of the trophoblast in the absence of an embryo (Kajii and Ohama, 1977).  
 
Imprinted genes are members of several gene families and encode gene products involved 
in a diversity of physiological processes, many of which are involved in growth control 
and development (Tycko and Morison, 2002). In mammals, they tend to occur in clusters 
in distinct regions on chromosomes which are referred as imprinted domains (Weksberg et 
al., 2005). These domains are characterized by regulatory systems known as imprinting 
centre which control expression of closely linked imprinted genes (Nicholls, 2000).  
Imprinting centres in these domains are characterized by the presence of differential 
methylation on the paternal and maternal chromosomes which result in differential cis-
regulation and transcription of imprinted genes. This results in different epigenotypes on 
the maternal and paternal alleles. To date, >50 imprinted genes have been identified in the 
human genome (Morison et al., 1998; Morison et al., 2005; Glaser et al., 2006).  
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Imprinting is a normal mechanism of gene regulation. However, deregulation of imprinting 
is associated with genetic diseases, for example abnormalities in the imprinted domain on 
chromosome 15q11-q13 are associated with Prader-Willi and Angelman syndromes 
(Nicholls, 2000) and with the imprinted domains on chromosome 11p15 with the 
imprinting disorder Beckwith-Wiedemann syndrome (BWS), a variety of human cancers 
including Wilm’s tumour and Silver-Russell syndrome (Reik and Maher, 1997; Tycko, 
2000). A number of mechanisms may cause an imprinting disorder including a failure to 
establish a normal genomic imprinting epigenotype, uniparental disomy (UPD), gene 
mutations and chromosome rearrangements such as inversion, duplication, deletion and 
translocation can also give rise to the syndromes. Chromosomes 7 and 14 also contain 
imprinted genes and imprinting defects associated with UPD of the chromosomes have 
been confirmed to cause certain diseases in humans (table 4.1).  
 
Table 4.1: Genetic diseases caused by imprinting effects in humans 
 
Imprinted region Disease References 
mUPD7 Silver-Russel syndrome Kotzot et al, 1995;Eggermann et 
al,1997;Preece et al,1997 
 
Segmental pUPD11p15.5 Beckwith-Wiedemann 
syndrome 
 
Henry et al,1993;Henry et 
al,1991;Slatter et al,1994 
mUPD14 MatUPD14 syndrome Healey et al,1994;Sanlaville et 
al,2000 
 
pUPD14 PatUPD14 syndrome Cotter et al, 1997 
mUPD15;chromosomal region 
15q11-q13 
Angelman syndrome Malcolm et al,1991;Nicholls et 
al,1992 
 
pUPD15; chromosomal region 
15q11-q13 
Prader-Willi syndrome Nicholls et al,1989; Robinson et 
al,1991 
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The list of imprinted genes is regularly being updated and can be found at the University 
of Otago’s Imprinted Gene Catalogue (http://igc.otago.ac.nz/home.html). 
 
4.1.1  Clinical genetics of Beckwith-Wiedemann syndrome (BWS) 
 
Beckwith-Wiedemann syndrome (BWS; MIM 130650) is a paediatric overgrowth disorder 
involving a predisposition to tumour development with an estimated incidence of 1 in 
13,700 livebirths (Junien, 1992).  It was first described by Beckwith in 1963 and 
Wiedemann in 1964 on children with features of exomphalos, macroglossia and gigantism. 
BWS is a prototypic imprinting disorder resulting from mutations or epimutations in genes 
from the imprinted cluster at chromosome 11p15.5 (Reik and Maher, 1997). Chromosome 
11p15.5 was first implicated by the finding of paternally derived duplications of 11p15.5 
in BWS patients (Turleau et al., 1984; Brown et al., 1992; Nystrom et al., 1992; Slavotinek 
et al., 1997). Subsequently, maternally inherited balanced rearrangements of 11p15 were 
also demonstrated to be associated with BWS (Norman et al., 1992; Tommerup et al., 
1993). The finding of chromosome 11 paternal uniparental disomy in a subset of sporadic 
BWS patients provided further evidence that BWS is an imprinting disorder (Henry et al., 
1991; Slatter et al., 1994).  
 
The penetrance and clinical presentation of BWS is highly variable but most frequently it 
is characterized by pre- and postnatal overgrowth, macroglossia and anterior abdominal 
wall defects (omphalocoele, umbilical hernia and diastasis recti). Additional features 
include visceromegaly (particularly kidneys, liver and pancreas), hypoglycaemia, 
hemihyperplasia, genitourinary abnormalities and embryonal tumours which occur in 5% 
of patients (most frequently, Wilm’s tumour) (Engel et al., 2000).  Other embryonal 
tumours include rhabdomyosarcoma, adrenocorticol carcinoma and neuroblastoma 
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(Sotelo-Avila et al., 1980; Pettenati et al., 1986; DeBaun et al., 1998; Lapunzina, 2005; 
Tan and Amor, 2006). Most of the tumours associated with BWS appear in the first 8-10 
years of life with very few reported beyond this age (DeBaun et al., 1998; Tan and Amor, 
2006). Clinical findings associated with higher risks of tumour development include 
hemihyperplasia, nephromegaly and nephrogenic rests (DeBaun et al., 1998; Coppes et al., 
1999).  
 
Three major groups of BWS are distinguished: sporadic (about 85%), familial (about 15%) 
and those with chromosome abnormalities (about 2%) (Slatter et al., 1994; Reik and 
Maher, 1997; Maher and Reik, 2000). The majority of BWS cases are sporadic with ~20% 
of these having paternal isodisomy which always includes the 11p15.5 imprinted gene 
cluster (Henry, 1991; Slatter, 1994; Catchpoole et al., 1997). Segmental UPD arises from 
post-zygotic somatic recombination event and therefore has a mosaic distribution (Cooper 
et al., 2007).   
 
The majority of familial and sporadic cases show no cytogenetic abnormality but about 2% 
of cases involve duplications, inversions, and translocations affecting distal 11p. 
Duplications are invariably derived from paternal whereas inversions and translocations 
always involve the maternal homologue (Maher and Reik, 2000). Based on the maternally 
inherited rearrangements in BWS, three distinct breakpoint cluster regions (BWSCRs) have 
been identified (figure 4.1).  
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Figure 4.1:  The imprinting cluster on human chromosome 11p15.5. The distal breakpoint cluster 
region (BWSCR1) is indicated. Breakpoints within BWSCR1 disrupt KvLQT1. Solid red symbols 
indicate allelic silencing; green/white symbols indicate allelic transcription. (Adapted from: Maher 
and Reik, 2000) 
 
 
 
The most frequent of these is BWSCR1 which map at 200-300 kb proximal to IGF2 
(Hoovers et al., 1995). BWSCR1 is in the centre of a region that contains multiple 
imprinted genes including IGF2, H19, CDK1C (also known as p57
kip2
), ASCL2 (also 
known as HASH2), and KCQ1 (also known as KVLQT1). All breakpoints in BWSCR1 
disrupt the imprinted KCQ1 gene which is maternally expressed (Lee et al., 1997b). 
However, in at least two patients, loss of imprinting (LOI) of IGF2 has also been shown to 
associated with a BWSCR1 breakpoint (Brown et al., 1996; Smilinich et al., 1999). The 
less frequent breakpoint cluster regions, BWSCR2 and BWSCR3 map respectively, 5 Mb 
and 7 Mb centromeric to BWSCR1 (Redeker et al., 1995). BWSCR2 is defined by two 
breakpoints and maybe associated with a distinct phenoytype (Alders et al., 2000).  In a 
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study of two BWS patients, Alders et al (2000) have isolated cDNAs encoding 2 zinc 
finger genes, ZF214 and ZF215 in the BWSCR2. ZF215 gene is imprinted in a tissue-
specific manner whereas ZF214 is not imprinted. Two of the five alternatively spliced 
ZF215 transcripts are disrupted by both BWSCR2 breakpoints. Parts of the 3-prime end 
of these splice forms are transcribed from the antisense strands of ZF214. These data 
supported a role for ZF215 and possibly ZF214 in the aetiology of BWS.  
 
4.1.2  BWS candidate genes in chromosome 11p15.5 
Sex bias in the transmission of BWS in families whereby the clinical features are passed 
on from mother to offspring two to three times more frequently than from father to 
offspring, the finding of UPD in BWS patients, and the sex bias in the chromosome 
anomalies associated with BWS (the duplications of 11p are always paternal and the 
balanced translocations and inversions are maternal) led to the hypothesis that the 
responsible gene(s) is imprinted (Niikawa et al., 1986; Elliott et al., 1994). 
 
A number of imprinted genes in 11p15.5 have been implicated in the aetiology of BWS 
including the paternally expressed (maternally imprinted) IGF2, KCQ1OT1 (LIT1) genes 
and the maternally expressed (paternally imprinted) H19 and CDK1C (p57
kip2
) genes 
(Engel et al., 2000).  
 
The association of IGF2 with BWS was demonstrated by Weksberg et al (1993). Control 
skin fibroblasts were shown to maintain monoallelic expression of paternal IGF2 but skin 
fibroblasts from 3 out of 5 patients of BWS demonstrated biallelic IGF2 expression. Their 
study has led to a conclusion that biallelic expression reflects disruption of IGF2 
imprinting and BWS can result from the loss of normal suppression of the maternally 
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inherited IGF2 gene. Biallelic expression of the gene was also detected in tumours 
including Wilm’s tumour (Ogawa et al., 1993; Rainier et al., 1993). IGF2 encodes a fetal 
growth factor and overgrowth in BWS is restricted to tissues in which IGF2 is expressed.  
H19 is a gene encoding a biologically active non-translated RNA that may function as 
tumour suppressor (Hao et al, 1993). The imprinted region at 11p15.5 includes regions that 
are differentially methylated between the parental genomes. The H19 differentially 
methylated region (DMR; located at 1.98 Mb) is paternally methylated and in the 
methylated state is proposed to promote the expression of IGF2 (Cui et al., 2001).  
 
KCQ1OT1 is a non-coding RNA with antisense transcription to KCQ1. The promoter 
for KCQ1OT1 is located in intron 10 of KCQ1. The 5’ end of this imprinted transcript 
overlaps with the differentially methylated imprinting centre for Domain 2 (IC2) or 
KvDMR (as it was originally called for ‘KvLQT1 DMR’) (Lee et al., 1999; Smilinch et al., 
1999). Normally the maternal allele of ICR2 is methylated and KCQ1OT1 is silenced and 
the paternal allele is unmethylated allowing transcription of the KCQ1OT1 transcript 
(Lee et al., 1999b; Smilinich et al., 1999). Maternal methylation at the KvDMR1 is thought 
to prevent transcription of the KCQ1OT1 gene and enable expression of KCQ1 and 
CDK1C (Smilinich et al., 1999; Lee et al., 1999; Horike et al., 2000; Fitzpatrick et al., 
2002; Diaz-Meyer et al., 2003).  
 
CDK1C is a member of the cyclin dependent kinase inhibitor and encodes a protein 
known as p57
kip2
 (Bhuiyan et al., 1999). The protein is involved in the negative regulation 
of the cell cycle (Lee et al., 1995; Matsuoka et al., 1995) and is critical during mouse 
embryogenesis (Zhang et al., 1997; Yan et al., 1997). In human, CDK1C is imprinted and 
primarily expressed from the maternal allele, though some expression (5–30%) is observed 
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from the paternal chromosome (Chung et al., 1996; Hatada et al., 1996). Other imprinted 
genes including TSSC3 and IMPT1 were both hypothesized to have negative growth 
regulatory functions and are thought to be regulated by ICR2 (Fitzpatrick et al., 2002).  
 
4.1.3  Epigenetics, genetics and cytogenetic basis of BWS 
4.1.3.1 Genomic imprinting of 11p15 
The genetics of BWS are complex, but all causes to date are associated with alterations in 
the expression or function of one or more imprinted genes in the 11p15.5 imprinted gene 
cluster (Maher and Reik, 2000). Up to 60% of sporadic cases are due to epigenetic 
mutations involving two imprinting centres (ICs), IC1 and IC2. Both of the ICs regulate 
the expression of the imprinted genes on 11p15 over a long distance (Weksberg et al., 
2003; Murrell et al., 2004).   
 
IC1 controls the imprinting of the H19 and IGF2 genes (Bell and Felsenfeld, 2000; Hark et 
al., 2000) while IC2 controls the imprinting of KCQ1, CDK1C, ASCL2, PHLDA2, 
TSSC4 and SLC22A1L (figure 4.2) (Smilinich et al., 1999; Lee et al., 1999; Maher and 
Reik, 2000). 
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Figure 4.2:  The cluster of imprinted genes on human chromosome 11p15.5. The maternal (Mat) 
and paternal (Pat) chromosomes are shown. The silenced allele is shown as a black box and the 
expressed alleles are shown as vertically striped boxes or white or grey boxes. The horizontal 
arrows indicate the direction of transcription. The diagonally striped box indicates the location of 
the CpG island that is studied here and is differentially maternally methylated (KvDMR1 or ICR2). 
The H19 DMR (ICR1) along with the 3’ enhancers (circles) are indicated. Some genes (e.g., 
TSSC4, TAPA1, ASCL2, NAP1L4, and OSBPL5) are imprinted in mouse but not human. MTR1 
is imprinted in human but not mouse. The dashed lines between NAP1L4 and OSBPL5 indicate the 
presence of intervening non-imprinted genes. Domains 1 and 2, indicated by the horizontal arrows 
at the top of the figure, are controlled by ICR1 and ICR2, respectively. The dashed arrow indicates 
that Domain 2 in mouse extends further to the right. (Adapted from: Minjie Du et al., 2003) 
 
 
 
IC1 (or ICR1) consists of a differentially methylated region (DMR1) positioned upstream 
of H19 and containing target sites for the insulator protein CTCF, which regulates access 
to the same enhancers of the two reciprocally imprinted genes H19 and IGF2 (Bell and 
Felsenfeld, 2000).  Methylation on the paternal allele prevents CTCF from binding DMR1, 
permitting expression of IGF2 and silencing of H19. On the unmethylated maternal allele, 
insulator protein binding prevents IGF2 promoters interacting with the enhancers 
downstream of H19 (Bell and Felsenfeld 2000; Lewis and Murrell, 2004), thus IGF2 is 
silenced and H19 is expressed. This region is known as domain 1 (figure 4.2).  
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Gain of methylation at the maternal H19 and IC1 is associated with loss of H19 expression 
and biallelic IGF2 expression (Joyce et al., 1997). This alteration is called H19-dependent 
IGF2 biallelic expression and is seen in approximately 5–10% of sporadic BWS cases 
(Catchpoole et al., 1997; Weksberg et al., 2001). Gain of methylation is almost always 
seen in sporadic cases without family history. However, three families with clinical 
features of BWS have also been reported to carry heritable DNA sequence abnormalities in 
IC1 that can disrupt imprint regulation in domain 1 (Sparago et al., 2004; Prawitt et al., 
2005). Another alteration is referred to as H19-independent biallelic expression and can be 
found in many cases of BWS as well as in isolated Wilm’s tumour. This alteration, first 
observed by Brown et al (1996) involved biallelic IGF2 expression accompanied by 
monoallelic H19 expression. BWS cases with this alteration show normal methylation and 
expression of H19 from the maternal allele with biallelic IGF2 expression (Weksberg et 
al., 2001).  
 
IC2 (or ICR2) is associated with a maternally methylated differentially methylated region 
(KvDMR1) and a paternally expressed untranslated RNA (KCQ1OT1 (LIT1)) (Smilinich 
et al., 1999). Loss of maternal methylation of IC2 is seen in 50%-60% of patients with 
sporadic BWS (Lee et al., 1999; Engel et al., 2000) and in these cases there is KCQ1OT1 
loss of imprinting (biallelic KCQ1OT1 expression) reduced CDK1C expression (Diaz-
Meyer et al., 2003) and variable loss of imprinting (LOI) of IGF2 (Lee et al., 1999). 
Deletion of the orthologous sequence in mice results in loss of imprint for several genes 
neighbouring KCQ1 suggesting that IC2 is critical for maintaining imprinted gene 
expression in domain 2 (Fitzpatrick et al., 2002).  
 
 
107 
 
4.1.3.2 Mutations in CDK1C 
There are however, cases of BWS which arise from germline mutations in CDK1C which 
include missense and frameshift mutations (Hatada et al., 1996). It has been reported in 
5%-10% of sporadic BWS (Hatada et al., 1996) and approximately 40% of BWS cases 
with positive family history (Lam et al., 1999). These cases provide evidence that, 
mutation in a single gene is sufficient to implicate the disease in some individuals with 
BWS.  
 
4.1.3.3 11p15 segmental uniparental disomy (UPD) 
Approximately 20-28% of patients with BWS have paternal UPD ie. two paternally 
derived copies of 11p15 and no maternal contribution for that region (Henry et al., 1991; 
Slatter and Elliott, 1994). The region of paternal UPD invariably includes the imprinted 
gene cluster at 11p15.5; however, the extent of isodisomy along chromosome 11 is 
variable (Catchpoole et al., 1997; Dutly et al., 1998). In a cohort of 52 children with BWS 
and UPD, it was found that all cases demonstrated mosaic paternal isodisomy, and IGF2 
and H19 were included in the segment of UPD in all cases. While the extent of segmental 
disomy was variable, there was no evidence of clustering of the proximal UPD breakpoint. 
In most cases (92% of those informative) UPD did not involve 11q, but 4 patients 
demonstrated UPD for the whole of chromosome 11 (Cooper et al., 2007). The findings 
that all cases demonstrated mosaic paternal disomy implies that UPD arises post-
zygotically as a result of a somatic recombination in early embryogenesis. A comparison 
of patients with BWS and UPD for chromosome 11 with BWS patients without UPD 
showed an increased incidence of hemihypertrophy (6/9 v 1/23) and a decreased incidence 
of exomphalos (0/9 v 13/23) (Elliott and Maher, 1994). Other studies have reported an 
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increased incidence of tumours in BWS patients with UPD (Henry et al., 1993; Schneid et 
al., 1993).  
 
4.1.3.4 11p15 chromosome rearrangements 
Cytogenetic abnormalities have been found in 2-3% of individuals with BWS (Elliott and 
Maher, 1994). Translocations and inversions are usually maternally inherited and are 
always balanced (Sait et al., 1994). Duplication of chromosomal region 11p13–p15 
responsible for BWS most frequently results from unbalanced segregation of a paternal 
translocation (Slavotinek et al., 1997) but de novo duplications of the paternally derived 
11p15 were also found (Slavotinek et al., 1997).  The most common aberration is 
duplications involving chromosome 11p15.5 due to unbalanced segregation of a paternal 
translocation (most frequent) or paternal inversion or de novo (table 4.2).  The clinical 
features in these patients are thought to be due to increased IGF2 expression from the extra 
paternal copy (Mannens et al., 1994). Additional types of chromosome rearrangements in 
BWS are translocations, inversions and deletions. Balanced chromosome translocations or 
inversions in 11p can be transmitted from a phenotypically normal parent to their offspring 
who then develop BWS. The breakpoints of these translocations and inversions have been 
found to cluster in two regions, BWSCR1, a 450 kb 200-400 kb centromeric to the IGF2 at 
11p15.5 and BWSCR2, a 2000 kb region proximal to BWSCR1 at 11p15.3-p15.4 which is 
subdivided into at least two regions (Weksberg et al., 1993; Mannens et al., 1994; Lee et 
al., 1997). With the advent of more sensitive and high resolution molecular methods, for 
example array CGH, microdeletions (Niemitz et al., 2004; Sparago et al., 2004; Prawitt et 
al., 2005) and microduplication (Algar et al., 2007) of 11p15 in BWS patients have been 
identified. 
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Table 4.2: Summary of published chromosome rearrangements in BWS 
 
Reference 
Chromosome 
rearrangement 
Karyotype of proband 
Cytogenetic 
anomaly 
Falk et al., 1973 Pat translocation 46,XY,t(2q +pat) Dup 11p 
Bajolle et al., 1978 Pat translocation 46,XY,der(5),t(5;11) (pl5;pl4)pat Dup 11pl5-pter 
Turleau et al., 1984 Pat translocation 46,XY,-4,+der(4) t(4;11)(q33;pl4)pat Dup 11pl4-pter 
Journel et al., 1985 Pat translocation 46,XY,-18,+der(11;18), 
t(11;18)(p15.4;p11. 1)pat 
Dup 11p15.4-pter 
Wales et al., 1986 Pat translocation 46,XY,-5, +der(5), 
t(5;11)(p15;p15.1)pat 
Dup 11p15.1 -
pter 
Okano et al., 1986 Pat translocation 46,XX,-4,+der(4), t(4;1 1)(q35;p13)pat Dup 11p13-pter 
Tonoki et al., 1991 Pat translocation 46,XX,-
14,+der(l4)t(11;14)(p15.3;q32.3) 
Dup 11p15.3-pter 
Brown et al., 1992 Pat translocation 46,XY,der(5)t(5;11) (p15.2;p14)pat Dup 11p14-pter 
Drut et al., 1996 Pat translocation 46,XY,-10,+der(10) t(10;11)(q26;p15) Dup 11p15-pter 
Krajewska-
Walasek et al., 
1996 
Pat translocation 46,XY,-
21,+der(21)t(11;21)(p15.2;q22.3)pat 
Dup 11p15.2 -
pter 
Slavotinek et al., 
1997 
Pat translocation 46,XY,der(5)t(5;11)(p15.3;p15.3)pat Dup 11p15.3-pter 
Fert-Ferrer et al, 
2000 
Pat translocation  Dup 11p15.5 
Russo et al., 2006 Pat translocation  Dup 11p11.5 
Delicado et al., 
2005 
Pat translocation 47,XX, inv (Y) (p11.2 q11.23), 
der(18)t (11;18) (p15.5;q23) pat. ish 
der(18) (D11S2071+, D18S1390-) 
Dup 11p15.5-pter 
Bliek et al., 2009 Pat translocation  Dup 11p15.5 
Kubota et al., 1994 De novo 
translocation 
46,X,-X,+der(X) t(X;11)(p22.l;p13) Dup 11p13-pter 
Waziri et al., 1983 pat inversion 46,XY,rec(11), dup(pl3-pl5),del(q23-
q25) 
Dup 11p13-p15.5 
Rethore et al., 1980 De novo 
duplication 
Trisomy l1p (excluding 11p13) Dup 11p 
(excluding 
11p13) 
Waziri et al., 1983 De novo 
duplication 
 Dup 11p15 
Turleau et al., 1984 De novo 
duplication 
 Dup 11p15 
Estabrooks et al., 
1989 
Mat duplication 46,XX,dup(15)(q11.2-ql3)mat Dup 15q11.2-q13 
Han et al., 2006 Pat duplication  Dup 11p13-p15.5 
Russo et al., 2006 Pat duplication  Dup 11p15.5 
Algar et al., 2007 Pat micro 
duplication 
 Dup 11p15.5 
Pueschel and Mat 46,XX,t(11p;22q) Breakpoint 11p 
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Padre-Mendoza, 
1984 
translocation 
Tommerup et al., 
1993 
Mat 
translocation 
46,XX,t(9;11) (p11.2;p15.5) Breakpoint 
11p15.5  
Weksberg et al., 
1993 
Mat 
translocation 
46,XX,t(11;16)(p15.5;q12) Breakpoint 
11p15.5 
Mannens et al., 
1994 
Mat 
translocation 
46,XX,t(4;l1)(p15.2;p15.4) Breakpoint 
11p15.4 
Hoovers et al., 
1995 
Mat 
translocation 
46,XX,t(11;12) (pl5.5;q13.1) Breakpoint 
11p15.5 
Hoovers et al., 
1995 
Mat 
translocation 
46,XX,t(l0;11)(p13;p15.5) Breakpoint 
11p15.5 
Newsham et al., 
1995 
Mat 
translocation 
46,XX,t(11;16)(p15;q13) Breakpoint 11p15 
Norman et al., 
1992 
Mat inversion 46,XX,inv(11)(p11.2p15.5) Breakpoint 
11p15.5 
Mannens et al., 
1994 
Mat inversion 46,XX,inv(l l)(p15.4;q22.3) Breakpoint 
11p15.4 
Grundy et al., 1998 Pat translocation  Breakpoint 11p14 
Alders et al., 2000 Mat 
translocation 
 Breakpoint 
11p15.5 
Alders et al., 2000 Mat 
translocation 
 Breakpoint 
11p15.4 
Squire et al., 2000 Mat 
translocation 
 Breakpoint 11p15 
Haas et al., 1986 De novo 
deletion 
46,XY,del(11)(p11.1p11.2) Del 11p11.1-11.2 
Schmutz, 1986 De novo 
deletion 
46,XX,del(11)(p11p13) Del 11p11-p13 
Zollino et al., 2009 De novo 
deletion 
 Del 11p15 
Niemitz et al., 
2004 
Mat 
microdeletion 
 Del 11p15.5 
Niemitz et al., 
2004 
Pat 
microdeletion 
 Del 11p15.5 
Sparago et al., 
2004 
Mat 
microdeletion 
 Del 11p15.5 
Prawitt et al., 2005 Mat 
microdeletion 
 Del 11p15.5 
Abbreviations: mat, maternal; pat, paternal; inv, inversion; del, deletion; der, derivative; dup, duplication; t, 
translocation. 
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4.1.4  Phenotype – genotype/epigenotype correlations 
The clinical expression of BWS may differ between patients with different molecular 
mechanisms and also between patients similar molecular abnormalities (e.g. from different 
levels of mosaicism in patients with UPD) (Itoh et al., 2000). Hemihyperplasia is highly 
positively correlated with UPD 11p15 (Engel et al., 2000; DeBaun et al., 2002; Cooper et 
al., 2005). This most likely reflects the somatic mosaicism associated with the 
chromosome alteration. Alterations in IC2 and mutations in CDK1C are positively 
correlated with exomphalos (omphalocoele) and, possibly, cleft palate (Lam et al., 1999; 
Bliek et al., 2001; Gaston et al., 2001; Li et al., 2001; Weksberg et al., 2001, Bliek et al., 
2004). However, there was no association between germline CDK1C mutations and risk 
of embryonal tumours (Lam et al., 1999). Patients with UPD 11p15 and those with H19 
hypermethylation have the highest tumour risks especially for Wilm’s tumour. In contrast, 
patients with loss of methylation at KvDMR1 (IC2) have a lower tumour risk, are 
apparently not at risk for Wilms tumour but are susceptible to non-Wilm’s tumours 
including hepatoblastoma, rhabdomyosarcoma and gonadoblastoma (Weksberg et al., 
2001, Bliek et al., 2004, Cooper et al., 2005).  The only tumour reported in patients with 
mutation of CDK1C is neuroblastoma (Lee et al., 1997; Gaston et al., 2001). 
 
To define and characterise the region of chromosome 11p15 involved in Beckwith-
Wiedemann syndrome (BWS), I have carried out a high resolution 250K SNP array 
analysis on seven patients and SNP6.0 array on one patient with features of BWS. 
Conventional and molecular cytogenetic techniques were also applied in two of the cases 
with chromosome rearrangements. 
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4.2  Materials and Methods 
4.2.1  Patients  
A total of eight BWS cases were studied which include two lymphoblast cell lines from 
patients BWSCA1 and BWSCA2 carrying the der(11)t(3;11)(q22;p15.4) and 
inv(11)(p15.4;q23.3) respectively and six genomic DNA samples from BWS patients. The 
DNA was extracted using standard methods and stored at -80
o
C. The two cell lines were 
cultured following standard protocol as described below. The DNA from the two cell lines 
were extracted following manufacturer’s (Qiagen, Germany) recommended procedure. 
The parents give consent for all diagnostic procedures.  
 
4.2.2  Cell culture 
500 ml RPMI 1640 medium (Gibco BRL, Grand Island,
 
NY, USA) was added with 50 ml 
fetal bovine serum, 5 ml 200 mM L-Glutamine and 5 ml penicillin/streptomycin. The 
medium was warmed in 37°C water bath and the class II cabinet was switched on at least 
15 minutes before starting.  The inside of the cabinet was swab with 70% ethanol as well 
as all bottles that have been in the water bath before placing them in the cabinet. The 
frozen cell lines (BWSCA1 and BWSCA2) were thawed at 37°C as quickly as possible 
and placed in the cabinet. The cells (~1 ml) were then pipetted into a 25 cm
2
 cell culture 
flasks. 9 ml of the warmed medium was slowly pipetted into the flasks and placed upright 
in the 37°C CO2 incubator. The cells survival rate was checked the next day and the 
medium was replaced with fresh 10 ml medium and placed back in the incubator. The cells 
were checked every 3-4 days, healthy cultures should appear orange to yellow in colour. 
When the cells were already confluence, they were transferred to 50 ml sterile tubes and 
centrifuge at 2000 rpm for 10 minutes at room temperature. The excess medium was 
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siphoned out with serological pipette attached to the vacuum system.  The cells were then 
harvested following standard procedure. 
 
 
4.2.3  Chromosome analysis 
 
Chromosome were stained with Giemsa and karyotyped. Twenty five metaphases were 
completely analysed. Karyotypes were described according to ISCN (1995).  
 
4.2.4  Fluorescence in situ hybridisation (FISH) 
Fluorescence in situ hybridisation (FISH) analysis was applied on both of the two cell lines 
to locate the breakpoints in chromosome 11p15. Bacterial artificial chromosome (BAC) 
clones spanning the region of breakpoint in chromosome 11p15.4-p15.5 were selected 
according to Ensemble Genome Browser (February 2007 release) (figure 4.3). The clones 
were obtained from Roswell Park Cancer Institute (RPCI, Buffalo NY, USA) and 
Bluegnome Limited (Cambridge, UK). For BWSCA1 cell line, eight BAC clones were 
used: RP11-295K3, RP11-847E17, RP4-608B4, RP11-38L8, RP11-774H09, RP11-
699D10, RP11-211E17 and RP11-89D4. Ten BAC clones were applied on BWSCA2 cell 
lines which include RP11-295K3, RP5-1075F20, RP11-847E17, RP11-304P12, RP11-
211E17, RP11-560B16, RP11-413N10, RP11-715M10, RP11-324J3 and RP11-89D4. The 
BAC probes purchased from Bluegnome include RP4-608B4, RP11-38L8, RP11-774H09, 
RP11-699D10, RP5-1075F20 were prelabelled with spectrum orange. The remaining of 
the RPCI BAC clones were labelled with Cy3-dUTP (Amersham Biosciences, USA) and 
the method is explained in detail in the next section. Telomeric probe for chromosome 11p 
(chr11:145,611-345,808) and centromeric probe for chromosome 11 (CEP11) (Vysis, 
USA) in spectrum green were used as controls.  Chromosomes were then counterstained 
with 4'-6-Diamidino-2-phenylindole (DAPI) (Abbott Molecular, Illinois, USA). 
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Hybridized metaphase spreads were analysed using a fluorescence microscope (Olympus, 
USA) coupled to a CCD camera and FISHView EXPO 2.0 software (Applied Imaging, 
USA). Fifteen metaphase spreads were evaluated.  
 
 
 
 
 
 
 
 
 
Figure 4.3: Imprinted gene map of chromosome 11p15.4-p15.5 and the localisation of the BAC 
clones applied in patients BWSCA1 and BWSCA2. The breakpoint in patient BWSCA1 and 
BWSCA2 is indicated by dashed blue line and dashed green line respectively. 
 
 
 
4.2.4.1 Labeling of RPCI BAC probes with Cy3 
Bioprime Labelling Kit (Invitrogen, USA) contains Klenow polymerase, 2.5X random 
primers and stop buffer (EDTA) and Cy3-dUTP (1mM) (Amersham Biosciences, USA) 
were used for BACs labelling. The DNA of the BAC clones was quantified using the 
NanoDrop 1000 spectrophotometer (Thermo Scientific, USA). The DNA was diluted to 
1000ng/ul using molecular grade water. Dilution was made depending on the 
concentration of the stock BAC DNA. For BACs with a concentration of >2000ng/ul, 20 
ul of 1000ng/ul DNA was made. For BACs with concentration <2000ng/ul, 10 ul of 
1000ng/ul was prepared. The 1000ng/ul BAC DNA was then pre-denatured by incubating 
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at 98°C for 5 minutes.  It was then left in ice until ready to use. The labelling master mix 
was prepared by adding these reagents in an eppendorf tube:  
For 1 sample,   20 ul 2.5 X random primers 
   18.5 ul sterile water 
   1 ul Cy3 
  5 ul low-C dNTPs (refer appendix A3 for preparation) 
 
The denatured BAC DNA was pulse spin and transferred 4 ul into the prepared master 
mix. The solution was then denatured in a hot block at 98°C for 5 minutes. It was then 
transferred immediately to ice and incubated for at least 5 minutes and then pulse spun. 
Klenow was taken out from the freezer, vortexed, spun and added 1ul to the solution. The 
solution was then vortexed, spun and incubated at 37°C overnight (16-18 hours) in a hot 
block covered with aluminium foil. The next day, the reaction was stopped by adding 5 ul 
of stop buffer, and then vortexed and pulse spun.  
 
Autoseq G50 (GE Healthcare, USA) was vortexed with the column inverted. The bottom 
closure was snapped and the lid unscrewed and refits to the column ¼ turn. The column 
was placed in a collection tube, spun at room temperature (~22°C) at 2000g for 1 minute. 
The gel column was then transferred to a new 1.5 ml eppendorf tube. The screw lid and 
recovery tube was discard. The labelling reaction master mix was carefully loaded onto the 
centre of the gel bed. Then, it was loaded into the Beckman 22R centrifuge, orientating the 
column so that the gel face is away from the centre. It was spun at room temperature at 
2000g for 1 minute. The used column was then discarded and the eppendorf tube 
containing the flow through was sealed. The measurement of dye incorporation was then 
made using the NanoDrop 1000 spectrophotometer (Thermo Scientific, USA). Ideally the 
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DNA BAC concentration is ≥100ng/ul and dye incorporation is ≥3 pmol/ul. The reaction 
can be stored in the -20°C freezer if not proceeding to the next step which is precipitation. 
Precipitation process was done in a low light to prevent fading of the fluorescent dye. The 
volume equivalent to 200ng of BAC was required in a precipitation. The volume was 
determined by using the formula: 
Precipitation volume (200ng) = 200/labelled BAC concentration (ng/ul) 
 
The reagents required per BAC were 5 ug of Cot-1 DNA (5 ul of 1 ug/ul stock), 1 ug of 
herring sperm DNA (1 ul of a 1/10 dilution of 10 ug/ul stock), appropriate amount of the 
BAC and the total volume of the precipitation should be topped up to 100 ul with sterile 
water (BAC volume + Cot-1 DNA + HS DNA + sterile water = 100 ul). The specified 
amounts of water, Cot-1 DNA, 1/10 HS dilution followed by BAC were pipetted in an 
eppendorf tube. 10 ul of 3M sodium acetate (retrieved from the fridge) followed by 200 ul 
100% cold ethanol (retrieved from the freezer) was then added to the reaction and mixed 
gently by inverting the tube several times. The tube was then placed in a polystyrene box 
with elastic band on the lid and stored in the -80°C freezer for at least 30 minutes. 
Alternatively, it can be precipitated at -20°C for at least 2 hours or on dry ice for 15 
minutes. The tube was then loaded in the centrifuge, hinge face outwards and centrifuged 
at 4°C for 30 minutes at full speed. The supernatant was discard and replaced with 200 ul 
of 70% ethanol to wash the pellet. The tube was inverted a few times and centrifuge again 
at full speed for another 10 minutes. The supernatant was discard. The tube was pulse spun 
and the excess ethanol was removed with a fine tip pipette. The pellet was air dried for 5 
minutes.  
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Next, the BAC pellet was resuspended in 5 ul hybridisation buffer (Vysis Inc., USA). The 
type of the hybridisation buffer used depends on the type of control probe applied: Vysis 
LSI buffer with site specific control probe and Vysis CEP buffer if centromeric was used. 
The resuspended pellet was then incubated in the 73°C/75°C water bath for 1 minute, then 
vortexed and pulse spun. The step was repeated if the pellet was not completely dissolved. 
The dissolved BAC can be stored in -20°C freezer if not proceeding to the next step.  
 
Before starting the hybridisation, the slide was incubated in the oven overnight at 60°C. If 
using centromeric or site specific probe, 0.5 ul of the probe was added to the BAC and 1 ul 
if using telomeric probe. The probe mix (approximately 6 ul per slide) was then transferred 
onto the slide and covered with a 22 X 22 mm coverslip. Any air bubbles were removed 
and the edges of the coverslip were sealed with rubber glue. The slide was then incubated 
overnight on Hybrite (Vysis Inc., USA), program1. The following day, the rubber glue and 
cover slip were removed. The slide was washed in 0.4XSSC/0.3% NP-40 (refer appendix 
A4 for preparation) for 2 minutes at 73°C, then 2XSSC/0.1% NP-40 (refer appendix A4 
for preparation) for 30 seconds at room temperature. The reverse of the slide was wiped 
and allowed to dry slightly in the dark. 7.5 ul of DAPI was pipette onto the slide and 
covered with 22 X 32 mm coverslip. Any air bubbles were removed and the slide was 
ready for analysis.  
 
4.2.5  Array analysis 
250K Sty1 SNP mapping arrays were applied in seven cases (BWSCA1, BWSCA2, 
BWSCA3, BWSCA4, BWSCA5, BWSCA7 and BWSCA8) and SNP 6.0 arrays in one 
case (BWSCA6). The methods applied were according to the manufacturer’s 
recommendations (Affymetrix, Inc., Santa Clara, CA) and described in detail in sections 
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2.1 and 2.2. The reference set for 250K Sty1 mapping arrays was 48 samples from the 
HapMap project (www.hapmap.org/downloads/raw_data/affy500k/) and 270 HapMap 
individuals of various populations for SNP 6.0 (Goldstein and Cavalleri, 2005). Copy 
number analysis was done using the Affymetrix Chromosome Copy Number Analysis 
Tool 4.0 (CNAT 4.0). 
 
4.3  Results 
4.3.1  Chromosome analysis 
BWSCA1 has a reciprocal translocation involving the long arm of chromosome 3 and the 
short arm of chromosome 11 (figure 4.4). The karyotype of BWSCA1 was described as 
46,XY,der(11)t(3;11)(q22;p15.4). BWSCA2 has a pericentric inversion in chromosome 11 
(figure 4.5) and the karyotype was described as 46,XX,inv(11)(p15.4;q23.3).   
 
 
Figure 4.4: Karyotype of BWSCA1 46,XY,der(11)t(3;11)(q22;p15.4) showing translocation of the 
long arm of chromosome 3 and the short arm of chromosome 11 (arrows).  
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Figure 4.5: Karyotype of BWSCA2 46,XX,inv(11)(p15.4;q23.3) with a pericentric inversion of 
chromosome 11 (arrow) 
 
 
 
4.3.2  FISH analysis 
 
4.3.2.1 Patient BWSCA1 
 
 
Eight BAC probes labelled with spectrum orange were used for FISH analysis to localise 
the breakpoint in chromosome 11p15.5 or 11p15.4 of patient BWSCA1. Centromeric 11 or 
telomeric 11p in spectrum green (Vysis, USA) were applied as controls. The hybridisation 
signals observed for each of the BAC probe used are shown in table 4.3.  
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Table 4.3: Patterns of the hybridisation signals of the BAC clone probes applied on the metaphase 
spreads of patient BWSCA1 
 
BAC probe Start position End position Length (bps) Pattern of BAC probe 
hybridisation signals   
RP11-295K3 
1672662 1785148 112487  
Translocated to the 
aberrant chromosome 3 
RP11-847E17 
2426546 2542863 116318 
Translocated to the 
aberrant chromosome 3 
RP4-608B4 2542864 2676679 133816 Split signal 
RP11-38L8 
 
2624666 2805691 181026 Split signal 
RP11-774H09 2627884 2812495 184611 Retained in der(11) 
RP11-699D10 2849462 2999871 150409 Retained in der(11) 
RP11-211E17 6433969 6580309 146341 Retained in der(11) 
RP11-89D4 7249883 7402046 152164 Retained in der(11) 
Abbreviation: bps, base pairs 
 
Examples of the pattern of FISH signal on the metaphase spreads of some of the BAC 
probes are shown in figure 4.6. Based on the results of FISH analysis of the BAC probes, 
the breakpoint in chromosome 11p15.5 was identified within RP4-608B4 and RP11-38L8, 
~2.62-2.67 Mb (or ~400 kb centromeric to IGF2) which is in the KCQ1 gene (figure 
4.3).  
 
 
 
 
 
 
                                   A                      
 
 
 
               
 
 
Figure 4.6: FISH analysis with BAC clone probes in spectrum orange and control probes in 
spectrum green on BWSCA1 metaphase spreads 
(CEN11) as control probe.  The normal chromosome 11 has both of the green and orange signals. 
Split signals of the BAC probe are seen on the der(11) and the aberrant chromosome 3 (arrow) 
indicating a breakpoint in the pro
699D10 and control centromic 11. Both of the signals are seen on the normal chromosome 11 and 
der(11 (C) Hybridisation of RP11
both of the signals while RP11
3(arrow).  
 
 
  
                                       B                                      
      
 
  C    
 
(A) BAC probe RP4-608B4 and centromeric 11 
be locus of chromosome 11p15.5. (B) Hybridisation of RP11
-847E17 and control (CEN11). Normal chromosome 11 exhibits 
-847E17 is seen translocated onto the aberrant chromosome 
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4.3.2.2 Patient BWSCA2 
Ten BAC probes (spectrum orange) and control telomeric 11p (spectrum green) (Vysis, 
USA) were used to map the breakpoint. The hybridisation signals observed for each of the 
BAC probe used are shown in table 4.4.  
 
Table 4.4: FISH results using BAC probes in patient BWSCA2 
 
BAC probe Start position End position Length (bps) Pattern of FISH  signals 
on the inv(11) 
RP11-295K3 
1672662 1785148 112487 
Fusion (green and 
orange) on chromosome 
inv(11) 
RP5-1075F20 
2266878 2406238 139361 
Fusion (green and 
orange) on chromosome 
inv(11) 
RP11-847E17 
2426546 2542863 116318 
Fusion (green and 
orange) on chromosome 
inv(11) 
RP11-304P12 3060165 3236511 176347 
Fusion (green and 
orange) on chromosome 
inv(11) 
RP11-211E17 6433969 6580309 146341 
Fusion (green and 
orange) on chromosome 
inv(11) 
RP11-560B16 6790739 6934157 143419 
Fusion (green and 
orange) on chromosome 
inv(11) 
RP11-413N10 6934158 6984344 50187 Break apart 
RP11-715M10 6984345 7179441 195097 Break apart 
RP11-324J3 7179442 7293306 113865 Break apart 
RP11-89D4 7249883 7402046 152164 Break apart 
Abbreviations: inv, inversion; bps, base pairs 
 
 
 
 
 Probe configurations for detection of breakpoint on the inver
fluorescence in situ hybridisation (FISH) are shown in the diagrams below. 
 
                                                                
 
                                  
 
Figure 4.7: Probe configurations for detection of breakpoint by fluorescence 
(FISH).  The green oval represents control probe 11p and the red oval represents BAC probe. 
Diagrams in the top section s
the BAC probe (spectrum orange). On the inv(11), the orange signal will be seen apart from the 
green signal (control 11p). If the break occurs proximal to the BAC probe, the signals wi
or fused together (orange and green) on the inv(11) as shown in the diagrams in the bottom section. 
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Based on the pattern of FISH signals exhibited by each of the BAC probes and control 11p 
probe on the metaphase spreads of BWSCA2, the breakpoint on chromosome 11p15 of the 
patient was determined (figures 4.8, 4.9 and table 4.4).  
 
         
     A      B 
 
         
      C      D 
 
Figure 4.8: FISH analysis with telomeric probe for chromosome 11p (spectrum green) and BAC 
probes (spectrum orange) on BWSCA2 metaphase spreads. (A, B, C and D) RP11-295K3, RP11-
847E17, RP11-211E17 and RP11-560B16 respectively, hybridised together with control probe 
telomeric 11p on the metaphase spreads. Both of the signals are seen together with the control 
telomeric 11 probe on the inv(11) indicating that the breakpoint is proximal to the BAC probes. 
         
      A 
 
       
      C 
 
Figure 4.9: FISH analysis using
(A, B, C and D) Hybridisation of RP11
respectively and the control telomeric 11p probe (spectrum green)
orange in the inv(11) indicating a breakpoint in between the BAC probes and
The breakpoint was determined to localise from RP11
observed from there onwards. 
 
 
 
All the BAC probes telomeric to 
indicating the region telomer
4.8A-D). Green and orange 
     B 
  
     D 
 BAC probes (spectrum orange) on BWSCA2 metaphase spreads
-413N10, RP11-715M10, RP11
 show split signals of green and 
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4.3.3  Array analysis
The reference set for 250K Sty1 mapping arrays 
(www.hapmap.org/downloads/raw_data/affy500k/
various populations for SNP 6.0
the seven samples (BWSCA1, BWSCA2, BWSCA3, BWSCA4, BWSCA5, BWSCA7
BWSCA8) was 96.46±2.88. Two cases, 
the 11p region. The duplication in 
telomeric 11p with the size of ~
 
 
 
Figure 4.10: Copy number analysis using Affymetrix CNAT v4.0 on patient BWSCA4. 
horizontal line represents copy number state
The duplicated region of 11p15.4
state= 3). Size of the duplicated region is called at 10.3 Mb. 
green horizontal lines represent region of 
genes within the area of analysis are displayed at the bottom of the figure.
 
 
 
breakpoint was localised in ~6.93-6.98 Mb of 11p15.4 
to the ZF215 gene (figure 4.3).  
 
was 48 samples from the HapMap project 
) and 270 HapMap individuals of 
 (Goldstein and Cavalleri, 2005). The average call rate for 
BWSCA4 and BWSCA3, showed dupli
BWSCA4 was observed in chromosome 11p15.4 to 
10.3 Mb (figure 4.10).  
 (2= diploid copy number, 1= haploid copy number). 
-pter is observed as an increase in copy number (copy number 
Blue and red vertical
gain and loss respectively. Ideogram of chromosome and 
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 bars below the 
 BWSCA3 had a smaller size of duplication, about 7.0 Mb in 11
(figure 4.11). The duplicated region in both of the cases involved the imprinted genes in 
two imprinting domains regulated by IC1and IC2. 
 
 
 
Figure 4.11: Copy number analysis using Affymetrix CNAT v4.0 on patient BWSCA3. 
horizontal line represents copy number state (2= diploid 
The duplicated region of 11p15.4
state= 3). Size of the duplicated region is called at 7.0 Mb.
green horizontal lines represent region of gain and loss respectively. Ideogram of chromosome and 
genes within the area of analysis are displayed at the bottom of the figure.
 
 
 
Although patient BWSCA5
loss of heterozygosity (LOH) detected involving almost the whole short arm of the 
chromosome (figure 4.12). This is caused by uniparental disomy (UPD) most probably 
inherited from the father.  
 
 
p15.4 to the telomere 
 
copy number, 1= haploid copy number).  
-pter is observed as an increase in copy number (copy number 
 Blue and red vertical bars below the 
    
 has a normal copy number of chromosome 11 but there was 
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Green 
  
Figure 4.12: Region of LOH (represented by a continuous blue bars in the top panel) 
BWSCA5 identified using Affymetrix CNAT v4.0. 
normal copy number (copy number state= 2) 
chromosome and genes within the area of analysis are displayed at the bottom of the figure.
 
 
 
 
No copy number changes or 
and BWSCA7. This could be due to e
loss of imprinting in the BWS imprinting centre 
were also no copy number alterations identified in patients 
suggesting of a balanced rearrangement. 
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LOH were detected in chromosome 11 of 
pigenetic mechanisms such as loss of met
or unidentified genetic mechanisms. 
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Figure 4.13: Chromosome 11 log2
arrays for patient BWSCA6. The 
(copy number state= 3) represented by the horizontal green line
region of gain in the chromosome
Mb. Ideogram of chromosome and genes within the area of analysis are displayed at the bottom of 
the figure.    
 
 
 
 
 
 one patient, BWSCA6. Duplication with the size of 3.4 Mb 
4.13) and a deletion in chromosome 4p16.2
).  
 ratio analysed using the Birdseed v1 algorithm for SNP 6.0 
duplicated region is shown as an increase in copy number state 
. Blue horizontal bar represents 
. Size of the duplicated region in 11p15.4
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-pter is called at 3.4 
 Figure 4.14: Chromosome 4 log2 ratio analysed using the Birdseed v1 al
arrays for patient BWSCA6. The deleted region is shown as a decrease in copy number state (copy 
number state= 1) represented by the horizontal green line. 
loss in the chromosome. The size of the d
of chromosome and genes within the area of analysis are displayed at the bottom of the figure.
 
 
Copy number analysis on the eight patients of BWS 
table 4.5. 
 
Table 4.5: Array analysis in the eight BWS patients studied.
Patient Chromosome aberration
BWSCA1 46,XY,t(3;11)(q22;p15.4)
BWSCA2 46,XX,inv(11)( p15.4;q23.3)
BWSCA3 Dup(11)(p15.4p15.5)
BWSCA4 Dup(11)(p15.4p15.5)
BWSCA5 No
BWSCA6 
Dup(11)( p15.4p15.5)
Del(4)(p16.2
BWSCA7 
No
BWSCA8 No
Abbreviations: Mb, megabase; t, translocation; dup, d
long arm 
gorithm for SNP 6.0 
Red horizontal bar represents region of 
eleted region in 4p16.2-pter is called at 3.8 Mb.
described above 
 
 LOH 
Start 
position 
(Mb) 
End position 
(Mb)
 No - 
 No - 
 No 0 7.057
 No 0 10.307
 Yes 0 48.0
 
-p16.3) 
No 0 
3.435
3.845
 
No - 
 No - 
uplication; del, deletion; inv, inversion; p, short arm; q, 
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 Ideogram 
    
is summarized in 
 
Size  
(Mb) 
- - 
- - 
 7.0 
 10.3 
 48.0 
 
 
3.4 
3.8 
- - 
- - 
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4.4  Discussion 
BWS due to chromosome translocations, duplications or inversions is rare, encountered in 
approximately 2% of the cases (Elliott and Maher, 1994). In this study, chromosomal 
rearrangements involving chromosome 11p15.4-p15.5 were observed in five out of the 
eight cases (these were highly selected cases derived from a large cohort (~400) of BWS 
patients). One of the advantages of using 250K SNP array is that the method allows 
simultaneous identification of LOH and copy number alterations in a single experiment. In 
the present study, region of LOH with normal copy number was detected in chromosome 
11p of patient BWSCA5. This indicates that both of the copies were derived from the same 
parent, also known as uniparental disomy (UPD). No copy number gain or loss observed in 
the two cell lines (BWSCA1 and BWSCA2) indicating the rearrangements are balanced 
(or the imbalance is very small). 
 
It cannot be ascertained whether the rearrangements in BWSCA1 and BWSCA2 are 
inherited or de novo, as the parents samples were not available for testing. However, it has 
been reported that patients with BWS who have cytogenetic abnormalities involving 
chromosome 11p15.5 duplications, inversions in distal 11p or balanced translocations that 
break in this region - genomic imprinting effects are evident in the parental origin of the 
affected chromosomes. Duplications in this group of patients are invariably derived from 
the patient’s father, whereas inversions and translocations always involve the maternal 
homologue (Maher and Reik, 2000).  
 
Evidence from the FISH mapping shows that the breakpoint in chromosome 11p15.5 of 
patient BWSCA1 occurs in BWSCR1 and disrupts the maternally expressed KCQ1 gene 
which spans >400 kb. This is consistent with the report that BWSCR1 contains multiple 
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balanced
 
chromosomal translocation breakpoints associated with BWS, which
 
were 
proposed to affect an imprinting control element (Lee et al., 1997). Several studies (Sait et 
al., 1994; Brown et al., 1996; Joyce et al., 1997; Li et al., 1998) have described 
chromosomal rearrangements including translocation and inversion involving chromosome 
11p15.5 in patients with BWS. Among the alteration observed were biallelic expression of 
IGF2 and normal imprinting of H19 in an affected BWS patients with maternally inherited 
inv(11)(p11.2;p15.5) (Brown et al., 1996). Data from a large series of sporadic BWS cases 
analysed by Engel et al (2000) suggested that loss of methylation of KvDMR1 on maternal 
allele results in epigenetic silencing of CDK1C and variable loss of imprinting of IGF2. 
In another study, loss of methylation of KvDMR1 in maternal allele is associated with 
expression of the antisense transcript, KCQ1OT1 from the maternal copy (Maher and 
Reik, 2000). Loss of maternal allele methylation at KvDMR1 and biallelic KCQ1OT1 
expression occurs in 50–60% of BWS patients (Lee et al., 1999; Engel et al., 2000). 
Relating these findings with BWSCA1, the BWS phenotype of the patient could be caused 
by loss of methylation of KvDMR1 on the maternal allele which altered the normal 
expression of KCQ1 or CDK1C or KCQ1OT1 or IGF2. Further investigation such as 
methylation status of the genes can provide the information of the exact cause of BWS in 
this patient.   
 
Breakpoint in BWSCA2 was localised in ZF215 in BWSCR2 by FISH mapping. It is very 
rare to find breakpoint in this region correlated with BWS and to date, only one report 
demonstrated association of ZF215 in BWS (Alders et al., 2000). They analysed the 
breakpoints in two patients – one with inv(11p15.4) and the other with 
t(10,11)(p13;p15.4), both presented with hemihyperplasia together with other minor BWS 
features which  is not seen in patients with chromosomal breakpoint in BWSCR1 and 
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BWSCR3. In both of the patients, the chromosomal rearrangements disrupt ZF215.  
ZF215 is imprinted and expressed preferentially from the maternal allele. The gene is 
expressed in a tissue specific manner and contains 4 zinc fingers, a KRABA domain, 
sequences similar to a KRABB domain, an N-terminal SCAN box and a nuclear 
localisation signal. The breakpoint in BWSCR2 disrupts alternative spliced ZF215 
transcripts which encode a truncated protein lacking the zinc fingers but retaining the 
KRAB and SCAN box functional domains (Alders et al., 2000). They suggested that there 
is a gene(s) at BWSCR2 and BWSCR3 that interacts with some components of the 
IGF2/BWSCR1 systems and influences the BWS phenotype through this mechanism. 
Although FISH results of this study agrees with the findings of Alders et al (2000), more 
tests have to be done to verify the results.  
Approximately 20% of sporadic BWS cases have segmental paternal uniparental disomy 
involving the imprinted gene cluster at 11p15.5 (Henry et al., 1991; Slatter et al., 1994). 
Previous reports (Slatter et al., 1994; Catchpoole et al., 1997; Dutly et al., 1998; Cooper et 
al., 2007) have also shown that all cases of BWS UPD are mosaic isodisomy. Thus, the 
process of UPD occurs postzygotically due to mitotic recombination in early 
embryogenesis and lack of one or more chromosome 11 maternally expressed genes may 
lead to embryonic lethality. The region of paternal UPD invariably includes the imprinted 
gene cluster at 11p15.5, however, the extent of isodisomy along chromosome 11 is 
variable (Catchpoole et al., 1997; Dutly et al., 1998; Cooper et al., 2007). Cases of BWS 
UPD involving the whole chromosome 11 has also been reported and to date there are only 
five such cases; 4 identified by Cooper et al (2007) and 1 by Dutly et al (1998). These 
suggest that BWS UPD due to mitotic recombination is more common than mitotic 
nondisjunction in early embryo. In the present study, the patient (BWSCA5) has UPD 
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spanning from the telomeric region 11p to p11.2 (48.0 Mb) identified by high resolution 
SNP array. Genotyping analysis on chromosome 11 shows homozygous region in the 
chromosome (data not shown). Although high resolution SNP array is useful in giving a 
precise region of LOH in this case, it is unable to give information whether the segment 
was derived from paternal or maternal. However, based from the previous reports (Maher 
and Reik, 2000; Cooper et al., 2007), it is presumed that the LOH segment of chromosome 
11p in BWSCA5 was paternal in origin.  BWS UPD cases are predicted to have increased 
IGF2, reduced H19 and reduced CDK1C expression (Cooper et al., 2005).   
Hemihyperplasia is highly positively correlated with UPD 11p15 in BWS (Engel et al., 
2000; DeBaun et al., 2002; Cooper et al., 2005) and in some cases, isodisomy can be 
detected in only a small subset of tissue in the patient (Weksberg et al., 2001). There is no 
known instance of recurrence of segmental UPD 11 and as a postzygotic event, it is 
assume no increased risk would apply. 
Paternally inherited cases of overgrowth have been described
 
previously; in these cases, 
unbalanced translocations
 
leading to trisomy for 11p with paternal duplication have been
 
responsible (Slavotinek et al., 1997), however de novo duplications of the paternally 
derived 11p15 region were also found. Using microsatellite analysis, Russo et al. (2006) 
have identified a small duplication at 11p15.5 involving IC1 and excluding IC2, spanning 
1.8 Mb in a patient with features of BWS who had a de novo paternal tandem duplication. 
This was proposed to result from an unequal recombination at
 
paternal meiosis 1. In the 
present study, patient BWSCA6 has an unbalanced translocation t(4;11)(p16.2;p15.4) 
leading to paternal duplication of 11p15.4-pter (3.4 Mb) and deletion of 4p16.2-pter (3.8 
Mb).  In addition to BWS, deletion of 4p16.3 contributes to the Wolf-Hirschhorn 
syndrome features in BWSCA6. Wolf-Hirschhorn syndrome is characterised by severe 
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growth and mental defect, microcephaly, 'Greek helmet' facies, and closure defects (cleft 
lip or palate), coloboma of the eye and cardiac septal defects (Hirschhorn et al., 1965; 
Wolf et al., 1965). Two other reports (Russo et al., 2006; Mikhail et al., 2007) have also 
described overlapping phenotype of Wolf-Hirschhorn and BWS in their patients.   The 
duplication 11p15.4-pter identified in BWSCA3 and BWSCA4 involved large segments, 
7.0 Mb and 10.3 Mb respectively, spanning from 11p15.4 to the telomere 11p. No copy 
number changes were detected in the other chromosomes, indicating that the duplication 
was not due to unbalanced translocation. Although the extent of the duplicated region in 
these patients is variable, the phenotypic expression of BWS is presumably due to the 
presence of a common duplicated region. 
 
The duplicated region 11p15.4-pter identified in BWSCA3, BWSCA4 and BWSCA6 
involved both of the ICs, therefore, all of the genes implicated with BWS in 11p15.4-p15.5 
were duplicated. The duplication is predicted to disrupt the dosage
 
and expression of 
normally paternally and maternally expressed genes as well as non-imprinted
 
genes.  The 
paternally expressed gene, IGF2 is thought to be overexpressed while effective dosage of 
maternally expressed genes including H19, KCQ1 and CDK1C are predicted to remain 
unchanged. The IGF2 gene encodes a fetal growth factor and overgrowth in BWS is 
restricted to those tissues in which IGF2 is expressed. In mice, over-expression of IGF2 
results in most of the symptoms of BWS, including prenatal overgrowth, polyhydramnios, 
fetal and neonatal lethality, disproportionate organ overgrowth and macroglossia (Sun et 
al., 1997). Cases  with maternal duplication 11p15 were also been reported but none of the 
patients showed features of BWS; three patients had growth retardation, in contrast to the 
overgrowth characteristic of BWS (Fisher et al., 2002) and two patients represented with 
Silver-Russel syndrome (Eggermann et al., 2006). These observations support the 
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hypothesis that paternally expressed genes promote growth and maternally expressed 
genes have the opposite effects. There were no copy number changes or LOH observed in 
BWSCA8 and BWSCA7, thus the BWS phenotype in the patients could be due to 
epimutations which alter the methylation or expression of the imprinted gene(s) in 11p15.  
 
The findings of this study is consistent with the previous reports; the breaks identified in 
11p15.4 due to inversion and translocation disrupts the imprinted genes in that region and 
alterations in the normal doses of genes caused by duplications of paternal allele or 
paternal UPD can also contribute to the BWS phenotype. To the best of my knowledge, 
patient BWSCA2 is the third BWS found with breakpoint in ZF215.  Thus, further 
studies should be taken to elucidate the role of ZF215 in BWS.    
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5 Analysis of copy number changes in primary tumours of clear cell renal 
cell carcinoma (cRCC) and renal cell carcinoma (RCC) cell lines using 
250K SP array  
 
5.1    Introduction 
Kidney cancer constitutes about 2% of all malignant tumours in adults (Clifford et al., 
1998). It is the seventh most common cancer in men and ninth most common in women,  a 
male-predominant (2:1) disease with a typical presentation in the sixth and seventh 
decades of life (median age about 60 years) (Maher et al., 1990a). Incidence rates for the 
cancer have been rising steadily each year in Europe and the United States (Mathew et al., 
2002) and it is estimated to account for about 209,000 new cases per year and 102,000 
deaths per year (Gupta et al., 2008). Incidence is generally highest in Western and Eastern 
European countries, Scandinavia, parts of Italy, North America and in Australia/New 
Zealand. The lowest incidence is reported in Asia and Africa (Ferlay et al., 2004).  
 
Several environmental factors have been reported to be associated with an increased risk of 
renal cell carcinoma (RCC). Active and passive cigarette smoking is an established risk 
factor for RCC (Yuan et al., 1998; Hunt et al., 2005). Obesity, specifically body mass 
index, also has a positive association with risk of RCC (Bjorge et al., 2004; van Dijk et al., 
2004). Another known risk factor is hypertension (Lipworth et al., 2006) with data 
showing hypertensive medication such as diuretic medications are not independently 
associated with the risk of the development of the cancer (McLaughlin et al., 1995; 
Grossman et al., 1999; Grossman et al., 2002). Patients with end stage renal failure, 
acquired renal cystic disease and various hereditary kidney cancer syndromes have a 
higher risk of developing RCC than in the general population (Ishikawa et al., 2003; 
Rakowski et al., 2006). Exposure to asbestos or trichloroethylene has not been 
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convincingly associated with RCC (McCredie et al., 1995). Other factors such as alcohol 
consumption, vegetable and fruit consumption, intake of micronutrients and vitamins 
showed less consistent association with the risk of RCC (Wolk et al., 1996; Mellemgaard 
et al., 1999; Dhote et al., 2000; Lindblad et al., 2004).  
 
Renal parenchyma (renal cell) cancer accounts for about 85% of kidney cancers diagnosed 
in the United states from 1992 to 2002 The remainder was composed mainly of renal 
pelvis cancer (approximately 12%) and other rare malignancies (approximately 2%). All 
renal cell cancers are adenocarcinomas and the majority of the renal pelvis cancers are 
transitional cell carcinomas (Lipworth et al., 2006). Renal cell carcinomas (RCC) are 
adenocarcinomas derived from tubular epithelium. Most cases of RCC occur sporadically, 
only about 2%-3% of cases are inherited (Maher, 1996a) RCC is divided into 5 subtypes 
based on histological pattern: clear cell (conventional) is the most common type (70%-
80%), papillary occurs in 10%-15% and chromophobe renal carcinoma occurs in 3%-5%, 
with the remaining being made up of collecting duct (1%) and unclassified (1%). Papillary 
is further divided into type 1 (5% of the cases) and type 2 (10% of the cases) (Kovacs et 
al., 1997).  These different types of RCC have different histological patterns, different 
clinical courses and each have a distinct genetic basis (Linehan et al., 2003).  
 
5.1.1   Classification of renal cell carcinoma (RCC) 
Renal cell carcinoma (RCC) originates from the tubular epithelial cells of the renal cortex 
and accounts for 80-85% of primary malignancies in kidney (Motzer et al., 1996). RCC 
comprises of different types of tumours, each derived from different parts of the nephron.  
The nephron consists of the renal corpuscle and renal tubule which is divided into four histo-
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physiological zones: proximal convoluted tubule, loop of Henle, distal convoluted tubule and 
collecting duct (figure 5.1). 
 
           
 
Figure 5.1: Anatomy of the kidney. The kidney is divided into two major structures: superficial is 
the renal cortex and deep is the renal medulla. Nephrons consist of the renal corpuscle and renal 
tubules and span the cortex and medulla.  
 
 
 
In 1996, the Heidelberg classification of RCC was proposed with the aim of integrating 
histological criteria and an understanding of genetic alterations (Kovacs et al., 1997). 
According to the classification, RCC can be classified into three major subtypes: clear cell 
RCC (also known as conventional RCC), papillary RCC and chromophobe RCC. Other 
less frequent subtypes include multilocular cRCC, collecting duct carcinoma, medullary 
carcinoma and unclassified type. The WHO classification of 2002 is more comprehensive 
and in addition to the previous subtypes also includes renal carcinoma associated with 
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neuroblastoma, Xp11 translocation carcinoma and mucinous tubular and spindle cell 
carcinoma (figure 5.2).  
 
           A 
 
         Clear cell                          Papillary type 1                      Papillary type 2 
            B         
                                                                                                                                       
                          Chromophobe                       Collecting duct                    Mucinous tubular 
                                                                             carcinoma 
                                      
Figure 5.2: The different RCC subtypes. (A) Clear cell RCC and papillary RCC from the proximal 
convoluted tubule (B) chromophobe RCC, collecting duct carcinoma and mucinous tubular and 
spindle cell carcinoma from the collecting tubule.  
 
The most common (~80%) forms of RCC are clear cell carcinoma (cRCC) and among the 
nonclear cell type, papillary (chromophilic) and chromophobic tumours are the most 
frequent (Thoenes et al., 1986). Most cases of cRCC are sporadic and the tumours are 
unilateral and unifocal. Papillary RCC are often bilateral and multifocal.  The 
chromophobe variant of RCC accounts for 5% of all cases of RCC and is thought to 
originate from type B intercalated cells of renal collecting ducts (Crotty et al., 1995; 
Storkel et al., 1997). Papillary RCC is further divided into type 1 and type 2. Type 1 
tumours are usually of lower-grade and stage than type 2 tumours (Amin et al., 1997; 
Delahunt et al., 2001). Collecting duct (Bellini duct) carcinomas are thought to originate 
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from the collecting ducts within the renal medulla (Rumpelt et al., 1991; Storkel et al., 
1997). Collecting duct RCC are very aggressive and tend to occur in younger patients. 
Medullary carcinoma is a variant of collecting duct carcinoma (Swartz et al., 2002) which 
preferentially appear in younger patients with sickle trait and regarded as a more 
aggressive variant of collecting duct carcinoma with a mean survival time after surgery of 
15 weeks (Srigley and Eble, 1998). The unclassified RCCs which accounts for 4-5% of all 
cases (Storkel et al., 1997; Kovacs et al., 1997) are a diagnostic category of renal tumours 
which do not fit into one of the other subtypes.  
 
Mucinous tubular and spindle cell carcinoma are thought to originate from the distal 
nephron (Argani et al., 2001) and are reported to be a low-grade renal epithelial neoplasm 
characterized by an indolent course and female predominance. RCC associated with 
neuroblastoma occurs in long term survivors of childhood neuroblastoma, is 
morphologically heterogeneous and prognosis correlates with tumour grade and stage 
(Koyle et al., 2001).  
 
 5.1.2   Genetics of clear cell renal cell carcinoma (cRCC) 
Zbar et al (1987) examined tumours from 18 patients with non-hereditary renal cell 
carcinoma and found loss of alleles at loci on the short arm of chromosome 3 in eleven of 
the patients. By studying loss of alleles at different chromosomal loci on normal and 
tumour tissue from 60 patients with various stages of renal cell carcinoma, Anglard et al 
(1991) suggested that the disease genes for sporadic renal cell carcinoma and for familial 
renal cell carcinoma associated with von Hippel-Lindau disease are in the same location. 
More importantly, they had refined the specific region in 3p21-p26.  Subsequently, genetic 
linkage studies in families with von Hippel-Lindau disease followed by physical mapping 
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analyses resulted in the identification of the von Hippel-Lindau (VHL) tumour suppressor 
gene in the 3p25-p26 region (Latif et al., 1993).  
 
Clear cell renal cell carcinoma is genetically characterized by deletions of the short arm of 
chromosome 3 and this was reported to be as the only karyotypic changes in about 10% of 
cases (Bodmer et al., 2002). Complete or partial loss of chromosome 3p is the most 
frequent alteration in cRCC suggesting the presence of one or more tumour suppressor 
gene(s) in this chromosome responsible for tumour development (Presti et al., 1998; 
Huebner, 2001; Sukosd et al., 2003). Deletions of 3p occur commonly in renal cell 
carcinoma associated with VHL disease and although von Hippel-Lindau disease is a rare 
cause of RCC, somatic inactivation of the VHL gene occurs in a high percentage of clear 
cell RCC tumours and cell lines from patients with sporadic (nonhereditary) clear cell 
renal carcinoma (Foster et al., 1994; Gnarra et al., 1994; Clifford et al., 1998; Zbar et al., 
2003; Kim et al., 2004; van Houwelingen et al., 2005; Weiss and Lin, 2006; Banks et al., 
2006). Inactivation of VHL can be due to somatic mutations, deletions, LOH or epigenetic 
inactivation such as promoter DNA methylation.  
 
Chromosome 3p deletions in cRCC are large and are not limited to the VHL gene region 
(3p25-p26). Loss of heterozygosity (LOH) study on sporadic cRCC identified three 
regions on chromosome 3p that are recurrently affected: 3p12-p14, 3p21-p22 and 3p25-
p26 (Van den Berg and Buys, 1997). It was suggested that an allelic loss in either 3p25 or 
3p12-p14 is associated with adenomas whereas in carcinoma also involved losses in 3p21 
together with 3p25 or 3p12-p14. In another studies to evaluate whether VHL gene 
inactivation is essential for tumour formation, the patterns and extent of allelic losses on 3p 
were compared in a set of cRCCs both with and without VHL mutations. This study 
143 
 
revealed that although the frequency of 3p12-p22 LOH was similar in both tumour types, 
LOH at 3p25-p26 was significantly less than LOH at 3p12-p22 in tumours without VHL 
mutation, whereas LOH at 3p25-p26 and 3p12-p22 was similar in tumours with VHL 
mutation (Teh et al., 1997; Martinez et al., 2000; Woodward et al., 2000a). These results 
supported the presence of both VHL-dependent and VHL-independent tumourigenic 
pathways and suggested that inactivation of a tumour suppressor gene at 3p12-p22 may 
play an important role in both these pathways. Subsequently the RASSF1A tumour 
suppressor gene that maps to 3p21 was found to be methylated in many RCC (Morrissey et 
al., 2001).  
 
Predisposition to clear cell carcinoma may be associated with constitutional cytogenetic 
rearrangements involving chromosome 3p. The first report was of an Italian-American 
family who was affected with renal carcinoma in multiple family members (Cohen et al., 
1979). Upon investigation of the affected family members, it was found that they had a 
germline balanced translocation involving chromosome 3p, t(3;8)(p14;q24). In another 
family, several siblings carried a constitutional t(3;6)(p13;q25) and one of them developed 
multiple bilateral RCCs (Kovacs et al., 1989). Positional cloning of the constitutional 3;8 
translocation breakpoints revealed that the FHIT gene spanned the chromosome 3 
breakpoint (Ohta et al., 1996). The gene co-localises with FRA3B, which is the most 
common inducible fragile site within the human genome (Ong et al., 1997). Hemi- or 
homozygous deletion of FHIT and reduced expression of the gene had been reported in 
several neoplasms including kidney, lung, cervix, esophagus, colon, stomach and pancreas 
tumours, implicating a role in tumour development (Sozzi et al., 1996; Virgilio et al., 
1996; Druck et al., 1997; Hadaczek et al., 1999; Eyzaguirre et al., 1999). The chromosome 
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8 breakpoint disrupted the TRC8 gene (Gemmill et al., 1998) and this gene may also 
function as a tumour suppressor gene (Teh et al., 1999).  
 
Two Dutch families were also reported to display an association between constitutional 
chromosome 3 translocations and RCC. The first one involved five members over three 
generations carrying a constitutional t(2;3)(q35;q21) who developed RCC (Koolen, et al., 
1998; Bodmer et al., 1998). In the second family, a t(3;6)(q12;q15) was transmitted and 
four members were diagnosed with cRCC (Eleveld et al., 2001). Other families have also 
been reported with different translocations e.g. t(3;4)(p13;p16), t(2;3)(q33;q21) and 
t(1;3)(q32;q13.3) (van Kessel et al., 1999; Kanayama et al., 2001; Podolski et al., 2001). 
Positional cloning of the familial t(2;3)(q35;q21) breakpoint revealed disruption of DIRC2 
which resides on chromosome 3 (Bodmer et al., 2002) while in the t(2;3)(q33;q21) family, 
DIRC1 on chromosome 2 was found to be disrupted (Druck et al., 2001). 
 
Although in some of the cases of familial cRCC associated with constitutional 
chromosome 3 translocations characterisation of the translocation breakpoint has revealed  
presence of a putative tumour suppressor gene for example (e.g. FHIT, TRC8, DIRC1, 
DIRC2, ORE1 and LSAMP) (Ohta et al., 1996; Gemmill et al., 1998; Druck et al., 2001; 
Bodmer et al., 2002; Chen et al., 2003; Poland et al., 2007) or fusion transcript, in some 
cases no gene is disrupted or the disrupted gene does not appear a likely candidate tumour 
suppressor gene (Gemmill et al., 1998; Bodmer et al., 2002; Bugert et al., 2007).
 
Hence in 
some cases it has been suggested that RCC susceptibility results not from direct disruption 
of a gene but from instability of the derivative chromosome 3 such that loss of the 
derivative chromosome 3 (that contains a VHL allele) through nondisjunction and 
subsequent somatic VHL gene mutation on the non-translocated chromosome 3 
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homologue. This process would result in homozygous loss of VHL function and has been 
termed a three-step
 
model of tumourigenesis (Schmidt et al., 1995; Bodmer et al., 1998; 
Bodmer et al., 2002). Thus the first
 
hit would be the occurrence of a germ line 
chromosome 3 translocation.
 
Non-disjunctional loss of the derivative chromosome that 
carries
 
the 3p segment would represent the second step. Finally, the
 
third step would 
involve a somatic mutation in the remaining
 
3p allele of an RCC-related tumour suppressor 
gene (TSG) such
 
as VHL. 
 
Recently developed high resolution methods for genomic copy number analysis such as 
array based comparative genomic hybridisation (aCGH) can offer a high resolution 
information on copy number changes in cancer on a genome-wide level. Genomic DNA 
copy number alterations (CNA) have been shown to be a contributing factor in the 
development and progression of cancer. In cRCC, common somatic chromosomal changes 
in sporadic cases include loss of 3p, 4q, 6q, 8p, 9q and 14 and gain of 5q and 7 have been 
reported (Sanjmyatav et al., 2005).  
 
5.1.3   Inherited renal cell carcinoma  
A number of inherited disorders may predispose to RCC.  Inherited RCC is characterised 
by an earlier age at diagnosis than in sporadic and inherited tumours are often multicentric 
and/or bilateral. Von Hippel-Lindau disease, hereditary type 1 papillary renal carcinoma 
(HPRC1), hereditary leiomyomatosis and renal cell carcinoma (HLRCC), Birt-Hogg-Dubé 
syndrome are examples of inherited disorders predisposing to renal cell carcinoma. 
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5.1.3.1 Hereditary papillary renal carcinoma (HPRC) 
HPRC is very rare with an approximate incidence 1 per 10 million persons. It is an 
autosomal dominant hereditary cancer syndrome, a highly penetrant disease in which 
patients have a high risk of developing bilateral and multifocal type 1 papillary RCC 
(pRCC) (Zbar et al., 1994).  The tumours are most often well differentiated, malignant and 
can metastasize. Genetic studies in kindreds with familial pRCC led to the identification of 
MET proto-oncogene located on the long arm of chromosome 7 (Schmidt et al., 1997). 
MET mutations are rare in sporadic pRCC, only about 5% of the cases (Schmidt et al., 
1997; Schmidt et al., 1999). Furthermore, about 75% of sporadic pRCC cases have trisomy 
of chromosome 7 (Cohen and McGovern, 2005).  
 
5.1.3.2 Hereditary leiomyomatosis renal cell carcinoma (HLRCC) 
HLRCC is rare and dominantly inherited disorder caused by germline mutations in the 
fumarate hydratase gene (FH) (Tomlinson et al., 2002). Fumarate hydratase is a key 
component of the tricarboxylic acid cycle (Krebs cycle) and catalyses the conversion of 
fumarate to malate. HLRCC was first described in a Finnish family in which eleven 
members had uterine leiomyomas, two had uterine leiomyosarcoma and seven individuals 
had a history of cutaneous nodules (two of which were confirmed to be cutaneous 
leiomyomatosis). In addition, four kidney cancer cases occurred in young (33-48 years 
old) females and the tumours are different from those that appear in patients with VHL, 
HPRC and BHD. Kidney cancers in HLRCC displayed a distinct papillary histology (type 
2 pRCC) and presented as unilateral solitary lesions that had metastasized at the time of 
diagnosis (Launonen et al., 2001).  
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5.1.3.3 Birt-Hogg-Dubé (BHD) syndrome 
BHD is a hereditary cancer syndrome with an autosomal dominant inheritance pattern. It is 
characterised by a cutaneous tumours (typically fibrofolliculomas), multiple lung cysts, 
spontaneous pneumothorax and renal tumours (Menko et al., 2009). Approximately a 
quarter of patients with BHD have RCC (mean age at diagnosis 50 years) with the 
youngest affected individual at 20 years (Menko et al., 2002; Toro et al., 2008). 
Chromophobe RCC and mixed chromophobe/oncocytic tumours are typical for BHD but 
the histopathology is variable and other histological subtypes including clear cell have 
been reported (Pavlovich et al., 2002). The BHD gene maps to 17p11.2 (Schmidt et al., 
2001; Khoo et al., 2001) and germline mutations in a novel gene, FLC, that encodes for 
folliculin was identified (Nickerson et al., 2002).  
 
5.1.3.4  Von Hippel-Lindau (VHL) disease 
Von Hippel-Lindau (VHL) disease (MIM number 193300) is a dominantly inherited 
familial cancer syndrome that affects approximately 1 in 36,000 individuals and ~20% of
 
cases arise as de novo mutations without a family history (Maher et al., 1991a; Richards et 
al., 1995). It was first reported in the medical literature more than 100 years ago by 
Treacher Collins who described bilateral vascular growths in the retinas of two siblings 
(Collins E, 1894). Ten years later, a similar observation was described in another family by 
a German ophthalmologist, Eugene von Hippel (Hippel Ev, 1904). Arvid Lindau, a 
Swedish pathologist, had noted that these retinal lesions were associated with an increased 
risk of developing hemangioblastoma of the brain and spinal cord (Lindau A, 1927). The 
disease was then referred as ‘Lindau’s disease’ until 1936 when Charles Davison first used 
the eponym ‘von Hippel-Lindau disease’ (Davison et al., 1936).  
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Individuals with VHL disease carry one wild-type VHL allele
 
and one inactivated VHL 
allele i.e. VHL patients
 
are VHL heterozygotes. Tumour or cyst development in VHL 
disease
 
is linked to somatic inactivation or loss of the remaining wild-type
 
VHL allele. 
Patients affected by VHL are at a high risk of developing clear cell RCC (>70% lifetime 
risk), retinal and cerebellar haemangioblastomas, phaeochromocytomas and renal, 
pancreatic and epididymal cysts (Maher, 2004).  VHL-associated renal tumours are 
uniformly of clear cell renal carcinoma and is often multifocal and bilateral (Mandriota et 
al., 2002).  The age at which clinical symptoms or signs develop is highly variable and the 
most common causes of death are unresectable hemangioblastoma or late diagnosed cRCC 
(Maher and Kaelin, 1997). It has been estimated that the risk of renal cell carcinoma in 
VHL disease is >70% by the age of 60 years (Maher et al., 1990b). 
 
Clinically, VHL families can be subdivided into type 1 or type 2 based on the absence or 
presence of pheochromocytoma. Type 1 is characterized by a low risk of 
pheochromocytoma. It is associated with large deletions and truncating mutations typically 
predispose to hemangioblastomas and RCC but not pheochromocytoma (Crossey et al., 
1994; Maher et al., 1996b; Zbar et al., 1996). Type 2 is usually caused by surface missense 
mutations and is associated with high risk of pheochromocytoma. An explanation for these 
findings would be that pheochromocytoma development is due to a mutant pVHL ‘gain-
of-function’ or complete loss of pVHL functions is incompatible with pheochromocytoma 
development (Kondo and Kaelin, 2001). Type 2 can be further divided into type 2A, type 
2B and type 2C. Type 2A has a low risk of RCC while type 2B has a high risk of RCC. 
Type 2C is associated with familial pheochromocytoma without the other stigmata of VHL 
disease (Crossey et al., 1995; Eng et al., 1995; Ritter et al., 1996; Woodward et al., 1997; 
Neumann et al., 1998; van der Harst et al., 1998).  
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Essentially, all VHL patients have a mutation in the VHL gene which resides in 3p25. VHL 
gene mutations have been reported in >500 VHL kindreds (Latif et al., 1993; Crossey et 
al., 1994; Chen et al., 1995; Zbar et al., 1996; Maher et al., 1996b; 
http://www.umd.necker.fr). Among patients with VHL
 
disease, ~40% of mutations are 
genomic deletions and the rest
 
are protein truncating mutations (nonsense, frameshift 
insertions and deletions, splice site mutations) or intragenic missense mutations. Recurrent 
missense mutations were also noted in some families which occur at a CpG mutation 
hotspot at codon 167, for example p.R167W and p.R167Q (Richards et al., 1995). 
Although a wide variety of mutations have been described, no mutations have been 
reported in the first 53 amino acids of pVHL30 (Woodward and Maher, 2006).  
 
5.1.4   Von Hippel-Lindau (VHL) gene  
Linkage analysis of VHL kindreds mapped the VHL locus to chromosome 3p25 (Seizinger 
et al., 1988). The gene, VHL, was isolated in 1993 using a positional cloning strategy 
through an international collaboration led by Eamonn Maher (University of Cambridge, 
England),  Michael Lerman, Marston Linehan and Berton Zbar (National Cancer
 
Institute, 
United States)(Latif et al., 1993). The VHL gene contains three exons and encodes an 
mRNA of approximately 4.5 kb with a long 3’-untranslated region (Latif et al., 1993; 
Renbaum, 1996). The VHL mRNA encodes a protein (pVHL) that contains 213 amino acid 
residues and migrates with apparent molecular weight of about 24 to 30 kDa (VHL30) 
(Iliopoulos et al., 1995). The primary sequence of pVHL does not closely resemble any of 
other known proteins. A second pVHL isoform of approximately 19kDa (VHL19) is 
produced as a result of internal translational initiation at an in-frame start codon (ATG) at 
codon 54 (Schoenfeld et al., 1998; Iliopoulos et al., 1998; Blankenship et al., 1999). pVHL 
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shuttles between the nucleus and cytoplasm (Duan et al., 1995; Lee et al., 1996; Ye et al., 
1998; Lee et al., 1999).  
 
Knowledge of the function of the VHL tumour suppressor gene product (pVHL) was 
derived from a number of strategies including observing the effects of reintroducing the 
wild-type VHL gene into cultures of cells which lack functional pVHL. Thus in sporadic 
clear cell RCC cell lines with pVHL inactivation, the reintroduction of wild-type pVHL 
into the VHL null RCC cell lines restored normal oxygen-dependent regulation of vascular 
endothelial growth
 
factor (VEGF) and other hypoxia-inducible RNAs (Siemeister et al., 
1996; Gnarra et al., 1996; Levy et al., 1996). Iliopoulos et al (1995) demonstrated that 
VHL was a tumour suppressor gene as, when introduced to VHL deficient cells, it 
suppressed tumour growth in nude mice. pVHL is regarded as a ‘gatekeeper’ tumour 
suppressor gene product rather than a ‘caretaker’ due to its ability to suppress growth of 
fully transformed cells.  
 
Both VHL gene products, pVHL30 and pVHL19 can inhibit the production of the hypoxia-
inducible proteins when reintroduced into renal carcinoma cells that lack the wild-type 
VHL allele. The relationship between VHL disease and HIF-α in RCC was first described 
by Maxwell et al (1999). They reported that cells lacking pVHL are unable to degrade 
HIF-α under both normoxic and hypoxic conditions, thus cells deficient in pVHL behave 
as being hypoxic (pseudohypoxic) even in normoxic conditions due to continuous HIF-α 
activation (Maxwell et al., 1999; Cohen and McGovern, 2005; Weiss and Lin, 2006). The 
fact that only a subgroup of VHL mutation carriers develop RCC and about 25%-30% of 
sporadic cRCC do not involved alterations in the VHL gene suggests involvement of other 
genes responsible for tumourigenesis of cRCC that might affect the same signalling 
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pathway as VHL or other mechanisms to inactivate VHL for example biallelic VHL 
inactivation due to loss of heterozygosity or methylation (Young et al., 2009).  
 
5.1.5   Function of the VHL protein (pVHL) 
The VHL protein (pVHL) has been implicated in several processes but the most well-
defined is its role in regulating proteolytic degradation of the α subunits of the hypoxia 
inducible factor (HIF), HIF-1 and HIF-2 transcription factors. pVHL has two distinct 
protein binding domains: an α domain interacts with the elongin C protein, which in turn 
interacts with elongin B and Cullin-2 to form a tetrameric VCBC complex, and a β domain 
surface binding site which binds HIF-1α and HIF-2α subunits (Pause et al., 1997; 
Lonergan et al., 1998; Maxwell et al., 1999). Moreover, the
 
Rbx-1 protein was then shown
 
to associate with the VCBC complex (Kamura et al., 1999).  
Hemangioblastoma and other VHL-related tumours are highly vascular and demonstrate 
over-production
 
of hypoxia-inducible mRNAs such as vascular endothelial growth
 
factor 
(VEGF) (Wizigmann-Voos et al., 1995). Many hypoxia-inducible
 
mRNAs are under the 
control of heterodimeric transcription factors
 
(HIF-1 and HIF-2), which consist of a 
degradable α subunit
 
and a stable constitutively expressed beta subunit (Schofield and 
Ratcliffe, 2004).
 
Under normoxic conditions, HIF-1α and HIF-2α are bound by VHL and 
VCBC complex induces polyubiquitylation and proteosomal degradation (Maxwell et al., 
1999; Cockman et al., 2000; Kamura et al., 2000) but under hypoxic conditions
 
the α 
subunits are stabilised and HIF-1 and HIF-2 activate
 
transcription of a wide repertoire of 
hypoxia-inducible mRNAs
 
(Schofield and Ratcliffe, 2004).
 
In the absence of functioning 
pVHL (mutant pVHL), HIF-1 and HIF-2 expression is upregulated, leading to 
upregulation in expression of hypoxia-inducible mRNAs (Maxwell et al., 1999; Cockman 
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et al., 2000) (Figure 5.3). The oxygen-dependent interaction of pVHL
 
with HIF-α is 
provided by the hydroxylation status of key HIF-α
 
proline residues (Pro-402 and Pro-564) 
(Ivan et al., 2001; Jaakkola et al., 2001;
 
Masson et al., 2001; Yu et al., 2001). Thus, in the 
presence of
 
oxygen, HIF-α subunits are hydroxylated at the conserved prolyl
 
residues by 
members of the egg laying defective nine (EGLN)
 
family (also known as the PHD family) 
(Bruick and McKnight 2001;
 
Epstein et al., 2001). Molecular oxygen and 2-oxoglutarate 
are
 
essential cosubstrates and iron is an essential cofactor (Epstein et al., 2001;
 
Schofield 
and Ratcliffe, 2004) and, in the absence of these,
 
hydroxylation does not occur and pVHL 
is unable to bind the
 
alpha subunits. In humans, three EGLN homologues have been 
implicated
 
in HIF-α modification (PHD1/EglN2/HIFPH1, PHD2/EglN1/HIFPH2 and
 
PHD3/EglN3/HIFPH3) (Bruick and McKnight 2001; Epstein et al., 2001).
  
 
 Figure 5.3: Relationship between VHL protein (pVHL) and regulation of hypoxia
α subunits. (A) Under normoxic conditions, pVHL binds to HI
ubiquitylation and proteosomal degradation. The ability of pVHL to bind an HIF
dependent on hydroxylation of two proline residues (POH). 
inactivation, the lack of wild
heterodimeric transcription factors activate expression of a wide repertoire of hypoxia
genes. (C) In hypoxia, the two critical proline residues in the α subunit are not hydroxylated (P) 
and pVHL is unable to bind HIF
(Adapted from: Woodward and Maher, 2006
 
5.1.6   Clear cell renal cell carcinoma and 
Mutations in the VHL gene are mostly restricted to cRCC (Banks et al.
patients with VHL disease are always of clear cell histology. 
VHL causes the von Hippel
type of this gene have been linked to the development of 
(Kim and Kaelin, 2004). 
 
F-α subunits leading to 
(B) In a tumour with pVHL 
-type pVHL allows HIF-α and HIF-ß subunits to interact and the 
-α, leading to activation of the hypoxia-inducible gene response.
) 
VHL tumour suppressor gene
, 2006) and RCC in 
Germline inactivation of the 
-Lindau disease, and somatic mutations of 
tumour or cyst in VHL disease 
 Thus VHL disease conforms to the Knudson 2
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-inducible factor 
-α subunit is 
-inducible 
 
 
the remaining wild 
-hit model 
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(Knudson, 1971). In sporadic form of cRCC, biallelic VHL inactivation (due to 
hypermeyhylation or mutation) is also common whereby both the first hit and second hit 
occur somatically ie. after conception rather than in the germline.  
 
Mutations in VHL are extremely heterogenous: 20-37% of VHL patients have large or 
partial germline deletion, 30-38% have missense mutations and 23-27% have nonsense or 
frameshift mutations (Maher and Kaelin, 1997; Stolle et al., 1998). The mutations are 
distributed throughout the coding sequence except that intragenic missense mutations are 
rarely observed in the first 50 codons (Zbar et al., 1996). Furthermore, type 2 VHL patients 
almost invariably harbour VHL missense mutations while patients with type 1 frequently 
harbour VHL deletions or truncation mutations (Crossey et al., 1994; Chen et al., 1995; 
Maher et al., 1996b; Zbar et al., 1996).  
 
Kidneys removed from VHL patients typically contain a multitude of smaller lesions or 
preneoplastic
 
renal cysts of varying sizes and renal cell carcinomas.  Immunohistochemical 
and
 
genetic evaluation of the epithelial cells lining these renal
 
cysts show early loss of VHL 
and overexpression of HIF and HIF
 
target genes such as VEGF (Zhuang et al., 1994; 
Zhuang et al., 1996; Lubensky et al., 1996; Wiesener et al., 2001; Mandriota et al., 2002).  
Overexpression of HIF-responsive
 
growth factors, as well as their receptors, is also a 
feature
 
of renal carcinomas (Mydlo
 
et al., 1989; Lubensky
 
et al., 1996). Thus, VHL likely 
serves as an early "gatekeeper" tumour suppressor
 
gene for renal cell carcinoma and it is 
presumed that further genetic alterations are
 
needed for progression of preneoplastic renal 
cysts to renal
 
carcinomas (figure 5.4). 
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Figure 5.4: Pathogenesis of von Hippel-Lindau (VHL) disease-associated renal cell carcinoma. 
Biallelic VHL inactivation in a renal tubular epithelial cell stabilizes HIF, correlating with the 
formation a premalignant renal cyst. Alterations at other loci are probably required for carcinoma 
development. In VHL disease, the first VHL mutation (hit) is present in the germline. 
(Adapted from Kim and Kaelin, 2004) 
 
 
This study is aim to identify copy number changes and characterise chromosomal changes 
in primary tumours of clear cell renal cell carcinoma from sporadic, VHL disease and renal 
cell carcinoma cell lines using 250K SNP Array.  
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5.2    Materials and methods 
5.2.1 DNA samples 
Genomic DNA was extracted from primary renal cancers (sporadic and VHL) and cell 
lines by standard methods and stored at -80
o
C. Three groups of renal cancers were 
investigated: (a) 21 clear cell RCC from 21 patients with von Hippel-Lindau disease, (b) 
13 sporadic clear cell RCC without evidence of somatic VHL mutations or promoter 
methylation (details of mutation and methylation analyses have been reported previously 
(McRonald et al., 2009) (c) 23 RCC cell lines which include 786O, 769P, A498, A704, 
ACHN, Caki1, Caki2, CAL54, KTCL26, KTCL140, RCC1, RCC4, RCC6, RCC11, 
RCC12, RCC48, SKRC18, SKRC39, SKRC45, SKRC47, SKRC54, UMRC2 and 
UMRC3. Ethical approval for collection of clinical material was obtained from the South 
Birmingham Ethics Committee and relevant local ethics committees. DNA concentrations 
were measured with Nanodrop model ND-1000 spectrophotometer (NanoDrop 
Technologies, Wilmington, DE).  
 
5.2.2  Affymetrix GeneChip 250K mapping arrays  
Experiments were performed according to standard protocols for Affymetrix GeneChip 
Mapping 250K sty1 arrays (Gene Chip Mapping 500K Assay Manual (P/N 701930 Rev2., 
Affymetrix Santa Clara, CA). Quality control, genotype calling, and probe level 
normalization were made in the Affymetrix GeneChip Genotyping Analysis Software 
(GTYPE) 4.1. The Dynamic Model (DM) algorithm was used to perform quality control, a 
call rate >93% was required. Genotype calls were made using the BRLMM algorithm 
(Rabbee and Speed, 2006). Subsequent analysis, including copy number normalization to 
produce log2 ratios was performed using the genotyping console (GTC) v2.0. The 
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reference set was 48 samples from the HapMap project 
(www.hapmap.org/downloads/raw_data/affy500k/). 
 
5.2.3 MLPA analysis 
MLPA was applied to confirm some of the deletions and duplications identified from SNP 
microarray. The MLPA Kit used was SALSA P007-A1 Human Chromosome Kit (MRC 
Holland, Amsterdam, The Netherlands) that contains probes for 40 different target 
sequences (refer appendix A5). Among these are many genes that are often deleted or 
amplified in various tumours. The analysis was performed according to the manufacturer’s 
instructions. The ligation products were amplified on a Tetrad thermal cycler (Peltier 225 
from MJR). PCR products were then separated by capillary electrophoresis on a Beckman 
Coulter CEQ 8000 genetic analyser. Electropherograms were analysed using GeneMarker 
MLPA Analysis (SoftGenetics, LLC, USA). Deletions were indicated by a value of <0.785 
and duplications by >1.33. 
 
5.3  Results of copy number changes of sporadic clear cell renal cell 
carcinoma (cRCC) using 250K SP array 
  
Clear cell renal cell carcinoma (cRCC) is genetically complex involving a large number of 
chromosome aberrations throughout the whole genome. Of the 13 cases of sporadic cRCC 
without VHL inactivation analysed using Affymetrix 250K SNP array, only one showed no 
copy number changes. Another one sample was not included because of excess 
background signal. The reference set for 250K Sty1 mapping arrays was 48 samples from 
the HapMap project (www.hapmap.org/downloads/raw_data/affy500k/) and six normal 
controls were used for MLPA, The average call rate of the 12 samples was 95.7±2.18. 
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Most of the changes involved large segments (> 10.5 Mb) of chromosome arm or the 
whole chromosome arm or even the whole chromosome (table 5.1 and figure 5.5). Whole 
arm/large fragment (≥10 Mb) deletions were seen slightly less frequent compared to 
duplications/amplifications with a total number of 62 and 70 respectively, making an 
average of deletions 5.2 and duplications/amplifications 5.8 per tumour. Similar findings 
were also observed with small (<10 Mb) changes; 7 deletions and 13 gains. The most 
common chromosome deletion was at 3p (6 cases, 50.0%). Among the 3 cases with whole 
3p deletion, 1(LS16) also had whole 3q loss (table 5.1 and table 5.2). Complete loss of 
chromosome arm was also found in 1p, 1q, 6p, 6q, 8p, 14q (table 5.1). Loss of 1p and 14q 
were the second most common deletion (5 cases, 41.7%) involving only large 
fragments/whole chromosome arm (table 5.1 and figure 5.5). Of the 5 cases of 1p deletion, 
2 cases (LS7 and LS21) were found to have complete loss of the chromosome while in 
chromosome 14, 3 cases were identified to have a total loss of the long arm of the 
chromosome (table 5.1 and table 5.2). Deletions were the sole event seen in 6q as well as 
in 10q and 17p, although at a lower frequencies, ~8.3%-25%. However, deletions were not 
detected in chromosomes 5, 7, 12, 15q, 19q and 20. Small deletions were identified in 
chromosomes 3q, 6p, 9p, 11p, 12p, 16p, 22q in only a handful of cases and at a very low 
frequency.  
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Table 5.1: Chromosome gains and losses in primary tumours of sporadic cRCC  
Chrom. 
arm 
Losses Gains 
Whole 
arm 
Fragment 
≥10 Mb 
Frequency Fragment 
<10 Mb 
Whole 
arm 
Fragment 
≥10 Mb 
Frequency Fragment 
<10 Mb 
1p 2 3 5 0 0 1 1 0 
1q 2 1 3 0 0 1 1 0 
2p 1 0 1 0 1 1 2 0 
2q 1 2 3 0 1 1 2 0 
3p 3 3 6 0 1 0 1 0 
3q 1 1 2 1 1 3 4 0 
4p 1 0 1 0 2 0 2 0 
4q 1 1 2 0 2 0 2 0 
5p 0 0 0 0 2 1 3 0 
5q 0 0 0 0 2 4* 6 2 
6p 2 1* 3 1 0 1 1 0 
6q 2 1 3 0 0 0 0 0 
7p 0 0 0 0 2 0 2 0 
7q 0 0 0 0 2 0 2 0 
8p 3 0 3 0 0 1 1 1 
8q 1 2 3 0 0 5 5 0 
9p 1 1 2 1 1 0 1 0 
9q 1 2 3 0 1 1 2 2* 
10p 1 0 1 0 1 0 1 0 
10q 1 0 1 0 0 0 0 0 
11p 0 1 1 1 1 0 1 0 
11q 0 2 2 1 1 0 1 0 
12p 0 0 0 0 3 0 3 0 
12q 0 0 0 0 3 0 3 0 
13q 0 3 3 0 0 1 1 0 
14q 3 2 5 0 1 0 1 0 
15q 0 0 0 0 2 0 2 0 
16p 0 1 1 1 1 1 2 1 
16q 0 1 1 0 1 2 3 0 
17p 1 0 1 0 0 0 0 0 
17q 1 0 1 0 0 0 0 1 
18p 1 0 1 0 0 1 1 0 
18q 1 1 2 0 0 2 2 1 
19p 0 1 1 0 0 0 0 3* 
19q 0 0 0 0 0 1 1 0 
20p 0 0 0 0 2 1 3 0 
20q 0 0 0 0 2 2 4 2 
21q 1 0 1 0 1 1 2 0 
22q 0 0 0 0 1 0 1 0 
*contain region ≥4 copies 
Abbreviations: p, short arm; q, long arm; Mb, megabase; Chrom, chromosome 
 Legend:  
 
               Gain <10 Mb    
                Loss <10 Mb 
                Loss of whole arm/fragment 
               Gain of whole arm/fragment 
 
Figure 5.5: Frequency of gains and losses in sporadic cRCC.
 
Overall, large gains involv
figure 5.5). In addition, chromosome gains involving large and small fragments were 
observed as the only event in chromosomes 5, 7, 12, 15q, 19q and 20. The most 
chromosome gain encountered in 5q 
small fragments. Of the six cases, 2 had whole gain of 5
whole chromosome. Region of amplification
(39.1 Mb). The two small gains were identified in 5q21.1
Mb). All the regions of gain in 8q (5 cases, 41.7%) involved large fragments ranging from 
14.4 Mb to 98.5 Mb. Among the 4 case
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 (table 5.1 and 
-q35.1 
19q 20q 22q
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whole chromosome 3 (table 5.1 and table 5.2). Of the 4 cases with gain 20q, two (LS8 and 
LS16) showed gain of the whole chromosome 20 (table 5.2). Gain of whole chromosome 
12 was detected in cases LS3, LS7 and LS8. Gain in chromosome 7 involved the whole 
chromosome which was found in two cases (LS7 and LS8). Other gains of whole 
chromosome arms included 5p, 16q, and 20p in ~25% of the csases.  
 
Table 5.2: Whole chromosome loss and gain in sporadic cRCC 
 
Amplification in small regions was found in 9q33.2-q34.11 (8.1 Mb) and 19p12 (1.7 Mb).  
All except one of the cases with deletion 3p involved large fragments involving deletion of 
VHL gene. Among the 6 cases, 3 showed complete 3p loss, 2 with almost complete loss 3p 
(spanning 3p12.1-p26.3) and 1 with interstitial deletion in 3p11.2-p13 (not including VHL 
gene in 3p25). In addition to large duplications in 5q, 2 small duplications were identified 
Cases 
 JS259 LS3 LS7 LS8 LS9 LS10 LS16 LS17 LS18 LS20 LS21 
CHR1   loss        loss 
CHR2   loss    gain     
CHR3   gain    loss     
CHR4   gain  loss  gain     
CHR5   gain         
CHR6   loss    loss     
CHR7   gain gain        
CHR8          loss  
CHR9   gain  loss       
CHR10   loss         
CHR11   gain         
CHR12  Gain gain gain        
CHR13            
CHR14   gain  loss  loss    loss 
CHR15   gain gain        
CHR16   gain         
CHR17   loss loss        
CHR18            
CHR19            
CHR20    gain   gain     
CHR21    gain       loss 
CHR22   gain         
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in 5q21.1-q21.3 and 5q35.3 with a size of ~5.2 Mb and ~2.9 Mb respectively. There was a 
region of amplification spanning 5q31.3-q35.1 (39.1 Mb).  Details of the overlapping 
regions in chromosomes 3 and 5 as well as other chromosomes together with MLPA 
analysis for confirmation in some of the regions are shown in table 5.3. Microarray and the 
MLPA copy number analysis results were concordant.  
 
Table 5.3: Overlap regions of gains and losses in ≥33% of sporadic cRCC cases 
Chrom. Region Start End Size 
(Mb) 
MLPA 
probes 
Gain      
3q 3q24-q29 146,340,000 196,600,000 49.7  
5q 5q31.3-q35.1 141,500,000 180,625,000 39.1* IL12B (5q33.1) 
5q 5q35.3 178,000,000 
 
180,857,866 2.9  
8q 8q11.21-q13.2 49,000,000 70,000,000 21.0  
8q 8q21.3-q24.3 90,800,000 146,264,000 55.5  
16p 16p11.2 28,450,000 31,325,000 2.9 MVP (16p11.2) 
20q 20q11.22-q11.23 32,170,000 35,980,000 3.8  
20q 20q13.2-q13.33 50,270,000 62,435,964 12.2  
Loss      
1p 1p13.3-p31.1 83,500,000 110,650,000 27.2  
1p 1p34.2-p36.33 0 43,200,000 43.2 CTPS (1p34.2) 
3p 3p12.1-p13 73,000,000 84,000,000 11.0  
3p 3p13-p26.3 0 73,000,000 73.0  
6p 6p21.2-p21.33 30,000,000 38,460,000 8.5 LTA (6p21.3), 
CDKN1A (6p21.2) 
14q 14q12-q31.2 25,380,000 82,685,000 57.3 NFKBIA (14q13) 
*≥4 copies (amplification) 
Abbreviations: p, short arm; q, long arm; Mb, megabase; Chrom, chromosome 
 
 
 
Some of the overlapping regions of deletion harboured known tumour suppressor genes, 
for example TP73 at 1p36.32 or oncogene such as myc at 8q24.21.  
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5.4   Discussion 
Previous reported cytogenetic and copy number analyses of sporadic RCC (Klatte et al., 
2009, Dalgliesh et al., 2010) will have comprised mainly clear cell RCC with VHL 
inactivation. For example, in an analysis of 282 tumours of unselected RCC,  Klatte et al 
(2009) had identified the most frequent cytogenetic changes were loss of 3p (60%), 14q 
(28%), 8p (20%), 6q (17%), loss of 9p (16%) and 4p (13%), gain of 5q (33%) and trisomy 
7 (26%).  Similarly, copy number analysis of sporadic RCC using high resolution SNP 
arrays abnormalities demonstrated recurrent losses on 3p, 4, 6q, 8p, 9p and 14q and 
recurrent gains on 1q, 2, 5q, 7 and 12 (Dalgleish et al 2010). In the present study, twelve 
cases of cRCC without evidence of VHL mutations or methylation were analysed for copy 
number changes using high resolution 250K SNP microarray. Large gains and losses were 
frequent and often involved the whole chromosome arm or the whole chromosome. 
Deletion 3p was found in 50% of the cases (5/6 tumours with 3p25 loss and 1/6 with 
3p11.2-p13 loss).  The fact that one of the VHL was deleted and the other was retained 
(without evidence of mutations or methylation) in these tumours is interesting and suggests 
several possible explanations. Firstly a VHL mutation might be present but not detectable 
by standard analysis (e.g. if located in an intron). Alternatively, other 3p TSGs may be 
implicated in these cases. Thus Bodmer et al (2002) suggested that region 3p12-p14 might 
contain gene(s) involved in tumour development and allele loss at 3p21/methylation of 
RASSF1A has also been implicated in RCC (Clifford et al., 1998, Morrissey et al., 2001). 
However, my findings suggest that there could be another group of cRCC which does not 
involved mutations, methylation or deletions of VHL as shown in the VHL wild type cRCC 
cases which do not have deletion 3p. Thus, suggesting alternative non-VHL independent 
pathway(s) as the mechanism in promoting tumourigenesis in this group of cRCC.  
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Large gain 5q was encountered in 6/12 (50%) of the cases with 5q35.3 as the smallest 
overlapping region. Among the genes that reside in the region is MAPK9 which are 
involved in a wide variety of cellular processes such as proliferation, differentiation, 
transcription regulation and development, thus might be a candidate gene for cRCC. 
Similar finding was observed by Chen et al (2009) using Ilumina’s 317K high resolution 
SNP arrays in a study of 80 patients with cRCC. Another common region in 5q was 
identified in 5q31.3-q35.1 (table 5.3). Gain in 5q31-qter had been associated with 
favourable prognosis in cRCC (Gunawan et al., 2001). Another interesting study had 
revealed TGFBI which resides in 5q31.1 may be a putative oncogene for cRCC (Matsuda 
et al., 2008). However, the region identified in the present study does not support the 
finding. 
  
The second most common gain was observed in chromosome 8q. All the five cases 
involved gain of large fragments (≥10 Mb). Minimal common gain was identified in two 
regions; 8q11.21-q13.2 and 8q21.3-q24.3 (table 5.3). One of the known proto-oncogene in 
8q24.21 is MYC and the gene was shown to be consistently overexpressed in tumours with 
8q24 amplification (Beroukhim et al., 2009).  
 
Deletion in chromosome 1p was also common in this study, 5/12 (41.7%) of the cases. 
Two cases showed deletion of the whole chromosome, one case with interstitial deletion 
spanning 1p12-p31.1 and the other two were terminal deletions. Two regions of common 
deletions in all of the five cases were shown to be in 1p13.3-p31.1 and 1p34.2-p36.33. 
Beroukhim et al (2009) carried out copy number and gene expression analysis on 90 cRCC 
tumours of both sporadic and VHL disease and identified gene RUX3 (in 1p36.11) as a 
candidate gene for cRCC. This gene encodes a member of the runt domain-containing 
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family of transcription factors. It functions as a tumour suppressor and is frequently 
deleted or transcriptionally silenced in cancer.  
 
With the same frequency as in deletion 1p, deletion 14q was another common finding in 
this study.  Of the five cases, three had deletion in the whole 14q and two with almost all 
of chromosome 14q deleted. Beroukhim et al (2009) had identified region 14q31.1 to be 
deleted in 42% of the cases and Toma et al (2008) found deletion 14q in 36% of cRCC 
cases. A positive correlation between allelic loss and chromosome 14q especially 14q24-
q31 and 14q31-q32 and poor prognosis were described (Mitsumori et al., 2002; Kaku et 
al., 2004; Alimov et al., 2004).  
 
Gain of chromosome 20q was found in four cases (33.3%). Two cases had duplication of 
the whole chromosome, two cases with interstitial and terminal duplications. Minimal 
overlap region of the four cases was identified in 20q11.22-q11.23 (~3.8 Mb) and 20q13.2-
q13.33 (~12.2 Mb). In another study, gain in 20q13.33 was identified in 20% of cRCC 
cases (Beroukhim et al., 2009). However, gain of chromosome 20q was shown to be more 
frequently detected in papillary RCC (Sanders et al., 2002; Brunelli et al., 2003).  Deletion 
in other chromosomes were also found at a lower frequency (~25%) which includes 1q, 
2q, 6p, 6q, 8p, 8q and 9q and gain of 5p, 12p, 12q and 16q. 
 
High resolution methods such as microarrays have facilitated the investigation of copy 
number changes in this study. At present the most widely detected copy number changes 
are large with deletion 3p, 1p and 14q and gain 5q and 8q as the most frequent changes. 
This study also suggests that there is a subset of cRCC without biallelic inactivation of 
VHL, similar to the findings made by Beroukhim et al (2009). Based on the expression 
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profiles and copy number changes, they separate the cRCC without biallelic inactivation 
into two groups: one with expression profiles including HIF-responsive genes, different 
from the majority of cRCC and the other with similar copy number and expression profiles 
to tumours with such inactivation.  The observation in the latter group raises the possibility 
that the former group has unobserved genetic alterations of the VHL pathway and may 
respond to treatment targeting this pathway.  
 
Interestingly, present study also suggests another group of cRCC with non-VHL 
inactivation i.e. VHL
+
/
+
.
 
Further investigations including expression study or application of 
higher resolution arrays and massive parallel sequencing techniques will give information 
as to whether this group really represent another group of cRCC or has unidentified VHL 
inactivation.  
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5.5  Results of copy number changes of clear cell renal cell carcinoma 
(cRCC) in VHL using 250K SP array 
 
 
The reference set for 250K Sty1 mapping arrays was 48 samples from the HapMap project 
(www.hapmap.org/downloads/raw_data/affy500k/). A total of 21 samples of cRCC from 
VHL patients were analysed. The average call rate of the samples was 97.19±1.47. In 
general, copy number changes in VHL cRCC were not complex. The majority of the cases 
had large deletion in 3p (15 cases, 71%) and duplication in 5q (13 cases, 62%) (table 5.4). 
Changes in the other chromosomes were also observed but not as frequent (<23%). 
Deletions of whole arm/fragment ≥10 Mb were encountered more than duplications, 62 
and 59 respectively. These tumours have on average 2.9 deletions and 2.8 duplications. 
Data in table 5.4 is summarized in figure 5.6.  
 
Table 5.4: Chromosome gains and losses identified in cRCC of the VHL tumours 
Chrom. 
arm 
Losses Gains 
Whole 
arm 
Fragment 
≥10 Mb 
Frequency Fragment 
<10 Mb 
Whole 
arm 
Fragment 
≥10 Mb 
Frequency Fragment 
<10 Mb 
1p 0 3 3 0 0 0 0 0 
1q 0 0 0 0 0 3 3 1 
2p 0 0 0 0 3 0 3 0 
2q 0 0 0 0 3 1 4 0 
3p 7 10 17 0 0 1 1 0 
3q 0 4 4 0 0 2 2 2 
4p 2 1 3 0 0 1 1 0 
4q 2 1 3 0 0 0 0 0 
5p 1 0 1 0 2 0 2 0 
5q 0 1 1 0 0 13 13 0 
6p 0 1 1 0 1 0 1 0 
6q 0 0 0 0 1 0 1 0 
7p 0 0 0 0 5 0 5 0 
7q 0 1 1 0 3 1 4 0 
8p 1 3 4 0 0 0 0 1* 
8q 0 1 1 0 0 3 3 0 
9p 1 0 1 0 1 0 1 0 
9q 1 0 1 2 1 0 1 0 
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10p 0 0 0 0 0 1 1 0 
10q 0 3 3 0 0 0 0 0 
11p 0 0 0 0 2 0 2 0 
11q 0 0 0 0 2 0 2 0 
12p 0 0 0 0 0 0 0 0 
12q 0 1 1 0 0 0 0 0 
13q 1 1 2 0 0 3 3 0 
14q 3 0 3 0 1 0 1 0 
15q 1 0 1 3 0 0 0 0 
16p 0 1 1 0 0 0 0 1 
16q 0 2 2 0 0 1 1 0 
17p 0 0 0 1 0 0 0 2 
17q 0 0 0 0 0 1 1 0 
18p 1 0 1 0 0 0 0 0 
18q 1 0 1 0 0 0 0 0 
19p 1 0 1 1 0 1 1 0 
19q 1 1 2 0 0 0 0 0 
20p 0 0 0 0 1 0 1 0 
20q 0 0 0 0 1 0 1 0 
21q 0 1 1 0 1 0 1 0 
22q 1 1 2 1 0 0 0 0 
* Contain ≥ 4 copies 
Abbreviations: p, short arm; q, long arm; Mb, megabase; Chrom, chromosome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Legend: 
 
  Gain <10 Mb 
  Loss <10 Mb 
  Loss of whole arm/fragment 
  Gain of whole arm/fragment 
 
Figure 5.6: Frequency of gains and losses of cRCC in VHL
 
Deletions in 3p involved whole arm/larg
large deletions on the chromosome arm (making it a total of 17, see table 5.4) and 7 
showed complete loss of 3p. Two recurrent duplications on 5q were identified in 5q32
q35.3 (~37.7 Mb) and 5q21.1
and involved the whole chromosome arm. Deletion 3q, 8p and gain 2q, 7q were not as 
common as shown in only about 19% of the tumours.  Details of overlapping regions were 
shown in table 5.5. MLPA analysis was don
Microarray and the MLPA copy number analysis results were concordant
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Table 5.5: Overlapping regions of gains and losses in ≥19% of cRCC in the VHL tumours studied 
Chrom. Region Start End Size (Mb) MLPA 
probes 
Gain      
2q 2q23.3-q37.3 153,000,000 242,951,149 89.9  
5q 5q32-q35.3 143,200,000 180,857,866 37.7 IL12B 
(5q33.1) 
7p 7p11.2-p22.3 
 
0 57,500,000 
 
57.5  
7q 7q11.21-q22.1 64,000,000 99,370,000 35.3  
7q 7q32.1-q36.3 127,600,000 158,821,424 31.2 CASP2 
(7q35) 
Loss      
3p 3p14.2-p21.1 52,000,000 61,820,000 9.8  
3p 3p21.31-p26.3 0 44,750,000 44.7  
3q 
3q 
3q13.11-q13.31 
3q11.2-q13.11 
 
104,880,000 
95,350,000 
 
116,409,600 
104,880,000 
 
11.5 
9.5 
 
8p 8p12-p23.3 0 34,880,000 34.9  
Abbreviations: p, short arm; q, long arm; Mb, megabase; Chrom, chromosome 
 
 
5.6    Discussion 
This is the second array-based genome wide analysis of copy number abnormalities in 
VHL disease associated cRCC. Beroukhim et al (2009) had analysed 36 metachronous 
primary tumours from 12 patients with VHL disease (in addition to 54 sporadic cRCC) 
using the same platform. The most frequent copy number change (86% of VHL RCC) was 
3p loss including the VHL tumour suppressor gene. 5q gain was the second most common 
with the smallest overlapping region identified in 5q32-q35.3. Similarly, the present study 
also observed deletion 3p as the most frequent (76.2%) and gain 5q (61.9%) as the second 
most common. Also common is gain 7p which was observed in 5 cases (23.8%) and all of 
them involved the whole short arm of the chromosome. Gain in chromosomes 1q, 2p, 2q, 
7q, 8q, 13q and deletion in 1p, 3q, 4p, 4q, 8p, 10q and 14q were encountered at a lower 
frequency ~14%-19% of the cases. Genome wide analysis of the previous studies were of 
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unselected cRCC (i.e. unspecified whether the tumours were from VHLs or sporadics). 
Comparing the findings of the present study with the previous reports (Cifola et al., 2007; 
Toma et al., 2008; Matsuda et al., 2008; Beroukhim et al., 2009) all of the changes 
observed were similar except gain 2p and 13q and loss 3q and 4p were identified only in 
the present study (table 5.6).  
 
Table 5.6: Previous studies of copy number changes in cRCC  
Author (year) Sample Method Chrom. Gain Chrom. Loss LOH 
Cifola et al (2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 cRCC tumour 
tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Affymetrix 100K 
SNP array 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4p15.1-q13.1 1p36.32-p36.31 1p36.22-36.21 
4q26-q28.3 1p36.11 2q36.3 
5p15.1-p14.1 3p26.3-p26.2 3p26.3 
5q11.2-q12.3 3p25.3-p25.1 3p26.2-p25.3 
5q14.3-q21.3 9q33.3-q34.11 3p24.3 
5q23.1-q34 22q13.1-q13.2 3p14.3 
7p21.3-p21.2   3q22.1 
7q21.11   6q16.1 
7q31.31-q31.32   6q22.1-q22.31 
11p15.1-q12.1   6q22.31 
11q14.2-q22.3   6q22.33-q23.2 
12q12-q15   6q25.2-q25.3 
12q21.31-q23.1   6q26 
14q21.1-q21.3   9q31.1-q31.2 
16p11.2-q11.1   13q33.2 
19p12-p11     
22p13-p11.2     
Toma et al (2008) 
 
 
 
22 primary cRCC 
and matched 
normal  kidney 
tissue 
 
 
 
Affymetrix 10K 
SNP array 
 
 
 
5q23.3-5qter 3pter-3p21.31 3p 
7q11.21-7qter 
14q23.3-
14q.32.31 
9 
  9pter-9qter 14 
  6q23.2-6q26  
Matsuda et al 
(2008) 
 
 
 
 
 
 
 
35 cRCC tissue and 
7 normal controls 
 
 
 
 
 
 
 
Affymetrix 100K 
SNP array 
 
 
 
 
 
 
 
3 1p   
5q22-qter 3p   
5q23.2-q34 10q   
7q31-q34 19p   
7p 6q   
8q 9p   
12q 11p   
16 13q   
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17 14q   
 
18   
  22q   
Beroukhim et al 
(2009) 
 
 
 
 
 
 
90 cRCC tumours 
(sporadics and 
VHLs) 
 
 
 
 
 
 
Affymetrix 250K 
SNP array 
 
 
 
 
1q 1p   
2q 3p   
5q 4q   
7q 6q   
8q 8p   
12p 9p   
20q 14q   
 
The VHL tumours without 3p deletion showed no LOH in the region (data not shown). In 
these cases, it is possible that the wild type VHL allele is inactivated by somatic mutation 
or exon deletion or promoter methylation that would not be detected by LOH analysis. 
Other 3p tumour suppressor genes (e.g. RASSF1A) might also be inactivated in a similar 
manner (though RASSF1A is usually inactivated by methylation rather than mutation 
(Morrissey et al., 2001).  
 
5.7     Results of copy number changes of RCC cell lines using 250K SP Array  
The average call rate (%) for the 23 samples was 96.2±2.15. All of the 23 RCC cell lines 
exhibited copy number changes with majority involving large/whole arm deletions and/or 
duplications (table 5.7, figure 5.7). Deletions of whole arm/large fragments were observed 
less than duplications/amplifications of whole arm/large fragments, 301 and 331 
respectively, making an average of 13.1 deletions and 14.4 duplications/amplifications per 
cell line. Deletion 14q was seen in all of the lines and most (21/23, 91.3%) involved almost 
the whole long arm. All of the cell lines except one (SKRC47) showed deletions in 3p. Of 
these, 19 (86.3%) showed VHL deletion and the remaining 3 cell lines had deletion in 
3p12.3-p21.31, 3p13-p22.2 and 3p14.2 respectively. Evidence of homozygous deletion in 
3p14.2 which harboured FHIT gene was found in RCC48.  
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Frequent loss of large fragment/whole arm was also detected in other chromosomes which 
includes 4q (18/23, 78.3%), 18q (18/23, 78.3%), 13q (16/23, 69.6%), 1p (16/23, 69.6%), 
4p (12/23, 52.2%), 8p (12/23, 52.2%), 9p (12/23, 52.2%), 9q (11/23, 47.8%), 15q (11/23, 
47.8%). Among the 12 cell lines with deletion 4p, 11 showed complete loss of 
chromosome 4.  The 9 cell lines which showed a complete loss of 18p also had a complete 
loss of 18q. Similar finding was observed in chromosome 9 where 5 of the cell lines 
showed a complete loss of the chromosome. In addition, homozygous deletion at 9p21.3 
was identified in 8 cell lines (ACHN, Caki1, CAL54, RCC1, RCC11, RCC4, RCC6 and 
SKRC54) and at 9p23-p24.1 in 3 cell lines (Caki1, RCC1 and RCC6). The former region 
with the size of an ~0.4 Mb contains 3 genes (MTAP, CDK2A, CDK2B) and the latter 
~1.0 Mb contains only 1 gene (PTPRD).  
 
The most common chromosomal gain were seen in chromosomes 7p (21/23, 91.3%), 7q 
(20/23, 86.9%),  12q (18/23, 78.3%), 8q (17/23, 73.9%), 5q (17/23, 73.9%), 2q (15/23, 
65.2%), 20q (15/23, 65.2%), 16p (14/23, 60.9%), 5p (13/23, 56.5%), 17q (13/23, 56.5%), 
16q (13/23, 56.5%), 1q (13/23, 56.5%), 3q (12/23, 52.2%), 20p (12/23, 52.2%), 2p (11/23, 
47.8%). Some of them also involved whole gain of the chromosome, for example in 
chromosomes 7 (14/23), 12 (8/23), 16 (9/23), 20 (11/23) (table 5.7).  
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Table 5.7: Chromosome gains and losses identified in the RCC cell lines 
Chr. 
arm 
Losses Gains 
Whole 
arm 
Fragment 
≥10 Mb 
Frequency Fragment 
<10 Mb 
Whole 
arm 
Fragment 
≥10 Mb 
Frequency Fragment 
<10 Mb 
1p 2 14 16 0 0 9 9 0 
1q 2 5 7 0 0 13* 13 0 
2p 0 6 6 0 5 6 11 0 
2q 0 3 3 3 5 10 15 0 
3p 4 18 22 1** 0 5 5 1 
3q 4 4 8 1 0 10* 10 1 
4p 11 1 12 0 0 4 4 0 
4q 11 7 18 0 0 3 3 1 
5p 2 2 4 0 5 8* 13 1* 
5q 2 5 7 1 5 12 17 1 
6p 5 0 5 0 3 3 6 2 
6q 5 4 9 0 3 6 9 0 
7p 0 1 1 0 14* 7 21 1* 
7q 0 1 1 0 14 6* 20 2* 
8p 0 12 12 0 2 1 3 0 
8q 0 3 3 1 2 15 17 1 
9p 5 7 12 11** 1 1* 2 0 
9q 5 6 11 0 1 5 6 0 
10p 3 6 9 0 2 1 3 2* 
10q 3 0 3 1 2 6 8 0 
11p 3 4 7 0 1 4 5 0 
11q 3 7 10 0 1 2 3 0 
12p 0 1 1 0 8 2 10 2 
12q 0 1 1 1 8 10* 18 0 
13q 0 16 16 1 0 3 3 1 
14q 0 23 23 0 0 0 0 0 
15q 0 11 11 0 0 3 3 2 
16p 1 2 3 0 9 5 14 0 
16q 1 2 3 2** 9 4 13 0 
17p 0 7 7 0 5 4 9 2* 
17q 0 1 1 2 5 8* 13 6 
18p 9 1 10 0 0 2 2 1 
18q 9 9 18 0 0 0 0 0 
19p 0 2 2 4 1 2 3 2 
19q 0 2 2 0 1 4 5 4 
20p 1 3 4 3 11 1 12 1 
20q 1 0 1 0 11 4 15 1 
21q 0 7 7 0 0 3 3 0 
22q 0 4 4 0 0 3 3 0 
*contain ≥4 copies (amplification)          ** contain homozygous deletion 
Abbreviations: p, short arm; q, long arm; Mb, megabase; Chr, chromosome 
 Legend:  
 
  Gain <10 Mb 
  Loss <10 Mb 
  Loss of whole arm/fragment 
  Gain of whole arm/fragment 
 
 
Figure 5.7: Frequency of gains and losses in RCC cell lines
 
Minimal overlapping region of the most common (>43%) copy number changes which 
include gain 2q, 5q, 7, 8q, 12q, 20q 
table 5.8.  
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Table 5.8: Minimal overlapping region of gains and losses in the RCC cell lines  
Chr. Location Start position End position Size 
(Mb) 
Frequency       
(%) 
Gain      
2 2q35-q36.3 216,000,000 228,800,000 12.8 11 (47.8) 
  2q24.3-q33.3 164,000,000 206,271,500 42.3 12 (52.2) 
  2q11.2-q14.3 95,000,000 122,660,000 27.7 12 (52.2) 
3 3q22.1-q29 133,228,000 
 
199,501,827 
 
66.2 10 (43.5) 
5 5q34-q35.3 164,700,000 180,857,866 16.2 17 (73.9) 
7 7p11.2-p12.1
a 
53,000,000 57,500,000 4.5 18 (78.3) 
  7p21.2-p22.3
b
 0 15,000,000 15.0 18 (78.3) 
  7q34-q36.3 138,434,000 158,821,424 20.4 18 (78.3) 
  7q11.21-11.22 
c
 61,500,000 68,635,000 7.1 18 (78.3) 
8 8q24.12-q24.3 120,000,000 146,274,826 26.2 16 (69.6) 
12 12q24.22-q24.33 116,500,000 132,349,534 15.8 12 (52.2) 
 12q12-q13.2 37,200,000 54,900,000 17.7 14 (60.9) 
16 16p11.2-p13.3 0 31,500,000 
 
31.5 14(60.9) 
20 20q11.21-q11.23 29,340,000 34,349,000 5.0 16 (69.6) 
      
Loss      
1 1p35.3-p36.33 0 28,800,000 28.8 13 (56.5) 
3 3p14.2 
d
 59,500,000 60,100,000 0.6 20 (87.0) 
 3p21.2-p26.3 0 51,680,000 51.6 19 (82.6) 
 3p11.2-p13 73,000,000 89,400,000 16.4 20 (87.0) 
4 4q12-q13.1 56,330,000 65,000,000 8.6 15 (65.2) 
  4q31.22-q35.2 146,000,000 191,273,063 45.2 16 (69.6) 
8 8p21.3-p23.3 
 
0 23,300,000 
 
23.3 12 (52.2) 
9 9p21.3 
e
 21,800,000 
 
22,200,000 
 
0.4 17 (73.9) 
 9p23-p24.1
f
 9,000,000 10,000,000 
 
1.0 14 (60.9) 
13 q12.1-q13.1 18,000,000 32,000,000 14.0 15 (65.2) 
14 q11.2-q13.1 20,000,000 32,000,000 12.0 23 (100) 
  q23.1-q32.33 56,000,000 106,368,585 50.4 22 (95.7) 
18 q22.3-q23 67,400,000 76,117,153 8.7 17 (73.9) 
Abbreviations: p, short arm; q, long arm; Mb, megabase; Chr, chromosome 
a
 contain  ≥4 copies (amplification) in 2/18 cases 
b
 contain  ≥4 copies (amplification) in 1/18 cases 
c 
contain  ≥4 copies (amplification) in 3/18 cases 
d
 homozygous deletion in 1/20 cases 
e 
homozygous deletion in 7/17 cases 
f 
homozygous deletion in 2/14 cases 
 
 The most copy number changes were found in Caki2 (24 gains and 22 losses) and the least 
in KTCL140 (4 gains and 5 losses) (figure 5.8, ta
high number of gains and losses (total gains and losses of 33
UMRC3, SKRC39, SKRC45, RCC 48 and Caki1. Total changes between 21 and 28 were 
seen in SKRC47, SKRC 54, SKRC18, RCC6, RCC1, RCC11, RC
Cell lines 769P, A704, RCC4, 786O, ACHN and KTCL 26 had 15 to 20 chromosomal 
changes (figure 5.8, table 5.9). 
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Figure 5.8: Number of gains and losses of the 23 RCC
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Table 5.9: Details of chromosome regions of gains and losses of the RCC cell lines 
 
Cell line Gains Total 
gain 
Losses Total 
loss 
769P 
 
1q23.1-q44, 2, 5q31.2-q35.3, 7, 
8q11.22-q24.3, 12, 17 
8 1p35.3-p36.33, 3, 6, 9p21.3-
p22.3, 9q12-q21.11, 
11q14.1-q25, 14q11.2-
q32.33 
7 
786O 
 
2p11.2-p24.3, 2q11-q37.3, 5p12-
p15.33, 5p12, 7, 8q11.21-q24.3, 
9q21.13-q34.3, 20q11.21-q13.33,  
 
9 3p11.2-p13, 3p21.2-p26.3, 
4q31.22-q35.2, 5q11.2-
q21.1, 8p11.21-p23.3, 
13q12.11-q34, 
14q11.2-q32.33, 18q12.2-
q23, 19q13.11-q13.42 
 
9 
A498 1q21.2-q44, 2p11.2-p25.3, 
2q11.2-q34, 5p12-p15.33, 7, 
8q11.21-q24.3, 9, 11p11.2-p15.5, 
16, 17, 19p12, 19q12, 19q13.11-
q13.12, 19q13.33-q13.43, 20p12.2-
p11.21, 20q11.21-q13.33, 21q11.2-
22.3  
 
18 1p35.1-p36.33, 2q22.1, 
3p21.2-p26.3, 6, 11q11.2-
q25, 14q11.2-q32.33, 
18q11.32-q23, 20p12.2-p13 
8 
A704 
 
3p12.1, 5q15-q35.3, 7, 12, 16p11.2-
p13.3 
 
6 1p35.1-p36.13, 3p12.3-
p26.3, 4, 6q21-q27, 9, 
14q11.2-q32.33, 16q12.1-
q24.3, 20p21 
 
8 
ACH 
 
1q21.1-q44, 2, 7, 10q11.21-q26.3,  
12, 16, 17 
 
 
7 1p35.1-p36.33, 3, 4, 5, 6, 
8p11.21-p23.3, 8q11.21-
q21.11, 9p21.3, 13q12.11-
q32.3, 15q11.2-q26.3, 
14q11.2-q32.33, 18q12.2-
q23, 20 
 
13 
Caki1 
 
1q21.1-q44, 3q12.1-q29, 4p12-
p16.3, 4q12-q13.3, 5p14.3-p15.33, 
5p12-p13.1, 5q15-q35.3, 7q22.3-
q36.3, 8q11.21-q24.3, 12q12-
q24.33,16q12.1-q24.3, 17q11.2-
q22, 17q22-q25.3, 18p11.21-
p11.32, 19p13.3, 20q11.21-q11.23 
16 1p21.3-p31.1, 3p12.3-p26.3, 
6q22.32-q27, 9p23-p24.1, 
9p21.3, 9q12-q21.11, 
11q14.1-q25, 12p11.21-
p13.33, 13q12.1-q13.1, 
15q11.2-q22.2, 14q11.2-
q32.33, 17p11.2-p13.3, 
18q11.2-q23, 19p13.3, 
20p11.21-p13, 21q11.2-
q22.3, 22q11.21-q13.33 
 
17 
Caki2 
 
1q21.1-q44, 2p11.2-p25.3, 2q11.2-
q14.3, 2q24.3-q33.3, 2q37.1-q37.3, 
3q22.1-q29, 4q12, 5q33.2-q35.3, 
6p11.2-p12.1, 6q12-q13, 6q16.1-
q21, 6q22.31-q24.1, 7, 12p11.21-
p11.22, 12q12-q14.2, 12q14.2-
q21.32, 12q24.22-q24.33, 15q26.1-
24 
 
1p12-p31.3, 2q37.1-q37.3, 
3p11.2-p26.3, 3q11.2-q21.3, 
4q12-q13.1, 6q25.1-q27, 
8p11.21-p23.3, 8q11.21-
q12.1, 9p11.2-p24.3, 9q12-
q21.33, 11p11.12-p14.1, 
11q12.1-q25, 12q21.32-
22 
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q26.3, 16p11.2-p13.3, 17q11.2-
q25.33, 19p12-p13.2, 19q12-
q13.43, 20, 22q11.21-q13.33 
q24.22, 13q12.11-q34, 
14q11.2-q13.1, 14q23.1-
q32.33, 16q11.2-q21, 16q21, 
17p11.2-p13.3, 18q11.2-q23, 
19p13.3, 19p13.2-p13.3 
 
CAL54 
 
 
2, 3p11.2-p12.3, 3q11.2-q29, 
7p15.2-p22.3, 7p11.2-p14.3, 
7q11.21-q34, 7q34-q36.3, 8, 
9q22.31-q34.3, 12, 16, 17, 20  
14 1, 3p12.3-p26.3, 4, 5, 6, 
9p11.2-p24.3, 9q12-q22.31, 
10, 11, 13q12.11-q34, 
15q11.2-q26.3, 14q11.2-
q32.33, 18, 21q11.2-q22.3 
 
14 
KTCL140 
 
 
5q21.3-q35.3, 15q11.2, 17q24.3-
q25.3 
 
4 1p35.2-p36.33, 3p14.1-
p26.3, 4, 5q11.2-q21.3, 
14q11.2-q32.33 
 
5 
KTCL26 
 
 
1p21.3-p31.3, 1q25.2-q44, 5, 6, 7, 
8q11.23-q24.23, 9q21.13-q34.3, 
11p11.2-p15.5, 16q12.1-q24.3, 20,  
10 2p11.2-p25.3, 3, 4, 9p11.2-
p24.3, 10p11.22-p15.3, 
11q22.3-q25, 13q12.11-
q14.3, 14q21.3-q32.33 
 
8 
RCC1 
 
1p11.2-p31.1, 3q22.1, 3q22.1-q29, 
5, 6p21.1, 6q14.1-q27, 7, 8q11.23-
q24.23, 10, 19p12-p13.3, 19q13.12-
q13.43, 20q11.21-q13.33, 
22q11.21-q13.33 
 
13 1q21.1-31.1, 3p11.2-p26.3, 
3q11.2-q21.3, 4, 8p11.21-
p23.3, 9, 15q25.3-q26.3, 
14q11.2-q32.33, 16, 18, 
21q11.2-q22.3 
 
11 
RCC11 
 
 
1p12-p33, 1q21.1-q44, 2, 5q21.3-
q35.3, 6, 7, 8q11.23-q24.23, 
12p11.21-p13.33, 15q11.2-q26.3, 
16, 17, 20, 21q11.2-q22.3, 
22q11.21-q13.33 
 
14 1p35.1-p36.33, 3, 4, 5p12-
p15.33, 5q11.2-q21.1, 
8p11.21-p23.3, 9, 10, 11, 
13q12.11-q34, 14q11.2-
q32.33, 18 
 
12 
RCC12 
 
 
2, 4p14-p16.3, 5q21.1-q35.3, 
6p12.1-p25.3, 6q12-q22.33, 7, 
8q11.21-q24.3, 9q21.13-q31.2, 11, 
12, 13q14.12-q21.33, 16p11.2-
p13.3,16q21-q23.1 
 
14 3p12.2-p26.3, 4q12-q35.2, 
8p11.21-p23.3, 9p13.1-
p24.3, 14q11.2-q32.33, 
15q11.2-q26.3, 14q11.2-
q32.33, 17p11.2-p13.2 
 
8 
RCC4 
 
1p32.2-p35.1, 5q23.3-q35.3, 6, 16, 
20 
 
 
6 1p35.1-p36.33, 3p12.3-p29, 
4,9p13.1-p22.3, 9q12-q34.3, 
13q12.11-q21.1, 15q11.2-
q26.3, 14q11.2-q32.33, 
21q11.2-q22.3 
 
9 
RCC48 
 
 
1p11.2-p35.3, 1q32.2-q44, 
2q11-q37.3, 3q11.2-q29, 5p12-
p15.33, 5q34-q35.3, 6p12.1-p25.3, 
6q12-q25.2, 7, 8q11.21-q24.3, 
11p11.22-p15.5, 12p11.21-p13.33, 
12q12-q13.2, 12q21.1-q21.32, 
15q11.2-q26.3, 17q21.31-q25.1, 
17q25.3, 20 
19 1p35.3-p36.33, 1q21.1-
q32.1, 2p11.2-p25.3, 2q22.3, 
3p12.3-p26.3, 4, 9, 10, 
12q14.2-q21.1, 13q12.11-
q34, 14q11.2-q32.33, 
16q24.1-q24.3, 17p11.2-
p13.1, 18, 19p12-p13.3, 
19q12-q13.32 
16 
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RCC6 
 
2p11.2-p25.3, 2q11.2-q24.1, 
2q35-q36.3, 3q21.1-q29, 5, 
6p12.1-p25.3, 7, 8q11.21-q24.3, 
12p13.33-q24.33, 16, 20 
10 1, 2q24.2-q34, 2q36.3-q37.3, 
3p12.3-p26.3, 3q11.2-q21.1, 
4, 8p12-p23.3, 9, 13q12.11-
q34, 14q11.2-q32.33, 
17p11.2-p13.3, 18, 
22q11.22-q12.3 
 
13 
SKRC18 
 
 
3q11.2-q29, 5, 7, 8q11.21-q24.3, 
10q11.21-q26.3, 12p11.21, 12q12-
q24.33, 16p11.2-p13.3, 17p11.2-
p13.3, 19q13.42-q13.43, 20 
11 1p32.3-p36.33, 1q23.3-
q25.2, 3p12.3-p21.31, 
11q13.2-q25, 13q12.11-q34, 
15q11.2-q22.31, 14q11.2-
q23.1, 17q25.3, 18q11.2-q23, 
22q11.22-q13.33 
 
10 
SKRC39 
 
 
1p31.3-p13.1, 1q25.2-q44, 
2q11-q37.3, 3p22.3-p26.3, 3p11.2-
p12.3, 5p12-p15.33, 5q15-q35.3, 
7p11.2-p22.3, 7q11.21-q34, 
8q11.23-q21.11, 8q24.12-q24.3, 
10p11.21-p11.22, 12q12-q23.3, 16, 
17p11.2, 17p13.2-p13.3, 17p13.1, 
17q21.32, 17q21.32-q21.33, 
17q24.2, 17q25.2-q25.3, 20,  
 
23 3p13-p22.2, 4q12-q35.2, 
6q26-q27, 7q35-q36.3, 8p12-
p23.3, 8q11.21-q11.23, 
9p13.1-p24.3, 10p11.22-
p15.3, 11p11.12-p15.5, 
13q12.11-q21.31, 13q33.3-
q34, 15q11.2-q21.1, 14q12-
q32.33, 18, 21q11.2-q21.1, 
21q22.2-q22.3, 
 
16 
SKRC45 
 
 
3p21.31-p26.3, 3p11.2-p14.1, 
3q21.1-q29, 3q11.2-q11.2, 4q26-
q31.23, 5q21.2-q21.3, 5q21.1-
q35.3, 7p11.2-p22.3, 7q11.21-
q11.22, 8q21.3-q24.3, 9p23-p24.3, 
10q11.21-q26.3, 11q12.1-q25, 12, 
13q31.2-q31.3, 16p11.2-p13.3, 
16q12.1-q23.2, 17q21.31-q25.3, 
18p11.21-p11.32, 21q11.2-q22.3 
 
20 3p14.2, 3q13.32-q21.1, 
3q26.1, 4p12-p16.3, 4q12-
q26, 5q11.2-q21.2, 5q21.3-
q22.1, 8p12-p23.3, 9p13.1-
p23, 10p11.21-p15.3, 11p13-
p15.1, 15q11.2-q26.3, 
14q11.2-q32.33, 18q12.1-
q22.1, 20p11.22-p13, 
22q11.22-q13.33 
 
16 
SKRC47 
 
 
5,7q34-q36.3, 10q11.21-q26.3, 
11p15.1-p15.5, 12q12-q23.1, 
13q12.11-q34, 17p11.2-p13.3, 
19q12-q13.2, 19q13.43, 20,  
11 1q24.2-q41, 2p24.1-p25.3, 4, 
8p11.21-p23.3, 9p21.3-
p24.3, 10p11.21-p15.3, 
15q11.2-q26.3, 14q11.2-
q32.33, 16p11.2-p13.3, 
17q11.2-q25.33, 18q21.33-
q23, 19p12-p13.3 
12 
SKRC54 
 
 
1q31.3-q44, 3q11.2-q29, 5p12-
p15.33, 7p11.2-p22.3, 7q11.21-
q11.22, 7q11.22-q36.3, 8q13.2-
q21.3, 10p12.31-p14, 10p11.1-
p11.22, 10q11.21-q26.3, 12, 16, 
17p11.2-p13.3, 19, 20 
 
16 3p12.3-p26.3, 8p11.21-
p23.3, 8q11.21-q13.1, 
9p21.3, 9q13-q31.1, 10p14-
p15.3, 13q12.11-q34, 
14q11.2-q32.33, 18 
9 
UMRC2 
 
1p31.3-p34.2, 1p11.2-p13.2, 
1q21.1-q44, 2q22.1-q37.3, 3q11.2-
q29, 4p12-p16.3, 4q12-q21.3, 
19 1p34.3-p36.33, 1p13.3-
p31.3, 2p11.2-p25.3, 2q11.2-
q22.1, 3p12.3-p26.3, 4q22.1-
21 
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5q14.3-q35.3, 7, 8, 9q32-q34.3, 10, 
11q13.1-q25, 12, 15q11.2-q25.3, 
16, 17q11.2, 17q12-q25.3, 
18p11.21 
q35.2, 5p12-p14.3, 5q11.2-
q14.1, 6, 11p11.12-p15.5, 
11q12.1-q13.1, 13q12.11-
q34, 15q25.3-q26.3, 
14q11.2-q32.33, 17p11.2-
p13.3, 17q11.2-q12, 
18p11.21-p11.32, 18q11.2-
q23, 19p13.12-p13.3, 
21q11.2-q22.3, 22q11.22-
q13.33 
 
UMRC3 
 
1p22.3-p34.3, 1q31.2-q42.2, 
1q42.3-q44, 2p16.3-p24.1, 2p13.2-
p14, 2q11.2-q37.3, 3q11.2-q29, 
4p12-p16.3, 4q12-q24, 5p12-
p15.33, 8p11.21-p12, 8q24.21-
q24.3, 10q11.23-q24.2, 12q21.31-
q24.33, 13q31.1-q33.3, 17q12-
q25.3, 20p11.21-p11.23, 20q11.21-
q13.33 
 
19 1p12-p22.3, 1q12-q31.1, 
2p24.1-p25.3, 2p12-p13.2, 
3p12.3-p26.3, 4q25-q35.2, 
7p11.2-p22.3, 8p21.3-p23.3, 
9p13.1-p24.3, 10p11.21-
p15.3, 10q11.23-q11.21, 11, 
13q12.11-q22.2, 13q33.3-
q34, 14q11.2-q32.33, 
16q11.2-q24.3, 17p11.2-
p13.3, 18q22.3-q23, 
20p12.3-p13, 20p12.1 
20 
Abbreviations: p, short arm; q, long arm 
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5.8   Discussion 
Copy number changes in the 23 RCC cell lines detected in the present study appears 
complex, involving the whole genome (table 5.7, figure 5.7). The changes were also most 
frequently involved large fragments (>10 Mb) with gains detected more frequently than 
losses (average of 14.4 duplications/amplifications and 13.1 deletions per cell line). Earlier 
report by Pavlovich et al (2003) had identified deletion 3p, gain 5q and trisomy 7 as the 
most common findings in 10 RCC cell lines and 5 renal tumours using spectral 
karyotyping (SKY) and comparative genomic hybridisation (CGH) methods. Strefford et 
al (2005) applied CGH on 19 RCC cell lines (of which nine of them were also investigated 
in the present study). Many of the findings are in agreement with the present report for 
example gain 1q, 5q, 7 and loss 1p, 3p, 14q. However, the increased resolution of 250K 
SNP array applied in the present study has allowed the detection of more regions of gains 
and losses on the chromosomes (table 5.10 and 5.11). Thus the use of microarray has given 
more information about the chromosomal changes associated with RCC.  
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Table 5.10: Regions of gain in the RCC cell lines identified by Strefford et al (2005) compared 
with the present study  
 
Cell line Gains (Strefford et al., 2005) Gains (present study) 
SKRC45 5q21~qter,7q21.1~pter,8q23~q24.3, 
9q,11q,13 
3p21.31-p26.3, 3p11.2-p14.1, 
3q21.1-q29, 3q11.2-q11.2, 4q26-q31.23, 5q21.2-
q21.3, 5q21.1-q35.3, 7p11.2-p22.3, 7q11.21-q11.22, 
8q21.3-q24.3, 9p23-p24.3, 10q11.21-q26.3, 
11q12.1-q25, 12, 13q31.2-q31.3, 16p11.2-p13.3, 
16q12.1-q23.2, 17q21.31-q25.3, 18p11.21-p11.32, 
21q11.2-q22.3 
 
769P 1q25~qtel,4q28~qtel,5p15.1~ptel, 
5q31~qtel,8q21.3~qtel,12q14~ptel 
1q23.1-q44, 2, 5q31.2-q35.3, 7, 8q11.22-q24.3, 12, 
17 
786O 1q32~qter,4p15.1~q21,5p10~pter,7q10~qt
er,8q10~qter,12q21.1~pter 
2p11.2-p24.3, 2q11-q37.3, 5p12-p15.33, 5p12, 7, 
8q11.21-q24.3, 9q21.13-q34.3, 20q11.21-q13.33 
A498 1q32~qter,2p10~pter,4q28~qter,5p10~pter
,5q23.3~qter,7,8q21.3~qter,9q31~q34.1,1
7q21.3~qter,20q10~qter 
1q21.2-q44, 2p11.2-p25.3, 
2q11.2-q34, 5p12-p15.33, 7, 
8q11.21-q24.3, 9, 11p11.2-p15.5, 16, 17, 19p12, 
19q12, 19q13.11-q13.12, 19q13.33-q13.43, 
20p12.2-p11.21, 20q11.21-q13.33, 21q11.2-22.3 
A704 1q32~qter,5q14~qter,7,11q10~qter,12, 
20q10~qter 
3p12.1, 5q15-q35.3, 7, 12, 16p11.2-p13.3 
ACHN 1q32~qter,2p10~pter,5p10~pter,7,12,16, 
17p10~pter 
1q21.1-q44, 2, 7, 10q11.21-q26.3,  12, 16, 17 
 
Caki1 1q21.3~qter,5q13~pter,7q21.2~qter, 
8q13~qter,11p12~pter,17q21.3~qter 
1q21.1-q44, 3q12.1-q29, 4p12-p16.3, 4q12-q13.3, 
5p14.3-p15.33, 5p12-p13.1, 5q15-q35.3, 7q22.3-
q36.3, 8q11.21-q24.3, 12q12-q24.33,16q12.1-q24.3, 
17q11.2-q22, 17q22-q25.3, 18p11.21-p11.32, 
19p13.3, 20q11.21-q11.23 
Caki2 7p15~pter,8q22.3~qter,12q13.3~qter,20, 
21,22q13.1~qter 
1q21.1-q44, 2p11.2-p25.3, 2q11.2-q14.3, 2q24.3-
q33.3, 2q37.1-q37.3, 3q22.1-q29, 4q12, 5q33.2-
q35.3, 6p11.2-p12.1, 6q12-q13, 6q16.1-q21, 
6q22.31-q24.1, 7, 12p11.21-p11.22, 12q12-q14.2, 
12q14.2-q21.32, 12q24.22-q24.33, 15q26.1-q26.3, 
16p11.2-p13.3, 17q11.2-q25.33, 19p12-p13.2, 
19q12-q13.43, 20, 22q11.21-q13.33 
CAL54 7,12q13.3~qter,20 2, 3p11.2-p12.3, 3q11.2-q29, 7p15.2-p22.3, 7p11.2-
p14.3, 7q11.21-q34, 7q34-q36.3, 8, 9q22.31-q34.3, 
12, 16, 17, 20 
Abbreviations: p, short arm; q, long arm; chrom., chromosome; ter, terminal 
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Table 5.11: Regions of loss in the RCC cell lines identified by Strefford et al (2005) compared with 
the present study 
 
Cell line Losses (Strefford et al., 2005) Losses (present study) 
SKRC45 1p31.1~pter,3p14.1~p21.3,6,8q21.1~pter,9q,1
4,15,16q22~qter,18q12.3~qter,19,22 
3p14.2, 3q13.32-q21.1, 3q26.1, 4p12-p16.3, 
4q12-q26, 5q11.2-q21.2, 5q21.3-q22.1, 8p12-
p23.3, 9p13.1-p23, 10p11.21-p15.3, 11p13-
p15.1, 15q11.2-q26.3, 14q11.2-q32.33, 
18q12.1-q22.1, 20p11.22-p13, 22q11.22-q13.33 
 
769P 1p34.6~ptel,3p13~ptel,11q14.3~qtel, 
14q13~qtel,Y 
1p35.3-p36.33, 3, 6, 9p21.3-p22.3, 9q12-
q21.11, 11q14.1-q25, 14q11.2-q32.33 
786O 1p32~pter,3p14.1~p22,4q32~qter,8p10~pter, 
10p10~ptel,14q13~qter,18q21.3~pter 
3p11.2-p13, 3p21.2-p26.3, 4q31.22-q35.2, 
5q11.2-q21.1, 8p11.21-p23.3, 13q12.11-
q34,14q11.2-q32.33, 18q12.2-q23, 19q13.11-
q13.42 
 
A498 1p32~pter,3p12~q25,6q15~qter,11q14.3~qter,
18,19q10~qter,Xq24~qter 
1p35.1-p36.33, 2q22.1, 3p21.2-p26.3, 6, 
11q11.2-q25, 14q11.2-q32.33, 18q11.32-q23, 
20p12.2-p13 
A704 3p10~pter,6q10~qter,9,14,16q13~qter, 
22q13.1~qter 
1p35.1-p36.13, 3p12.3-p26.3, 4, 6q21-q27, 9, 
14q11.2-q32.33, 16q12.1-q24.3, 20p21 
 
ACHN 4q10~qter,9p10~pter,Y 1p35.1-p36.33, 3, 4, 5, 6, 8p11.21-p23.3, 
8q11.21-q21.11, 9p21.3, 13q12.11-q32.3, 
15q11.2-q26.3, 14q11.2-q32.33, 18q12.2-q23, 
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Caki1 3p14.2~p23,6,9p12~p21,14q11.2~qter,15, 
18q10~qter,22q11.2~qter,Y 
1p21.3-p31.1, 3p12.3-p26.3, 6q22.32-q27, 
9p23-p24.1, 9p21.3, 9q12-q21.11, 11q14.1-q25, 
12p11.21-p13.33, 13q12.1-q13.1, 15q11.2-
q22.2, 14q11.2-q32.33, 17p11.2-p13.3, 
18q11.2-q23, 19p13.3, 20p11.21-p13, 21q11.2-
q22.3, 22q11.21-q13.33 
 
Caki2 3p14.2~p23,9p10~pter,11q13.5~qter, 
13q23.3~qter,17p10~pter,18q10~qter 
1p12-p31.3, 2q37.1-q37.3, 3p11.2-p26.3, 
3q11.2-q21.3, 4q12-q13.1, 6q25.1-q27, 
8p11.21-p23.3, 8q11.21-q12.1, 9p11.2-p24.3, 
9q12-q21.33, 11p11.12-p14.1, 11q12.1-q25, 
12q21.32-q24.22, 13q12.11-q34, 14q11.2-
q13.1, 14q23.1-q32.33, 16q11.2-q21, 16q21, 
17p11.2-p13.3, 18q11.2-q23, 19p13.3, 19p13.2-
p13.3 
 
CAL54 3p12~p21.3,9p10~pter,10q21.2~qter, 
13q21.1~q1 
1, 3p12.3-p26.3, 4, 5, 6, 
9p11.2-p24.3, 9q12-q22.31, 10, 11, 13q12.11-
q34, 15q11.2-q26.3, 14q11.2-q32.33, 18, 
21q11.2-q22.3 
 
Abbreviations: p, short arm; q, long arm; chrom., chromosome; ter, terminal 
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Deletion 1p, 3p, 4q, 9p, 13q 14q and 18q and gain 1q, 2q, 5p, 5q, 7p, 7q, 8q, 12q, 16p, 
16q, 17q, 20p and 20q were the most common changes (>52%) observed in the present 
study. A previous analysis of a very large number of unselected RCC tumours reported 
that the most frequent cytogenetic changes were loss of 3p (60%), 14q (28%), 8p (20%), 
6q (17%), loss of 9p (16%) and 4p (13%), gain of 5q (33%) and trisomy 7 (26%) (Klatte et 
al., 2009). Similarly, copy number analysis of sporadic RCC tumours using high resolution 
SNP arrays abnormalities demonstrated recurrent losses on 3p, 4, 6q, 8p, 9p and 14q and 
recurrent gains on 1q, 2, 5q, 7 and 12 (Dalgliesh et al., 2010) and Beroukhim et al (2009) 
reported amplification 1q, 2q, 5q, 7q, 8q, 12p and 20q and deletion 1p, 3p, 4q, 6q, 8p, 9p 
and 14q as the most frequent copy number changes in cRCC tumours (sporadics and 
VHLs). All of the changes found in the present study were also found in the previous 
reports (Beroukhim et al., 2009; Klatte et al., 2009; Dalgliesh et al., 2010) except deletion 
13q, 18q and gain 16, 17q and 20p. These might reflect changes associated with the 
different subtype of RCC other than the clear cell. For example, large deletion 13q was 
associated with chromophobe subtype of RCC (Schwerdtle et al., 1996).  
 
Deletion 14q was seen in all of the cell lines studied with all having large deletions. A 
similar study by Strefford et al (2005) identified deletion 14qtel in more than 63% of the 
19 RCC cell lines. Although it had also been detected in cRCC tumours but the frequency 
was not as high, for example Beroukhim et al (2009) detected deletion in 14q31.1 in 42% 
of the 90 cRCC tumours from sporadic and VHL, Toma et al (2008) found deletion 
14q23.3-q32.31 in 36% of the 22 cRCC tumour samples. Deletion 14q had been related 
with a sarcomatoid component in RCC which is usually aggressive, potentially metastatic 
and associate with poor prognosis (Matsuda et al., 2008). LOH in 14q was shown to be 
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related with tumour aggressiveness and poor survival in RCC (Mitsumori et al., 2002; 
Alimov et al., 2004).  
 
All except one cell line (22/23, 95.7%) showed deletion in 3p. Most of the deletions 
involved large fragments and of the 22 cell lines, 19 (86.4%) showed deletion of the VHL 
gene which maps to 3p25.3. This study has identified three most frequently deleted regions 
on 3p; 3p14.2, 3p21.2-p26.3, 3p11.2-p13 (table 5.8). Many reports before have focused on 
three regions as rearrangements have been repeatedly observed in them: 3p12-p14, 3p21 
and 3p25-p26 (Lubinski et al., 1994; van den Berg and Buys, 1997). Deletion in either 
3p25 or 3p12-14 occurred in adenomas whereas carcinomas occurred in 3p21 together 
with losses in 3p25 or 3p12-14 or both. In the present study, most of the deletion involved 
long and terminal 3p thus supporting the previous observation (Chudek et al., 1997; 
Alimov et al., 2000; Sukosd et al., 2003). In addition, one of the cell lines, SKRC45, had a 
focal interstitial deletion in 3p14.2, without deletion in the other two regions (3p21.2-p26.3 
and 3p11.2-p13). The only gene which resides in the region is FHIT and this suggests that 
deletion of the gene alone can implicate cRCC. Another cell line, RCC48 had a 
homozygous deletion in the same region with the same size (~0.6 Mb), although deletions 
in the other two regions were also observed. The FHIT gene is a putative tumour 
suppressor factor that has been related to malignancies of the lungs, head and neck, breast 
carcinoma, Merkel cell carcinoma, colon tumours, cervical carcinomas and renal 
carcinomas (Virgilio et al., 1996; Sozzi et al., 1996; Ohta et al., 1996; Negrini et al., 1996; 
Hadaczek et al., 1998; Luceri et al., 2000).   
 
Previous reports had identified deletions or loss of heterozygosity in the 3p14.2 region and 
altered expression of the FHIT protein occurs in kidney cancers (Hadaczek et al., 1999; 
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Velickovic et al., 1999; Sukosd et al., 2003). The FHIT gene has been shown to suppress 
growth of cancer cells in vitro and in vivo (Roz et al., 2002) and restoration of FHIT gene 
expression in FHIT-deficient mice prevents tumour development (Dumon et al., 2001). 
Reports by Chudek et al (1997) and Sukosd et al (2003) described a terminal 3p deletion in 
most of the cases they studied and concluded that interstitial deletions did not exist in 
cRCC and that the interstitial 3p deletions identified by some of the studies could be due to 
technical artifacts.  The number of cell lines involved with interstitial 3p deletions in the 
present study were too low (3/22), therefore it cannot be concluded whether the 
observation reflect the true genetic mechanism or only an artifact.  
 
The next most common changes were gain of chromosome 7p and 7q with most of the cell 
lines showing whole chromosome gain (table 5.7). Minimal overlap region was found in 
7p11.2-p12.1, 7p21.2-p22.3, 7q11.21-11.22 and 7q34-7q36.3 with the first three regions 
showing amplification. One of the many genes in 7p11.2-p12.1 is EGFR, a cell surface 
protein that binds to epidermal growth factor which then induces receptor dimerization and 
tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are 
associated with a number of cancers including lung cancer and anal cancer (Kobayashi et 
al., 2005; Walker et al., 2009). Furthermore, EGFR was previously described only in 
primary papillary RCC (Kovacs et al., 1991) but other study have also revealed high 
frequency of gain (Strefford et al., 2005) and increased levels of the gene in RCC (Moch et 
al., 1998). Gain on chromosome 7 were also related with high grade clear cell carcinoma 
(Matsuda et al., 2008) and duplication/amplification of MET at 7q31-q34 have been 
identified in cRCC (Pavlovich et al., 2003). There was also a positive correlation observed 
between MET expression and high nuclear grade (Choi et al., 2006).  
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Gain of 5q was found in 73.9% of the cell lines with the minimal overlap region identified 
in 5q34-q35.3 (table 5.8). Beroukhim et al (2009) have analysed 90 cRCC tumours (both 
sporadic and VHL-disease associated tumours) using the same platform and found gain 5q 
as the second most common changes after deletion 3p. They used GISTIC-based analysis 
to point the peak region and the region identified on 5q was in 5q35.3. However, no 
oncogene or TSG detected in that region. Gain of 5q after the initial loss of 3p may 
contribute to tumour progression in cRCC (Brauch et al., 1994; Meloni et al., 2002; Nagao 
et al., 2005). Nagao et al (2005) also concluded that allelic loss of 3p25 including the VHL 
gene is thought to be an immediate event in the development of cRCC and copy number 
gains or losses of 5q21 approximately q23 are thought to be events that lead to tumour 
progression although the clinical significance of either gains or losses is not well known. 
Other regions identified were in 5q33-q35 (Strefford et al., 2005; Toma et al., 2008) and 
5q22.1-q23.2 (Toma et al., 2008). Gain of 5q is associated with t(3;5) which is common in 
cRCC and patients with deletion 3p and gain 5q22.3-q23.3 have been associated with 
better disease-free survival compared to those who had the deletion without the gain 
(Nagao et al., 2005).  
 
In addition to duplication 5q34-q35.3, an interstitial gain in 5q21.2-q21.3 with the size 
~4.3 Mb was detected in 1 case, SKRC45. Other cell lines which overlap the region were 
identified in 10 cases. The region contains three genes; RAB9P1, EFA5 and FBXL17. 
RAB9P1 is a member of RAS oncogene family, FBXL17 is a member of the F-box protein 
family and interact with SKP1 through the F box, and they interact with ubiquitination 
targets through other protein interaction domains (Jin et al., 2004) and EFA5 is a member 
of the ephrin gene family, prevents axon bundling in cocultures of cortical neurons with 
189 
 
astrocytes, a model of late stage nervous system development and differentiation. Further 
investigation of the genes is important to elucidate its function in relation to RCC.  
 
Other copy number alterations ocurred in ~65%-78% of the cell lines were loss of 1p, 4q, 
18q and gain of 2q, 8q, 12q and 20q. Deletion 4q is associated with sarcomatoid 
transformation in RCCs and one of the most frequently encountered chromosomal changes 
in papillary renal cell carcinoma (Jiang et al., 1998). The region of deletion on 18q found 
in this study (18q22.3-q23) is not in the same region identified by the previous reports. 
Both Hirata et al (2005) and Strefford et al (2005) identified LOH and deletion in 18q21.1-
q21.3. The putative TSGs identified in the region include SMAD4, BCL2 and DCC.  
Possible reasons that might contribute to the discrepancies seen are the differences in the 
methods applied, the sample size and the differences in the samples used, for example 
Strefford et al (2005) applied comparative genomic hybridisation (CGH) in their study.  
 
1p35.3-p36.33 was identified as one of the most common region loss in the present study. 
Cifola et al (2008) and Beroukhim et al (2009) had each identified deletion in 1p36.11-
p36.32 and 1p36.11 in cRCC tumours and RCC cell lines respectively. Among the many 
genes in the region is RUX3 which resides in 1p36.11 and has been shown to suffer gene 
silencing, homozygous deletion,  hypermethylated or protein mislocalization to the 
cytoplasm in a variety of cancers (Li et al.,  2002; Ito et al., 2005; Imamura et al., 2005; 
Vogiatzi et al., 2006; Tsunematsu et al., 2009). Gain of chromosomes 2, 12 and 20 were 
shown to be associated with papillary RCC (Brunelli et al., 2003; Matsuda et al., 2008). 
Complete gain of chromosome 20 (found in 11/23, 47.8% of the cell lines) and 12 (found 
in 8/23, 34.8% of the cell lines) were frequently encountered in this study (table 5.7).  
 
190 
 
The minimal common gain region in the 16/23 (69.6%) of the cases with gain of 
chromosome 8q was identified in 8q24.12-q24.3 where MYC resides. The gene participates 
in most aspects of cellular function, including replication, growth, metabolism, 
differentiation and apoptosis (Packham and Cleveland 1995; Hoffman and Liebermann 
1998; Dang 1999; Elend and Eilers 1999; Prendergast, 1999). It has been shown to be 
amplified and/or overexpressed in numerous human cancers such as breast cancer, 
urothelial carcinoma, metastatic prostatic carcinoma, small cell lung cancer (Johnson et al., 
1992; Jenkins et al., 1997; Christoph et al., 1999; Liao and Dickson, 2000; Naidu et al., 
2002). Regions of homozygous deletion were seen in 9p21.3 and 9p23-p24.1 in 7/17 and 
2/14 of the cases respectively. Three genes reside in the 9p21.3 are MTAP, CDK2A, 
CDK2B which were reported to be deficient in many cancers. PTPRD is the only gene in 
9p22-p23 and the protein encoded by this gene regulates a variety of processes including 
cell growth, differentiation, mitotic cycle and oncogenic transformation. A study carried 
out by Grady et al (2001) on renal cell carcinoma has revealed a high incidence of LOH on 
chromosome 9 particularly 9p21 and 9p22-p23 suggesting several putative TSGs in the 
regions.  It has also been shown that LOH on chromosome 9 have a higher risk of 
recurrence, poor prognosis and shorter tumour-specific survival (Schraml et al., 2001; 
Presti et al., 2002; Toma et al., 2008).  
 
At present, copy number changes observed in RCC cell lines usually are large with 
frequent loss detected in 1p, 3p, 4q, 9p, 13q, 14q and 18q and gain 1q, 2q, 5p, 5q, 7p, 7q, 
8q, 12q, 16p, 16q, 17q, 20p and 20q. These changes were also found in primary RCC 
tumours, therefore RCC cell lines represent a useful model for studying renal cancer. 
Although the aberrations identified in the cell lines could also be associated with in vitro 
karyotype evolution, it retains much of the genetic information of the primary tumour as 
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shown in the present study and the previous report (Pavlovich et al., 2003).  High 
resolution 250K SNP microarrays is a useful method which allows detail characterisation 
of RCC to be carried out as shown in the results of this study.  
 
5.9   Comparison of copy number changes identified in primary tumours and 
RCC cell lines  
 
 Overall, the RCC cell lines have more copy number changes than the primary tumours 
and more changes were seen in the cRCC sporadic tumours than in the VHLs (table 5.12). 
Overlapping changes that were common to the two sets of tumours and the cell lines are 
loss of 3p and gain of 5q. Gain of 2q, 7 and loss of 3q, 8p were more common in VHL 
(≥19%) than in sporadic tumours. On the other hand, gain 3q, 8q, 16p, 20q and loss 1p, 6p 
and 14q were observed more frequently (≥33%) in the sporadic than in the VHL tumours. 
However, the findings observed were not statistically significant except for gain 20q.  
 
Table 5.12: Most common regions of gains and losses identified in cRCC primary tumours 
(sporadics and VHLs) and RCC cell lines using 250K SNP array 
 
  cRCC  
RCC cell line sporadic VHL 
gain  2q23.3-q37.3 2q35-q36.3 
    2q24.3-q33.3 
    2q11.2-q14.3 
  3q24-q29  3q22.1-q29 
  5q31.3-q35.1 5q32-q35.3 5q34-q35.3 
 5q35.3   
   7p11.2-p22.3 7p11.2-p12.1 
   7q11.21-q22.1 7p21.2-p22.3 
   7q32.1-q36.3 7q34-q36.3 
    7q11.21-11.22 
  8q11.21-q13.2  8q24.12-q24.3 
 8q21.3-q24.3   
    12q24.22-q24.33 
    12q12-q13.2 
  16p11.2  16p11.2-p13.3 
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  20q11.22-q11.23  20q11.21-q11.23 
  20q13.2-q13.33   
loss 1p13.3-p31.1  1p35.3-p36.33 
 1p34.2-p36.33   
 3p12.1-p13 3p14.2-p21.1 3p14.2 
 3p13-p26.3 3p21.31-p26.3 3p21.2-p26.3 
  3q13.11-q13.31 
3q11.2-q13.11 
 
3p11.2-p13 
   4q12-q13.1 
   4q31.22-q35.2 
 6p21.2-p21.33   
  8p12-p23.3 8p21.3-p23.3 
   9p21.3 
   9p23-p24.1 
   13q12.1-q13.1 
 14q12-q31.2  14q11.2-q13.1 
   14q23.1-q32.33 
   18q22.3-q23 
     Abbreviations: p, short arm; q, long arm 
 
Most VHL associated RCC are detected presymptomatically and removed when the 
tumour reaches ~3 cm. In contrast, only a minority of sporadic RCC is detected 
presymptomatically and so, on average, sporadic tumours are larger. Hence genetic 
differences between VHL cRCC and sporadic VHL wild type cRCC might reflect (a) 
differences in stage of tumourigenesis (i.e. later in sporadic cases), (b) differences in 
mechanisms of tumourigenesis according to the presence or absence of VHL mutations.  
Deletion 3p including the VHL gene, was detected in 71% of the VHL tumours, 50% of the 
sporadic tumours and 95.7% of the cell lines.  
 
Gain of 5q35.3 was common both in the primary tumours and the cell lines.  Among the 
genes that reside in the region is MAPK9 which are involved in a wide variety of cellular 
processes such as proliferation, differentiation, transcription regulation and development, 
thus might be a candidate gene for RCC.  
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High resolution SNP array has allowed detailed analysis of copy number changes in the 
cRCC primary tumours (sporadic and VHLs) and RCC cell lines as demonstrated in the 
present study. Most often the changes identified are large and in some cases involve the 
whole arm or the whole chromosome. Although there is overlap between the copy number 
changes detected in VHL cRCC and sporadic cRCC, some changes (e.g. 1p, 14q loss and 
8q, 20q gain) are preferentially associated with the latter. Further studies are required to 
determine the potential role of individual gene within these regions with the use of more 
advanced methods such as higher resolution arrays and massive parallel sequencing 
techniques.  
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6 Identification of copy number changes in sporadic clear cell renal cell 
carcinoma (cRCC) using high resolution array SP6.0 
 
6.1  Introduction 
Human cancers are partly due to irreversible structural mutations which can produce DNA 
copy number alterations at distinct locations in the genome (Albertson et al., 2003). In 
most solid tumours, copy number alterations are shown to be a common feature (Weir et 
al., 2004; Kops et al., 2005; Albertson, 2006). Chromosome segments that are deleted or 
duplicated/amplified harbour tumour suppressor genes (TSG) or oncogenes respectively. 
For example, small single nucleotide mutation can inactivate TSG on an allele and 
hemizygous deletion can remove the other allele to achieve functional inactivation. This 
results in loss of heterozygosity (LOH) across the loci. LOH can also be due to 
homozygous deletion (deletion on both alleles), uniparental disomy (UPD), mitotic 
recombination or gene conversions. Conversely, genomic amplification of oncogenes 
contributes to uncontrolled positive growth signaling. These alterations contribute to 
tumourigenesis and progression by enabling the aberrant function of genes that positively 
and negatively regulate aspects of cell proliferation, apoptosis, genome stability, 
angiogenesis, invasion and metastasis (Hanahan and Weinberg, 2000). Measuring gene 
dosage at high resolution and with accuracy is very important for dissecting the 
mechanism of cancer development (Garraway et al., 2005). Thus identifying these changes 
offer a basis for a better understanding of cancer development and subsequently improved 
tools for clinical management such as new diagnostics and therapeutic targets. 
Comparative genomic hybridisation (CGH) was the first developed technique for genome 
wide characterisation of copy number changes especially in cancer (Kallionemi et al., 
1992). Subsequently, higher resolution array-based CGH methods were introduced 
 replacing target metaphase spreads used in CGH with a large number of discrete genomic
or cDNA clones (Albertson et al
example, arrays consisting
spanning the entire human genome, with a resolution of less than 100 kb allowing 
comprehensive analyses of cancer genomes (Ishkanian et al
technology using synthetic high
2003; Bignell et al., 2004; Huang et al
et al., 2004; Zhao et al., 2004; Zhou et al
changes to be identified 
methods. These high throughput 
genotype thousands of single nucleotide polymorphisms (SNP
Among the different proposed platforms, Affymetrix
genome wide studies using 25 nucleotides long probes and developed different types of 
SNP microarrays; 10K array 
10K), 100K array - a pair of arrays covering 116,
50K Xba array and Hind Array) and 500K array 
(GeneChip Human Mapping
arrays were designed so that each SNP is interrogated by 24 to 40 unique probes. Of these, 
half are perfectly complementary to the sequence harbo
probes), while half mismatch the sequence at the probe's middle nucleotide (mismatch 
probes). The mismatch probes were intended to capture background effects such as cross
hybridization. For the Affymetrix GeneChip 500
However, the probes are not uniformly distributed across the genome and are particularly 
sparse in regions of segmental duplication and complex CNV
the design of robust genotyping SNP assays in these regions. As a result, the resolution of 
., 2000; Hodgson et al., 2001; Pollack et al
 
of 32,433 bacterial artificial chromosomes (
., 2004).  More recent 
-density oligonucleotide
 
microarrays (
., 2004; Janne et al., 2004; Rauch et al
., 2004) has enabled LOH and copy number 
simultaneously at even higher resolution than the previou
microarrays are commercially available and designed to 
s) in human genomic DNA. 
 
Human Mapping Array
- an
 
array covering 10,204 SNPs (GeneChip Human Mapping
204  SNPs (GeneChip
- a pair of arrays
 
covering 
 
250K Nsp Array and Sty Array). These
uring the SNP site (perfect match 
K, SNPs have a median spacing of 2.5 kb. 
. These create
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., 2002). For 
BAC) clones 
Lieberfarb et al., 
., 2004; Wong 
s 
 
offers
 
 
 
Human Mapping 
504,152 SNPs 
 Affymetrix SNP 
-
 problems for 
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the array is variable across the genome and CNV detection has a lower limit of 10–40 kb 
(Carter, 2007). Therefore, Affymetrix has included additional nonpolymorphic probes on 
their latest SNP Array 6.0 to overcome the problem.  
The SNP Array 6.0, which interrogates nearly one million SNPs and differs fundamentally 
from previous versions. First, each SNP on the 6.0 array is interrogated only by six or 
eight perfect match probes - three or four replicates of the same probe sequence for each of 
the two alleles. Therefore, intensity data for each SNP consist of three or four repeated 
pairs of measurements. Second, the SNP probe sets are augmented with nearly one million 
CNV probes, which are meant to interrogate regions of the genome that do not harbour 
SNPs, but that may be polymorphic with regard to copy number. Each such CNV site is 
interrogated by only one probe. The Affymetrix SNP array 6.0 (Genome-Wide Human 
SNP Array 6.0) (McCarroll et al, 2008) contains more than 1.8 million markers; 906,600 
single nucleotide polymorphisms (SNPs) and more than 946,000 probes for the detection 
of copy number variation, thus providing the highest physical coverage of the genome with 
median marker spacing of 680 bases (GenomeWide Human SNP Array 6.0 (Affymetrix) 
http://www.affymetrix.com/products_services/arrays/specific/genome_wide_snp6/genome
_wide_snp_6.affx). Details of the SNPs selection and its description for array SNP6.0 are 
available from http://www.affymetrix.com/support/support_result.affx. The SNP6.0 arrays 
have been applied for studies of common diseases such as diabetes and heart disease 
(McPherson et al., 2007; Saxena et al., 2007; Zeggini et al., 2007), detection of UPD and 
characterisation of chromosome breakpoint in chronic lymphocytic leukemia (Hagenkord 
et al., 2010) and identification of copy number alterations and LOH in tumours (Greenman 
et al., 2010; Gorringe et al., 2009). The arrays were also successfully applied on fresh 
frozen tissue (Tuefferd et al, 2008) as well as archived samples (Tuefferd et al., 2008; 
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Bucasas et al, 2009). The Birdseed algorithm (Korn et al, 2008) is specifically designed for 
the Genome-Wide Human SNP Array 6.0 to process data from the arrays.   
 
The main aim of this study is to precisely characterise and identify copy number changes 
associated with sporadic clear cell renal cell carcinoma (cRCC). Therefore, I took 
advantage of the latest microarray technology, Affymetrix array SNP6.0, to study copy 
number changes of 37 samples of sporadic cRCC. The data was then compared with the 
results of sporadic cRCC obtained using the 250K SNP array.  
 
6.2  Materials and methods 
6.2.1  DNA sample 
A total of 37 genomic DNA from sporadic primary clear cell renal cell carcinoma tumours 
were studied. Genomic DNA was extracted following standard methods and stored at -
80
o
C. 
 
6.2.2 SNP Array 6.0 analysis 
The methods were described in detail in sections 2.1 and 2.2. The SNP Array 6.0 platform 
offers the genotype calling algorithm "Birdseed" to determine the genotypes of 909,622 
SNPs (Affymetrix, Inc. http://www.affymetrix.com/index.affx). The Birdseed algorithm 
performs a multiple-chip analysis to estimate signal intensity for each allele of each SNP, 
fitting probe-specific effects to increase precision, and then makes genotype calls by fitting 
a Gaussian mixture model in the two-dimensional A-signal vs. B-signal space, using SNP-
specific models to improve accuracy. In addition, this array also contains 945,826 copy 
number probes designed to interrogate CNVs in the genome; 115,000 of these probes 
interrogate previously identified CNVs while the remaining 831,000 are distributed across 
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the genome for improved CNV detection (Affymetrix, Inc. 
http://www.affymetrix.com/index.affx). Copy number analysis was performed with 
Affymetrix Genotyping Console v3.0.2 (GTC v3.0.2). 
 
6.2.3  MLPA analysis 
MLPA was applied on 20 samples to confirm some of the deletions and duplications 
identified from the array SNP6.0 microarray. The MLPA Kit used was SALSA P007-A1 
Human Chromosome Kit (MRC Holland, Amsterdam, The Netherlands) that contains 
probes for 40 different target sequences (appendix A5). Among these are many genes that 
are often deleted or amplified in various tumours. The analysis was performed according 
to the manufacturer’s instructions. The ligation products were amplified on a Tetrad 
thermal cycler (Peltier 225 from MJR). PCR products were then separated by capillary 
electrophoresis on a Beckman Coulter CEQ 8000 genetic analyzer. Electropherograms 
were analyzed using GeneMarker MLPA Analysis (SoftGenetics, LLC, USA). Deletions 
were indicated by a value of <0.785 and duplications by >1.33. 
 
6.3  Results 
 
6.3.1  SNP Array 6.0 analysis 
 
The reference set for 250K Sty1 mapping arrays was 48 samples from the HapMap project 
(www.hapmap.org/downloads/raw_data/affy500k/) and 270 HapMap individuals of 
various populations for SNP 6.0 (Goldstein and Cavalleri, 2005). Six normal controls were 
used for MLPA. The average call rate of the 37 samples was 95.13±1.78. Overall, 325 
gains (mean per tumour was 8.78) and 269 losses (mean per tumour was 7.27) were 
detected with majority of them involved the whole chromosome arm or segments ≥10 Mb 
(table 6.1 and figure 6.1). Small deletions and duplications were not a common feature and 
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all of the small regions (<10 Mb) identified were not recurrent. Deletion 3p was the most 
frequently encountered aberrations, seen in 28(75.7%) of the cases and all of them 
involved deletion of the whole 3p or segments ≥10 Mb. Gain of 5q was encountered in 
16(43.2%) of the cases and among these, 8 cases showed deletion in 3p. Loss of 
chromosome 1, 3, 6, 9, 14 and gain of chromosome 5, 7, 11, 12, 17 were observed in 
~19%-32% of the cases. Loss of whole 8p and 14q were seen in 13(35.1%) and 12(32.4%) 
respectively. In addition, small deleted regions (<10 Mb) were identified in 14q11.2 (7.6 
Mb), 8p21.2 containing 7 genes, 8p12 containing 15 genes and 1p36.11-p36.12 containing 
43 genes.  
 
Gain of 16q were found as frequently as gain 5q and the small gain segments identified in 
16q came from the same sample at different regions on the chromosome. Gain of 
chromosome 7, 11, 12 and 17q were also fairly common, encountered in 29.7%-37.8% of 
the cases (table 6.1).  
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Table 6.1: Chromosome gains and losses in the 37 samples of sporadic cRCC analysed with array 
SNP6.0 
Chrom. 
 
Loss 
 
Gain 
 
Whole 
chrom. 
arm 
 
≥10 Mb 
 
<10 Mb 
 
Total  
 
Whole 
chrom. 
arm 
≥10 Mb 
 
<10 Mb 
 
Total 
 
1p 13 3 1 17  2 2 0 4 
1q 12 0 0 12 5 0 0 5 
2p 5 0 0 5 3 0 0 3 
2q 5 1 0 6 3 1 0 4 
3p 13 15 0 28 6 4 1 11 
3q 10 0 0 10 7 1 0 8 
4p 3 2 0 5 6 1 0 7 
4q 3 1 0 4 7 0 0 7 
5p 3 0 1 4 9 2 0 11 
5q 4 0 0 4 9 7 0 16 
6p 10 1 0 11 6 2 0 8 
6q 10 2 0 12 6 0 0 6 
7p 0 2 0 2 14 0 0 14 
7q 0 3 0 3 14 0 0 14 
8p 13 0 2 15 5 0 1 6 
8q 6 2 1 9 7 3 0 10 
9p 7 0 0 7 5 0 1 6 
9q 7 0 0 7 5 0 2 7 
10p 6 0 0 6 5 0 0 5 
10q 7 0 0 7 5 1 0 6 
11p 2 0 0 2 11 0 0 11 
11q 2 1 0 3 10 0 0 10 
12p 0 3 0 3 10 0 1 11 
12q 0 1 0 1 10 1 0 11 
13q 6 1 0 7 11 0 0 11 
14q 12 2 1 15 4 0 1 5 
15q 3 1 0 4 5 1 0 6 
16p 0 0 0 0 6 0 0 6 
16q 0 2 2 4 8 2 6 16 
17p 5 1 1 7 8 0 0 8 
17q 5 0 0 5 8 3 0 11 
18p 3 0 0 3 6 0 0 6 
18q 3 4 0 7 6 0 0 6 
19p 5 1 1 7 3 1 1 5 
19q 5 0 0 5 3 1 1 5 
20p 0 0 0 0 3 2 0 5 
20q 0 0 0 0 3 1 1 5 
21q 5 0 1 6 4 0 2 6 
22q 4 0 0 4 5 0 0 5 
Abbreviations: p, short arm; q, long arm; chrom., chromosome; Mb, megabase 
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      Legends:                                
 Loss whole arm 
 Loss ≥10 Mb 
 Loss <10 Mb 
 Gain whole arm 
 Gain ≥10 Mb 
 Gain <10 Mb 
 
 
 
Figure 6.1: Frequency of chromosome gains and losses identified in the 37 samples of sporadic 
cRCC studied. 
 
 
 
Minimal overlapping regions of the most common (>27%) copy number changes is shown 
in table 6.2. MLPA analysis was done to verify the changes in some of the regions. 
Microarray and the MLPA copy number analysis results was concordant (table 6.2). 
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Table 6.2: Minimal overlapping regions of gains and losses of the most common copy number 
changes in the sporadic cRCC studied.  
 
  Affected region Start pos. End pos. Size (Mb) MLPA probes 
Loss 1p22.3-p31.3 65,000,000 87,285,000 22.28  
  3p14.3-p26.3 0 55,280,000 55  
  6q16.3-q27 103,700,000 170,899,992 67.19  
  6p21.1-p25.3 0 40,000,000 40 
CDKN1A (6p21.2), 
LTA (6p21.3) 
  8p12 36,000,000 38,000,000 2  
  8p21.2 23,680,000 25,060,000 13.8  
   14q11.2  18,000,000 25,626,000  7.62  
 14q23.2-q32.33 63,212,700 106,368,585 43.15  
Gain 3p11.2 87,450,000 90,400,000 29.5  
  3p22.2-p24.1 28,400,000 38,680,000 10.28  
  5p15.1-p15.33 0 18,000,000 18  
  5q31.1-q35.3 131,000,000 180,857,866 49.85 IL12B (5q33.1) 
  8q11.21-q21.1 47,000,000 76,200,000 29.2  
  8q21.11-q22.3 76,200,000 106,000,000 29.8  
  
8q23.1-q24.3 106,100,000 145,200,000 39.1 
MYC(8q24.12), 
PTK2 (8q24),  
SLA (8q24.2) 
  11p11.12-p15.5 0 51,400,000 51  
  12p13.32-p13.33 0 4,400,000 4  
  12q12-q21.32 37,636,000 86,175,000 48.54  
  16q12.1 45,000,000 46,200,000 1.2  
  16q12.1 49,200,000 49,885,000 0.68  
  16q12.1-q12.2 50,000,000 53,700,000 3.7  
  16q12.2-q21 53,700,000 59,000,000 6.7  
  16q21-q22.3 59,200,000 70,000,000 10.8  
  16q22.3 70,180,000 71,000,000 1.18  
  17q24.1-q25.3 60,900,000 78,774,742 17.87  
  17q21.2-q24.2 35,075,000 61,863,600 26.78 TOP2A (17q21.2) 
Abbreviations: p, short arm; q, long arm; pos, position; Mb, megabase 
 
 
In the present study, there were 18 small gain regions (<10Mb) and 11 small loss regions 
identified.  Four regions of amplification (≥4 copies) were identified on chromosome 16q 
(table 6.3).  
 
203 
 
Table 6.3: Small regions (<10 Mb) of gains and losses in the 37 samples sporadic cRCC studied 
with array SNP6.0 
 
Gain (<10 Mb) Loss (<10 Mb) 
Chrom. band 
Start 
pos. 
End 
pos. 
Size 
(Mb) 
Chrom. band 
Start 
pos. 
End 
pos. 
Size 
(Mb) 
3p11.2 87.45 
 
90.40 
 
2.95 1p36.11-p36.12 
 
21.89 
 
24.25 
 
2.36 
8p21.1-p21.2 
 
26.80 
 
29.06 
 
2.26 5p14.1 26.75 29.14 2.39 
9p11.2 40.50 
 
47.20 
 
6.70 8p12 
 
36.00 
 
38.00 
 
2.0 
9q12 65.34 
 
69.26 
 
3.92 8p21.2 
 
23.68 25.06 
 
1.38 
9q34.2-q34.3 
 
136.40 
 
140.27 
 
3.87 8q11.21-q11.22 
 
48.00 
 
50.80 2.80 
12p13.32-p13.33 
 
0 7.24 
 
7.24 14q11.2 
 
18.00 25.63 
 
7.63 
14q32.33 
 
105.00 
 
106.37 
 
1.37 16q12.1 
 
46.55 
 
48.95 
 
2.40 
16q12.1* 
 
45.00 
 
46.20 
 
1.20 16q23.2-q24.3 
 
79.20 
 
88.83 
 
9.63 
16q12.1* 
 
49.20 
 
49.89 
 
0.69 17p12 
 
14.00 
 
15.43 
 
1.43 
16q12.1-q12.2 
 
50.00 
 
53.70 
 
3.70 19p12 
 
22.00 
 
24.26 
 
2.26 
16q22.3* 
 
70.18 
 
71.00 
 
0.82 21q11.2 
 
13.30 
 
14.18 
 
0.88 
16q23.1* 
 
75.25 
 
76.09 
 
0.84     
16q23.1-q23.2 
 
77.35 
 
78.97 
 
1.62     
19p13.3 
 
0 3.00 
 
3.00     
19q13.31-q13.32 
 
48.93 
 
51.60 
 
2.67     
20q13.33 
 
59.80 
 
62.44 
 
2.64     
21q21.2-q21.3 
 
24.25 
 
26.00 
 
1.75     
21q22.11-q22.12 
 
33.50 
 
35.37 
 
1.87     
*contain ≥4 copies 
Abbreviations: p, short arm; q, long arm; chrom., chromosome; pos., position; Mb, megabase 
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6.3.2 Comparison of copy number changes identified in sporadic cRCC using array 
SNP6.0 and 250K SNP array 
 
 
Both methods have shown that gains involving large segments (>10 Mb) were more 
common than deletions. Deletion 3p, 1p, 14q and gain 5q were the most frequently 
encountered alterations, found in >40% of the cases. Both methods also agree that deletion 
20 was not associated with RCC and gain in chromosome 7 usually involved the whole 
chromosome. Gain of whole chromosome 7 and 16q and deletion 8p were shown as a 
common event (~37%-43% of the cases) in sporadic cRCC by SNP6.0, however, results 
from 250K array identified the aberrations not as common (<26% of the cases). Other 
fairly common aberrations, encountered in ~27%-32% of the cases with SNP6.0 were loss 
of 1q, 3q, 6 and gain of 3p, 5p, 8q, 11, 12, 13q and 17q.  These aberrations were seen in 
~8%-25% of the cases identified by 250K SNP array except gain 8q which was 
encountered in 41.6% of the cases. In general more copy number abnormalities were 
observed in sporadic group than VHLs.  This could reflect the use of SNP 6.0 arrays or the 
fact that in general, sporadic tumours will be at a more advanced stage at operation. Some 
of the differences (e.g. gain 16q, loss 1p, loss 1q and loss 6q were statistically significant) 
after allowance for multiple testing (Bonferroni corrected P value ~0.0024).  
 
Small regions of deletion and gain were identified using both arrays; Array SNP6.0 has 
identified 11 small deletions and 18 small gains while 250K SNP array has detected 7 
small deletions and 13 small gains (table 6.4). Mean size of the smallest region identified 
with SNP6.0 was 2.90 and 4.65 for 250K array.  Almost all of the small regions identified 
with 250K arrays were not in the same regions detected using SNP6.0 except for gain in 
the regions 9q and 19p (table 6.4). These might reflect the heterogenous characteristic of 
these tumours or it could be due to the smaller sample size analysed by 250K compared to 
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array SNP6.0. Therefore, copy number changes in sporadic RCC for this study are 
combined results obtained using 250K and SNP6.0 arrays.  
 
Table 6.4: Small regions (<10 Mb) of gains and losses detected in sporadic cRCC using 250K SNP 
array and array SNP6.0  
 
  250K SP array SP6.0 array 
Loss 
Chrom. band Size (Mb) Chrom. band Size (Mb) 
3q11.2 2.7 1p36.11-p36.12 2.36 
6p21.2-p21.33 8.46 5p14.1 2.39 
9p13.1-p21.1 6 8p12 2 
11p11.12-p11.2 4.71 8p21.2 1.38 
11q14.1-q14.3 7.1 8q11.21-q11.22 2.8 
11q12.1-q12.2 3.3 14q11.2 7.63 
16p13.2-p13.3 1 16q12.1 2.4 
   16q23.2-q24.3 9.63 
   17p12 1.43 
   19p12 2.26 
   21q11.2 0.88 
Gain 
5q21.1-q21.3 5.16 3p11.2 2.95 
5q35.3 2.86 8p21.1-p21.2 2.26 
8p11.21-p12 9.97 9p11.2 6.7 
6p12.3-p21.2* 8.2 9q12 3.92 
9q33.2-q34.11* 8.14 9q34.2-q34.3 3.87 
9q34.3 1.87 12p13.32-p13.33 7.24 
16p11.2 2.88 14q32.33 1.37 
17q21.33-q22 1.67 16q12.1* 1.2 
18q11.2-q12.1 8.45 16q12.1* 0.69 
19p13.13-p13.2 2.13 16q12.1-q12.2 3.7 
19p12-p13.11 3.8 16q22.3* 0.82 
19p12* 1.73 16q23.1* 0.84 
20q11.21-q11.23 6.45 16q23.1-q23.2 1.62 
    19p13.3 3 
    19q13.31-q13.32 2.67 
    20q13.33 2.64 
    21q21.2-q21.3 1.75 
    21q22.11-q22.12 1.87 
*contain ≥4 copies 
Abbreviations: chrom., chromosome; Mb, megabase 
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6.4  Discussion 
It is evidence from both of the 250K SNP array and SNP6.0 arrays data that copy number 
changes in sporadic cRCC tumours most frequently involved large segments of the 
chromosomes and with preference to chromosome gains. This suggests that cRCC 
tumourigenesis requires elimination and gain of multiple genes on many chromosomes 
which also involved many ‘passenger’ and ‘driver’ events.  
 
Recent findings have shown that known cancer genes that are frequently mutated in other 
adult epithelial cancers, for example the RAS genes, BRAF, TP53, RB (also known as 
RB1), CDK2A, PIK3CA, PTE, EGFR and ERBB2, make only a small contribution to 
cRCC (http://www.sanger.ac.uk/genetics/CGP/cosmic/). Deletion 3p which is a hallmark 
of cRCC was detected in 50% and 75.5% of the sporadic cRCC cases using 250K SNP 
array and SNP6.0 array, respectively, making it the most common findings, thus 
supporting previous reports (Banks et al., 2006; Monzon et al, 2009; Beroukhim et al., 
2009; Klatte et al., 2009). The deletion contributed to the loss of function of the VHL gene 
(maps to 3p25.3), a step known to be an important event in the pathogenesis of cRCC 
(Zbar et al., 2003). However, it has been shown that VHL inactivation alone induces 
senescence, therefore a requirement for further mutations to further promote ccRCC 
development is required (Young et al., 2008).   
 
The present study shows that almost all of the chromosomes were involved in the copy 
number alterations, with some more common than the other (table 6.1). Large deletion 1p, 
14q and gain 5q were also found to be strongly related with cRCC as demonstrated by 
~40%-50% of the cases having these alterations from the results of both arrays. In 
addition, gain of chromosome 7 and 16q and deletion 8p identified using array SNP6.0 and 
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gain 8q identified by 250K SNP array were also a common alteration in cRCC, seen in 
~37%-42% of the cases. Other fairly common alterations (~32%-33% of the cases) include 
deletion 1q and 6q detected by array SNP6.0 and gain 20q detected by 250K SNP array.  
These results are in agreement with the previous report (Beroukhim et al, 2009), except for 
chromosome 1q which was found to be frequently deleted in this study was shown to be 
among the most commonly amplified chromosomes in the report. The frequently found 
alterations indicate that the genes in that particular chromosome are highly implicated in 
cRCC. Only one alteration, deletion 20p, does not seem to play a role in cRCC as 
demonstrated by both arrays.  
 
Since most of the deletion on 3p involved large segments, it is thought that additional 
TSGs on the chromosome must have contributed to the cRCC tumourigenesis. Our data 
supports this idea as majority of the cases from both arrays with 3p deletion involved the 
whole arm or large segments. Mapping studies have shown the presence of additional 
TSGs in more centromeric regions of 3p particularly 3p12-p14 and 3p21 (van den Berg 
and Buys, 1997). A number of other genes have been identified as a candidate of TSGs on 
3p, including FHIT, ROBO and RASSF1A. RASSF1A maps to 3p21.3 and was reported 
inactivated by promoter methylation and epigenetic silencing in 40%-50% of cRCC. The 
gene product appears to have multiple functions and modulates apoptosis, cell motility, 
cell cycle and microtubule stability (Agathanggelou et al, 2005). FHIT located in 3p14.2 is 
altered by deletion or translocation in many types of cancer including lung, cervix, 
esophagus, bladder and kidney carcinoma (Ohta et al, 1996; Virgilio et al, 1996; Sozzi et 
al, 1996; Druck et al, 1997; Mori et al, 2000; Baffa et al, 2000). Most recently, a new 
report identified SETD2 as a novel 3p TSG in cRCC (Duns et al., 2010).  
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Identification of small regions may lead to important discovery of TSGs or oncogenes 
implicated with the cancer. Array SNP6.0 has identified copy number changes in more 
chromosome regions compared to 250K SNP array due to its higher resolution and the 
larger number of samples analysed compared to 250K SNP array. This was demonstrated 
by the higher number of small regions detected by the array (table 6.3). However, the 
majority of the small regions were not recurrent and all of them occurred together with 
large deletions or gains. Therefore, it was difficult to unequivocally assess the significance 
of these findings and associate the small regions with candidate TSGs or oncogene. A 
possible explanation to the observation is that the various regions of small gains and losses 
may represent random changes from genomic instability or it could be that some changes 
reflect rare CNVs and ideally constitutional DNA should be investigated at the same time 
(however large (≥690 kb) constitutional CNVs are rare and none of the copy number gains 
or losses identified in my studies corresponded to those identified in a recent publication of 
constitutional DNAs analysed with the Affymetrix 6.0 array platform (Närvä et al, 2010)). 
 
In conclusion, copy number changes in sporadic cRCC usually involved large segments 
and chromosome gains were more common than chromosome loss. Eleven copy number 
changes were identified including 6 regions of deletion on chromosome 3p, 1q, 14q, 8p, 
1q, 6q and 5 regions of gain including chromosome 5q, 7, 16q, 8q, 20q. More 
chromosomal changes were revealed in this study as the application of high resolution 
array SNP6.0 as well as the use of a larger number of samples has assists in the 
identification of the changes associated with cRCC.   
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7  Future works and recent developments 
One of the important factors in determining accurate results in cancer studies is the purity 
of the DNA used. An alternative to the method applied in this study for obtaining the DNA 
from cancer samples with minimal contamination of normal cells is the use of laser 
microdissection to isolate specific cells of interest from microscopic regions of tissue or 
cell or organisms (Emmert-Buck et al., 1996; Espina et al., 2007). The tool has been 
applied in various cancer studies and on a variety of tissue samples such as solid tissues, 
cell cultures, cytologic preparations, frozen and paraffin embedded tissue (Wild et al., 
2000; Orba et al., 2003; Dahl et al., 2006; Korekane et al., 2007; Kawamura et al., 2010). 
Due to the high degree of purity (95%) in the cell populations obtained using the tool, 
Nakamura et al (2004) have detected a large proportion of genes that were upregulated or 
downregulated in pancreatic cancers that were different from those reported in previous 
studies. They suggests laser microdissection  is useful  in providing  important information 
for finding candidate genes whose products might serve as specific tumour markers and/or 
as molecular targets for treatment of patients with pancreatic cancer.  
 
Genetic aberrations associated with cRCC are complex as demonstrated by the present 
study as well as previous reports. Identifying copy number changes is one genetic aspect of 
the cancer but to understand the precise genetic basis and the mechanisms involved 
requires a comprehensive knowledge of mutational, transcriptional, epigenetic and copy 
number status of individual genes. Further advances in the evaluation of gene copy number 
analysis for example higher resolution arrays and massive parallel sequencing techniques 
(also referred to as next-generation or second-generation sequencing) will facilitate the 
investigation on copy number status of individual genes. The next-generation sequencing 
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technology available commercially are for example 454 sequencing (used in the 454 
Genome Sequencers, Roche Applied Science, Basel), Solexa technology (used in the 
Illumina (San Diego, Genome Analyzer), the SOLiD platform (Applied Biosystems, 
Foster City, CA, USA), the Polonator (Dover/Harvard) and the HeliScope Single Molecule 
Sequencer technology (Helicos, Cambridge, MA, USA). These platforms rely on 
sequencing by synthesis (i.e. serial extension of primed templates) using either polymerase 
(Mitra et al., 2003; Turcatti et al., 2008) or a ligase (Brenner, et al., 2000; Shendure et al., 
2005) as the enzyme. This new technology has been applied in various aspects of cancer 
studies such as targeted gene re-sequencing, mutation detection, copy number variation 
(CNV), single nucleotide polymorphism (SNP), changes in chromatin architecture, and 
epigenetic changes such as methylation pattern alteration (Thomas et al., 2006; Chen et al., 
2008; Jones et al., 2008; Parsons et al., 2008; Sugarbaker et al., 2008; Chiang et al., 2009; 
Maher et al., 2009; Stephens et al., 2009). With the ability to analyse entire genomes, these 
technologies hold promise to global mapping of normal variation and mutations of all 
types for correlation with disease propensity, diagnosis, treatment, prognosis as well as 
identification of new targets for interventional therapy discovery and development 
(Mullighan et al., 2007; Jones et al., 2008; Sugarbaker et al., 2008).  
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8  Conclusions 
The application of high resolution and high throughput SNP microarray has significantly 
contributed to the knowledge of constitutional disorders such as 3p deletion syndrome and 
Beckwith-Wiedemann syndrome (BWS) as well as cancer studies of cRCC (in VHL and 
sporadic) as  demonstrated in the present study. Current evidence suggests SRGAP3 as the 
major determinant of psychomotor retardation in 3p deletion syndrome. A region for 
congenital heart disease (CHD) was identified in an interval ~200 Kb (between 11.15 Mb 
and 11.35 Mb), however the two genes (HRH1 and ATG7) contained in the region are not 
associated with cardiovascular development. Thus, further investigations on a larger 
number of samples using a more comprehensive approach that includes mutational, 
transcriptional, epigenetic and copy number analysis of individual genes may help to 
understand the genetic basis of CHD and 3p deletion syndrome. Combination of FISH and 
microarray methods has successfully characterised chromosome aberrations on 11p15.4-
p15.5 in six BWS patients. Breakpoint in ZF215 is very rare and to date, this is the 
second to report such findings. Therefore, further investigation of the gene is important to 
know its relation with BWS.  
 
Within the limitations of the analysis, imposed by both the unknown ploidy of the cancer 
samples and the variable degree of contamination by normal cells, the overall pattern of 
copy number changes in the primary tumours involved large regions, most often the whole 
chromosome arm or the whole chromosome. Copy number changes pattern in VHL were 
more homogenous in contrast to sporadic cRCC. In addition to deletion 3p and gain 5q as 
the most common findings in both sets of the tumours, gain of 2q, 7 and loss of 3q, 8p 
were more common in VHL cRCC. Sporadic tumours appeared to have more changes (for 
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example loss of 1p, 14q, 6p and gain of 8q, 16p, 20q). As the changes observed in the 
primary tumours overlap with the cell lines, therefore RCC cell lines can be used as a 
model for studying cRCC.  
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Appendix A1 
GEOMIC DA GEERAL REQUIREMETS FOR 250K SP ARRAY AD 
SP 6.0 ARRAY 
 
• DNA must be double-stranded (not single-stranded). 
This requirement relates to the restriction enzyme digestion step in the protocol. 
• DNA must be free of PCR inhibitors. 
Examples of inhibitors include high concentrations of heme (from blood) and high 
concentrations of chelating agents (i.e., EDTA). The genomic DNA extraction/purification 
method should render DNA that is generally salt-free because high concentrations of 
certain salts can also inhibit PCR and other enzyme reactions.  
• DNA must not be contaminated with other human genomic DNA sources, or with 
genomic DNA from other organisms. PCR amplification of the ligated genomic DNA is 
not human specific, so sufficient quantities of nonhuman DNA may also be amplified and 
could potentially result in compromised genotype calls. Contaminated or mixed DNA may 
manifest as high detection rates and low call rates. 
• DNA must not be highly degraded. For any particular SNP, the genomic DNA fragment 
containing the SNP must have Nsp I (or Sty I) restriction sites intact so that ligation can 
occur on both ends of the fragment and PCR can be successful. The approximate average 
size of genomic DNA may be assessed on a 1% or 2% agarose gel using an appropriate 
size standard control. Ref 103 can be run on the same gel for side-by-side comparison. 
High quality genomic DNA will run as a major band at approximately 10-20 kb on the gel. 
Pre-amplification methods or pre-digestion with restriction enzymes other than Nsp I or 
Sty I have not been tested by Affymetrix. If other methods are desired, it is recommended 
conducting experiments to evaluate their performance with this assay. 
 
255 
 
Sources of Human Genomic DA 
The following sources of human genomic DNA have been successfully tested in the 
laboratories at Affymetrix for DNA that meets the requirements described in the section  
• blood 
• cell line 
 
Success with other types of samples such as saliva will depend on quality (degree of 
degradation, degree of inhibitors present, etc.), quantity of genomic DNA extracted, and 
purity of these types of samples 
 
Genomic DA Extraction/Purification Methods 
Genomic DNA extraction and purification methods that meet the general requirements 
outlined above should yield successful results. Methods that include boiling or strong 
denaturants are not acceptable, because the DNA would be rendered single-stranded. 
Genomic DNA extracted using the following methods have been tested at Affymetrix: 
SDS/ProK digestion, phenol-chloroform extraction, Microcon® or Centricon® 
(Millipore) ultrapurification and concentration. 
QIAGEN; QIAamp® DNA Blood Maxi Kit 
 
DA Cleanup 
If a genomic DNA preparation is suspected to contain inhibitors, the following cleanup 
procedure can be used: 
1. Add 0.5 volumes of 7.5 M NH4OAc, 2.5 volumes of absolute ethanol (stored at –20°C), 
and 0.5 µL of glycogen (5 mg/mL) to 250 ng genomic DNA. 
2. Vortex and incubate at –20°C for 1 hr. 
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3. Centrifuge at 12,000x g in a microcentrifuge at room temperature for 20 min. 
4. Remove supernatant and wash pellet with 0.5 mL of 80% ethanol. 
5. Centrifuge at 12,000x g at room temperature for 5 min. 
6. Remove the 80% ethanol and repeat the 80% ethanol wash one more time. 
7. Resuspend the pellet in reduced EDTA TE buffer (10 mM Tris, pH 8.0, 0.1 mM EDTA, 
pH 8.0). 
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Appendix A2 
 
Shutting Down the Fluidics Station 
1. After removing a probe array from the probe array holder, the LCD window displays the 
message ENGAGE WASHBLOCK. 
2. For the FS-450, gently lift up the cartridge lever to engage or close, the washblock. 
The fluidics station automatically performs a Cleanout procedure. The LCD window 
indicates the progress of the Cleanout procedure. 
3. When the fluidics station LCD window indicates REMOVE VIALS, the Cleanout 
procedure is complete. 
4. Remove the sample microcentrifuge vial(s) from the sample holder(s). 
5. If no other processing is to be performed, place wash lines into a bottle filled with 
deionized water. 
6. Choose Shutdown_450 for all modules from the drop-down Protocol list in the Fluidics 
Station dialog box. Click the Run button for all modules. The Shutdown protocol is critical 
to instrument reliability.  
7. After Shutdown protocol is complete, flip the ON/OFF switch of the fluidics station to 
the OFF position. 
8. Place buffer lines in a different bottle of deionized water than the one used for the 
shutdown protocol. 
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Appendix A3 
Preparation of low-C dTPs 
The reagents required are: 10 mM dCTP 
          10 mM dTTP 
          10mM dATP 
          10 mM dGTP  
           Sterile water for injections 
 
The 10 mM dNTPs (Sigma-Aldrich Inc., USA) were retrieved from the -20°C freezer and 
thawed at room temperature.  They were then briefly vortexed, spun and placed in a tube 
rack. 150 ul of sterile water, 100 ul of dTTP, 100 ul of dATP, 100 ul of dGTP and 50 ul of 
dCTP were pippetted into a 1.5 ml eppendorf tube. The solution was vortexed and 
aliquoted 50 ul into 0.5 ml eppendorf tubes. The tubes were stored in -20°C freezer until 
required.  
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Appendix A4 
 
Preparation of washing solution  
0.4XSSC/0.3% NP-40 
20 ml 20XSSC and 950 ml distilled water were mixed together in a sterile glass bottle. 3 
ml of NP-40 (Roche Ltd., Basel, Switzerland) was added and mixed thoroughly. The 
solution was adjusted to pH 7.0-7.5 with NaOH. Distilled water was added to make 1 litre 
final volume. The solution was kept at room temperature and discarded after 6 months.  
 
2XSSC/0.1% NP-40 
100 ml 20XSSC and 850 ml distilled water was mixed together in a sterile glass bottle. 1 
ml of NP-40 (Roche Ltd., Basel, Switzerland) was added to the solution and mixed 
thoroughly. The pH was adjusted to 7.0-7.5 with NaOH. Distilled water was added to 
make 1 litre final volume. The solution was kept at room temperature and discarded after 6 
months.   
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Appendix A5 
SALSA MLPA kit P007 Human Chromosomal Abberation-3 probe mix 
Length 
(nt) SALSA MLPA probe 
  
Chromosomal position 
 
    
64-70-76-82 Q-fragments: DNA quantity; only visible with less than 100 ng sample DNA   
88-92-96 
D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete 
denaturation  
136 LTA00662-L00158 06p21.3 
142 CFLAR00663-L00074 02q33.1 
148‡ PTE00522-L00387 10q23.3 
154 MYC00580-L00145 08q24.12 
160 BCL2L100843-L00105 20q11.21 
166 TFRSF1B00553-L00122 01p36.22 
175 TFRSF1A00554-L00123 12p13.31 
184 CASP100559-L00128 11q22.3 
194 B2M00349-L00175 15q21.1 
202 MME00487-L00069 03q25.1 
211 IFG00472-L00088 12q14 
220 SLA00488-L00080 08q24.2 
229* LHX110813-L12283 17q12 
238 TIF200974-L00561 14q12 
247 MSH200911-L00499 02p21 
256 TOP2A01055-L00628 17q21.2 
265 THBD00474-L00388 20p11.2 
274 BCL201019-L00365 18q21.33 
283 FMR200493-L00369 Xq28 
292‡ TFF100509-L02263 21q22.3 
301 BCL600494-L00072 03q27 
310 IL1800471-L00054 11q23.1 
319 CTPS10812-L00143 1p34.2 
328 CDK1A00543-L00370 06p21.2 
337 Hs.57051800497-L00071 03q26 
346 MVP00550-L00372 16p11.2 
355 BIRC200547-L00116 11q22 
364 MDM200337-L00163 12q14.3 
373 IL200655-L00183 04q26 
382 IL12B00470-L00053 05q33.1 
391 FKBIA00478-L00061 14q13 
400 PRKDC00545-L00114 08q11 
409 CD4400669-L00373 11p12 
418 HLAF00656-L00393 06p21.3 
427 CASP200680-L00121 07q35 
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435 COA301015-L00595 20q13.12 
445 IG100802-L00320 13q34 
454 IGF1R00605-L00018 15q26 
461 TP5300844-L00302 17p13.1 
470 PTK201021-L00188 08q24 
* New in lot 0108; replaces the 17q12 probe for SCYA3 present in previous lots. 
‡ Small change in length or peak height, no change in sequence detected as compared to previous lots. 
 
 
